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ABSTRACT 
 
The Department of Health aim to reduce smoking prevalence to 10% by 2020; however 
estimates suggest this shall not be achieved.  One way to increase the decline may be to 
introduce new cessation interventions into NHS Stop Smoking Services.  Literature reviews 
and meta-analyses were used to test the efficacy of smoking reduction and nicotine preloading 
in comparison to current NHS treatments (abrupt quitting and nicotine replacement therapy 
post-quit, respectively), in smokers who wanted to quit. Results of the two reviews suggest 
that both approaches produce similar quit rates to their comparators.  We suggest that pre-quit 
reduction should be offered alongside abrupt quitting, to encourage more smokers to use 
cessation services. However the use of nicotine preloading would be premature, as evidence 
of benefit is inconclusive. The protocol for a randomised controlled non-inferiority trial using 
both approaches is presented. Trial participant interviews suggest that reduction methods are 
feasible and may have more enduring popularity than abrupt quitting, providing further 
support for this approach. Accounts also suggest potential mechanisms of preloading, 
although a literature review provided little evidence of these. Further research should establish 
the effect of preloading, its mechanisms of action, and the best way to advise smokers to 
reduce. 
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  CHAPTER 1: INTRODUCTION 
 
 
1 
CHAPTER 1: INTRODUCTION TO THE THESIS 
 
1.1  Prevalence and predictions  
Since 1970, when around 55% of the population smoked cigarettes, the prevalence of 
smoking in adults, in England, has been reducing (Cancer Research UK 2011). Between 1980 
and 2009 it decreased from 39% to 21% (Office for National Statistics 2011) (Figure 1).  
 
In February 2010 the Department of Health (DoH) published its new tobacco control strategy 
for England (Department of Health 2010).  One of the goals stated is to reduce adult smoking 
prevalence to 10% or less by 2020, which it claims will reduce hospital admissions due to 
smoking related illnesses by over 50,000 each year and save over 400,000 lives. 
 
The DoH will assess whether this goal has been achieved using figures from the Office for 
National Statistics annual Integrated Household Survey.  This survey is made up of a number 
of questionnaires, including the General Lifestyle Survey. This contains questions about 
smoking behaviour, which are used to establish prevalence (Office for National Statistics 
2010). At the time of writing the most up to date smoking prevalence data available from this 
survey is the 21% recorded in 2009. Therefore at least an 11% decline would be required to 
meet this target.  The DoH admit that to achieve this the decline will need to be among the 
best in the world (Department of Health 2010). Norway achieved a decline of over 1% per 
year from 2000-2010 that has been attributed to public health measures to prohibit the 
advertising of tobacco, health warnings on cigarette packets and a ban on smoking in indoor 
public spaces (Statistics Norway 2011). These have all also taken place in the UK, however  
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Figure 1: Adult smoking prevalence in England from the General Lifestyle Survey 1980 
to 2009 (Office for National Statistics 2011) 
 
unlike the UK the use of snus (moist smokeless tobacco placed inside the mouth, under the 
lip) is common in Norway and is rising in young people; so that now 25% of men from the 
age of 16-24 use it daily (Statistics Norway 2011). This suggests that the decline in cigarette 
smoking is due, to some extent, to the substitution of cigarettes for this less harmful tobacco 
product (Foulds et al. 2003). However snus is illegal in the European Union, as despite posing 
a reduced risk in comparison to cigarettes it is still classed as a carcinogen and outside of 
regulation (Gray 2005), and so is currently unlikely to be used as part of a public health 
strategy in the UK. Therefore reducing smoking to the extent suggested by the DoH may be a 
challenge and in order to reach this target tobacco control will need to be prioritised. 
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To make a rough estimate of how prevalent smoking may be in the future we carried out a 
projection analysis using existing prevalence data from the General Lifestyle Survey 2003 to 
2009 (Office for National Statistics 2011). We did this by carrying out a regression analysis 
on the existing data, and using the resulting formula to calculate an estimate of prevalence in 
2020. This analysis can provide only a crude estimate, as it does not account for short-term 
fluctuations in prevalence. This could only be accounted for by a times series analysis; 
however analysis such as this is beyond the scope of the introduction of this thesis. We strive 
only to provide a rough idea of the trend in prevalence, and how this may impact on future 
rates if this continues, using methods that have previously been used in the field (West 2010). 
Based on our analysis we predict that, based on the previous rate of decline, in 2020 12% of 
adults in England will be smokers (Figure 2).  
 
Figure 2: A forecast of adult smoking prevalence rates in England up to 2020 based on 
actual rates from the General Lifestyle Survey 2003 to 2009 (Office for National 
Statistics 2011).  
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Therefore using current practice and at the current rate of decline it looks like it will not be 
possible to reach the DoH’s target. In addition, it could become progressively harder to 
achieve a reduction in smoking prevalence as time goes on. As more people quit it is likely 
that the smokers remaining will be those that do not wish to quit or have found it hardest in 
the past (Hughes 2011). Another smoking prevalence survey (The English Smoking Toolkit 
Study (STS), which has taken monthly reports of smoking prevalence up to as recently as 
September 2010, also shows that in more recent times (September 2008 to September 2010) 
the rate of the decline has diminished and remained relatively stable (West 2010); so that 
forecasts based on these data (calculated as outlined above) predict prevalence will have 
dropped to only 16% in 2020 (Figure 3). 
 
Figure 3: A forecast of adult smoking prevalence rates in England up to September 
2020, based on actual rates from the Smoking Toolkit Study from September 2008 to 
September 2010 (West 2010) 
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Robert West created and carries out the STS and has hypothesised that this change in the rate 
of decline may be due to the global economic recession (Roberts 2010), which began in 2008 
(Baldwin 2009). This is supported by a survey, which found that smokers do not see financial 
problems as a reason to quit; they would rather continue to smoke to help them cope with 
stress, and cut back on other spending during these times (West 2009). During a recession 
there are several causes of stress, such as unemployment, a reduction in wages and decreased 
job stability; as well as cutbacks in community and health services.  
 
In the light of these obstacles to reaching the DoH target it is important to consider new ways 
to reduce smoking prevalence. Smoking prevalence is a function of both the rate of uptake of 
smoking by young people (the inflow) and the number of smokers who successfully quit (the 
outflow). The focus of this thesis shall be on increasing the outflow. There are three main 
ways that this could be addressed: 
 
1) By increasing the number of smokers who wish to quit smoking; 
2) Increasing the number of smokers who access treatment services to quit, as these 
services result in higher quit rates than unsupported quit attempts (Section 1.3); and 
3) Improving the services available to aid a smoker to quit. 
 
The following outlines ways that the third objective could be achieved, thereby perhaps 
indirectly contributing to objectives 1) and 2); the availability of new, potentially more 
effective treatment services may increase both a smoker’s motivation to quit and the 
likelihood that they will access these services to do so. The first suggestion is the introduction 
of a completely new intervention- reducing smoking to quit- into the UK National Health 
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Service (NHS) Stop Smoking Services (SSS), and the second is to endeavour to increase the 
efficacy of nicotine replacement therapy (NRT) by implementing its use before quit day, as 
well as after (nicotine preloading). According to anecdotal evidence both of these methods are 
already being used tentatively by some individuals, outside and inside the NHS SSS. 
Therefore formal investigation is needed to see whether they do offer a benefit, and as a result 
whether they should be recommended to smokers, and rolled out across the entire NHS SSS.  
 
1.2 Using the neural mechanisms of addiction to inform treatment 
One of the primary motivators for suggesting these two interventions relates to the 
neurobiological mechanisms thought to underlie nicotine addiction, and the ways that these 
could be capitalised upon to aid and maintain abstinence.   
 
1.2.1 The neurobiology of nicotine addiction 
One of the key neural pathways thought to be responsible for the addictive properties of most 
drugs of dependence, including nicotine, is the mesolimbic dopamine (DA) system. 
Experiments with animals have found that when electrodes are inserted into dopaminergic 
pathways in their brains, they will learn to stimulate these through lever pressing. This lever 
pressing is reduced if the animals are also treated with nicotine, as less is required to achieve 
reinforcement (Bozarth et al.1998).  
 
When inhaled the nicotine in cigarettes acts on the mesolimbic dopaminergic reward system. 
It does this by binding with acetylcholine receptors (AChR) on dopaminergic neurones in the 
ventral tegmental area, leading to the release of DA in the nucleus accumbens (NA) 
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(Cummings & Hyland 2005). Experimental evidence suggests that repeated exposure to 
nicotine results in neuroadaptation, and a sensitisation to its effects, leading to an overflow of 
DA in the NA (Benwell & Balfour 1992).  Although these effects have been associated with 
reward and thus the reinforcement of smoking behaviour, the reinforcing psychological 
effects of nicotine are subtle when compared with other drugs of dependence. Therefore, these 
effects of nicotine do not seem to reflect the difficulty that many smokers have attaining and 
maintaining abstinence (Caggiula et al. 2001). This suggests that other factors contribute. 
Balfour (2009) has hypothesised that there are two routes to dependence on nicotine, 
facilitated through the overflow of DA in the NA. The NA incorporates two structural 
subdivisions: 1) the core, and 2) the shell. Balfour hypothesises that it is DA overflow in the 
shell that results in reward and thus leads to drug seeking in the pursuit of pleasure (as 
outlined above); whilst DA overflow in the core plays a complementary role. This is 
supported by evidence that when food (Hall et al. 2001) and cocaine (Ito et al. 2004) rewards 
are provided as a result of responses to a co-presented, conditioned stimulus, lesions of 
neurones in the core of the NA have been found to reduce the number of responses to the 
stimulus. Evidence such as this is not available specifically for nicotine; however Goldberg et 
al. (1981) found that squirrel monkeys responded significantly more to intravenous nicotine 
when visual stimuli were also presented. These studies suggest that sensory stimuli play an 
important role in drug addiction. This is supported by Rose et al.’s (1993) findings that 
humans regulate their smoking behaviour to maximise the sensory intensity of cigarettes, 
rather than primarily to maximise nicotine intake. Balfour (2009) suggests that this 
mechanism will enhance drug seeking behaviour in response to stimuli or cues associated 
with nicotine administration, which may explain cue-induced urges to smoke during 
abstinence (Miranda Jr. et al. 2008; Liu et al. 2010). There is evidence that urges such as these 
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are likely to lead to lapsing and relapse (Abrams et al. 1988, Doherty et al. 1995; Killen & 
Fortnum 1997). 
 
Another way that nicotine is thought to exert its effects to ensure continuation of use is 
through the aversive abstinence syndrome (Balfour 2009). Kenny & Markou (2001) have 
theorised that when an individual stops taking a drug this may lead to a decrease in the 
overflow of DA in the NA, and that it is this decrease which mediates the aversive abstinence 
syndrome.  However they are only able to speculate about the exact nature of this mediation. 
Some withdrawal symptoms commonly experienced as a result of the nicotine abstinence 
syndrome are irritability, restlessness, difficulty concentrating, impaired task performance, 
anxiety, hunger, weight gain, sleep disturbance, cravings and drowsiness (American 
Psychiatric Association 1994).  Therefore it has been suggested that many smokers continue 
smoking to avoid these negative effects of abstinence (Balfour & Fagerstrom 1996). If this is 
the case then even if smoking abstinence were attempted the experience of these withdrawal 
symptoms may be enough to drive an individual to return to smoking. 
 
For a more detailed discussion of the mechanisms of nicotine addiction highlighted here see 
Balfour (2009). 
    
1.2.2 The potential effects of smoking reduction on neural mechanisms to 
facilitate and maintain abstinence  
There appears to be two ways that reducing smoking before quitting could influence the 
neural mechanisms above, and therefore improve the likelihood of abstinence. The first is 
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based on the aforementioned neuroadaptation in the form of up-regulation of nicotinic AChR, 
and sensitisation of DA pathways. If neuroadaptation to high doses of nicotine has occurred, 
then neuroadaptation in the reverse direction may occur in response to reducing doses of 
nicotine.  Once abstinence is attempted, this may reduce craving and withdrawal symptoms. 
Benowitz & Henningfield (1994) suggested that it would be good public policy to mandate a 
gradual reduction in the nicotine content of cigarettes.  To support this proposal Benowitz et 
al. (2007) tested the feasibility of the approach with 20 participants, and found that after a 
reduction in nicotine content over six weeks 25% of participants had spontaneously quit 
smoking four weeks later, and those participants who had returned to their usual brand of 
cigarettes were smoking fewer, suggesting lower levels of dependence.  However these results 
are preliminary and should be treated with caution. Due to the lack of a control group it is 
difficult to tell whether the observed cessation/reduction was as a result of the reduction in 
nicotine content or other factors, such as general participation in a smoking intervention or the 
switch to cigarettes of a different brand.  
 
Benowitz and Henningfield (1994) also observed that smokers known as chippers, who 
smoke five or fewer cigarettes per day (cpd), appear not to be as dependent as heavier 
smokers. They do not seem to experience withdrawal symptoms and can avoid smoking for 
long periods without emotional distress. However, as Henningfield et al. (1998) also 
recognise, due to the neuroadaptation that is likely to have occurred, we cannot assume that 
the low levels of nicotine, to which chippers are exposed, would not be addictive to smokers 
who have been exposed to higher doses of nicotine in the past. Nevertheless, a study 
investigating the use of a nicotine conjugate vaccine, which has been found to reduce the 
distribution of nicotine to the brain (Hieda et al. 1999; Pentel et al. 2000; Cerny et al. 2002; 
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Lindblom et al. 2002; Meijler et al. 2003; Sanderson et al. 2003), found that rats trained to 
self-administer nicotine and given the vaccine were less likely to maintain self-administration 
than controls (LeSage et al. 2006). This suggests that a reduction in the dose of nicotine 
received could reduce dependence in smokers who have previously received higher doses. 
Further research in humans, examining the specific effects of reducing cpd on the neural 
mechanisms of addiction and markers of dependence would be beneficial.   
 
The second reason that smoking reduction may aid quitting is based on Balfour’s (2009) 
hypothesis that DA overflow in the core of the NA leads to conditioned relationships between 
environmental stimuli and smoking. Smoking reduction is likely to lead to a deconditioning of 
some of these relationships; as, at least in some cases, smoking will not take place when 
environmental stimuli create the urge to do so. Some smoking reduction methods have been 
specifically designed with this in mind. For example, Cinciripini et al. (1995) asked smokers 
to reduce their smoking before quitting using the inter-cigarette interval (ICI) method. Using 
this method the time in the day is divided by the number of cpd smoked at baseline, giving the 
baseline ICI. Over the reduction period this interval is gradually lengthened, so that less 
cigarettes are smoked each day.  Smoking on a schedule, such as this, means that smokers are 
unlikely to ever be smoking in response to the environmental cues that would usually trigger 
their smoking, thus breaking the association between the stimuli and the behaviour.  If all 
associations are broken in this way prior to the quit day, then the appearance of these cues 
when abstinent is unlikely to result in an urge to smoke, which should in turn reduce the 
likelihood of relapse.   
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1.2.3 The potential effects of nicotine preloading on neural mechanisms to 
facilitate and maintain abstinence   
The nicotine present in NRT acts as an agonist by binding to the same AChR as the nicotine 
present in tobacco smoke.  When NRT is administered after all smoking has ceased abruptly 
then the aim is to ameliorate withdrawal (Balfour & Fagerstrom 1996). However, using NRT 
in this way means that the learned associations between smoking cues and the reward 
experienced from smoking will still exist on the quit day; for example, as a result of usually 
smoking when drinking a cup of tea or coffee the smoker may still feel the urge to smoke 
when they drink tea or coffee post-quit. By using NRT in parallel to smoking before quitting 
(preloading), an attempt can be made to break these associations before the smoker stops 
smoking altogether (as suggested in Section 1.2.2), making it easier to manage their cravings 
post-quit (Hajek 2006). 
 
Evidence suggests that depending on the type of NRT preparation AChR are activated or 
desensitised by the nicotine they deliver (Balfour 1994). Faster acting forms of NRT such as 
gum and nasal spray, most closely mimic the nicotine delivery of cigarettes, are more likely to 
mirror directly the effects of smoking, and so activate receptors. As nicotine patches are 
typically worn for 16-24 hours a day they provide a constant low stream of nicotine which 
keep nicotine levels constant and are more likely to desensitise nicotinic receptors.  This 
means that receptors cannot respond to exogenous nicotine and this will undermine reward 
and reinforcement of smoking (Balfour 1994). This is likely to decondition the relationship 
between smoking cues and the smoking behaviour. If acute NRT is being used to preload (for 
example, if smoking is also reduced pre-quit) an urge to smoke can be partly satiated with the 
use of NRT rather than smoking a cigarette. This means the reinforcement in response to 
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nicotine should still be present, but the link between the smoking cue and smoking behaviour 
should weaken. This could lead to a fear that the smoker will become addicted to the NRT 
itself, however despite acute NRT mimicking the effects of cigarette smoking more closely 
than patches, nicotine is still delivered at a much slower rate than through smoking, and so 
does not have the same abuse potential (Balfour et al. 2000). 
 
The theories and evidence from non-human animal studies described above argue that 
smoking reduction and nicotine preloading could be effective treatments for nicotine 
addiction, and therefore that their adoption by the NHS SSS may be beneficial. In the 
following sections I shall present further evidence to suggest that this is the case, and identify 
where further research is necessary.  
 
1.3 Current smoking cessation services 
In response to the DoH’s White paper- Smoking Kills (1998) NHS SSS were implemented for 
the first time in 1999; firstly in those areas with greatest deprivation (Health Action Zones) 
and later across the whole of the UK. In 2009 the DoH aimed to optimise and ensure the 
quality of the support available through these services by commissioning the NHS Centre for 
Smoking Cessation and Training (NCSCT), led by University College London, to support the 
NHS SSS by developing training standards and delivering accredited smoking cessation 
training (NCSCT 2010a). As a result the NCSCT have produced a Standard Treatment 
Programme, which reflects the current accepted and evidence-based practice for cessation 
advisors in the NHS (NCSCT 2010b). Some of the key features of these guidelines are: 
 
  CHAPTER 1: INTRODUCTION 
 
 
13 
 The NHS SSS treatment programme is six to seven weeks, but can vary across 
services; 
 Weekly contact between the service and the client is extremely important for the full 
duration of the course of smoking cessation support; 
 The NHS SSS support smokers to stop smoking completely and abruptly, and not to 
cut down smoking before quitting; 
 A quit date is set through agreement between the smoker and the practitioner, usually 
one to two weeks after the first appointment with the service; 
 The ‘not a puff rule’- the client is informed that stopping smoking through the service 
involves a rule of not smoking even one puff after their quit date; 
 Regular carbon monoxide (CO) monitoring to measure the amount of CO (a by-
product of smoking) in the client’s blood; 
 The discussion of withdrawal symptoms and cravings to smoke and how these can be 
dealt with; 
 The identification and discussion of strategies to counteract any potential high risk 
situations which could arise and compromise the quit attempt; 
 Prompting a commitment from the client to quit smoking; 
 The provision of information about and medication to aid smoking cessation, in the 
form of NRT, varenicline or buproprion. 
 
Based on data from the STS (West 2010), using the NHS SSS in partnership with smoking 
cessation medication appears more successful than medication on prescription (Rx) or over-
the-counter (OTC) alone, and was almost four times more effective than no medication or 
support in assisting smokers to quit during 2009/2010. However over the same time period 
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the number of quit attempts by smokers, supported by attendance of these services was very 
low (2%), with 52% of quit attempts carried out with no support, 31% supported by over-the-
counter NRT, and 15% using cessation medication on prescription. As using the NHS SSS 
results in higher quit rates than not, in the interest of raising quit rates overall, it would be 
beneficial to increase the number of smokers who approach the NHS SSS for help.  
 
1.4  Improving the reach of the NHS SSS 
Abrupt quitting is the only behavioural approach to smoking cessation treatment available 
through the NHS. The SSS are now encountering a number of individuals who have been 
through this same system a number of times without success.  It would not be surprising if 
these individuals were disillusioned with the approach and therefore unenthusiastic about 
using it again. Nevertheless surveys suggest that the majority of smokers who use the NHS 
SSS are both satisfied with the service and willing to recommend it to others (May et al. 2009; 
May & McEwen 2011). However these participants may not consider that reduction is an 
option, and so responses may not take into account the possibility of an alternative treatment. 
In any case even if users do continue to use the SSS it seems nonsensical to keep providing 
the same treatment to people who it has not worked for in the past. Providing an alternative 
behavioural treatment to abrupt quitting, and therefore offering smokers a menu of quitting 
options may improve the appeal of the NHS SSS. 
 
1.4.1  Interest in gradual cessation 
The STS has found that although the NHS SSS advise that people stop smoking abruptly only 
61% of those smokers who make a quit attempt actually do it in this way; 39% quit gradually 
  CHAPTER 1: INTRODUCTION 
 
 
15 
by reducing first (West 2008). Additionally Hughes and colleagues found, using surveys 
carried out in the US, that significantly more smokers were interested in gradual than abrupt 
cessation (Hughes et al. 2006), and that those who chose gradual cessation were as motivated 
to stop and as confident of success in their quit attempt as those who chose abrupt cessation 
(Hughes 2007). This suggests that there is a demand for gradual cessation services that is not 
being fulfilled by the NHS SSS, and as a result that there is a pool of smokers who are 
unlikely to seek treatment, but who may do so if gradual reduction were offered.  The best 
proof for this untapped demand would be to conduct a trial advertising these services within 
the NHS SSS, and to monitor the effects of this on uptake to the services. However to do this 
now would be premature; it is important that we first establish the efficacy of the method, 
particularly in the light of previous fears about its use. 
 
1.4.2 Reluctance to adopt gradual cessation 
In the 1970s, smoking reduction was used as a method to accomplish cessation, and studies 
testing different behavioural interventions were conducted (Levinson et al. 1971; Marston & 
McFall 1971; Katz et al. 1977). However discovery of the central role of nicotine in tobacco 
addiction, and the efficacy of abrupt cessation seemed to have rendered this older literature 
obsolete.  
 
The NHS SSS implementation of the abrupt quitting method is based on the Maudsley 
Hospital’s Smokers Clinic, withdrawal-orientated therapy treatment model (Hajek 1989) and 
is in agreement with National Institute for Health and Clinical Excellence (NICE) 
recommendations (2008). These state that there is not enough evidence available to endorse 
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reducing smoking before quitting, and so gradual quitting should only be used in “properly 
designed and conducted research studies” (p.17). Abrupt quitting is the treatment of choice 
as it is based on the traditional model of addiction, which suggests that smokers are addicted 
to nicotine (as described in Section 1.2.1), that drug addiction is a disorder, and addicts need 
to abstain from all psychoactive drugs for the rest of their lives, or this disease may prove 
fatal (Denning 2002). Therefore treatment begins with discontinuation of drug use before 
dealing with any other concomitant psychological issues.  This is because addicts are believed 
to be unreliable and to have no control over their drug use, making them unable to carry out a 
more complex treatment regimen, such as the reduction of drug use before stopping 
completely.  However, Denning (2002) believes that in reality drug users are no more 
impaired in their ability to adhere to a medical treatment than those who do not use drugs. 
 
Observational studies (Cheong et al. 2007; West & Fidler 2011) have shown that smokers 
who reduce their smoking before quitting are less likely to succeed. One reason for this may 
be that abrupt quitting is by its nature quite a structured straightforward way to quit, providing 
less of a need for behavioural support. Reduction on the other hand offers a lot of potential for 
variation in how it is carried out and perhaps provides more opportunity to put-off quitting 
altogether. However if a structured behavioural support programme were available it would 
limit the opportunity for this variation and for avoiding the quit day altogether. Thus there 
may be reason to believe that reduction, when offered alongside support and some structure, 
would result in better quit rates, as hypothesised by Cheong et al. (2007).  
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1.4.3 Reduction- a feasible approach to quitting 
There is some evidence to suggest that reducing smoking is a feasible approach to quitting. A 
review by Hughes and Carpenter (2005) found that whereas little spontaneous reduction 
occurs in smokers- offering support for the observational studies (Cheong et al. 2007; West & 
Fidler 2011) - it is possible for a smoker to reduce their smoking and maintain that reduction 
when part of a treatment programme. Evidence was also found that using NRT aids reduction 
more so than placebo (Hughes & Carpenter 2005; Moore et al. 2009). Although some 
compensatory smoking occurred, for example by taking bigger, longer puffs, reduction in CO 
levels still occurred (Hughes & Carpenter (2005). This also supports Denning’s (2002) view - 
that an addict is able to deal with more complex treatment regimens than abrupt stopping 
only.  
 
There has been substantial concern that if a smoker aims to reduce initially rather than stop 
abruptly this could undermine their attempt at complete cessation, as reduction will be seen as 
a favourable alternative (Hatsukami et al. 2004). However there is evidence to suggest this is 
not the case and that reduction actually increases the likelihood of later cessation. In their 
systematic review Hughes & Carpenter (2006) found 19 studies that reported on both changes 
in cpd and whether future cessation had occurred. Participants were smokers who had either 
spontaneously reduced or not in observational studies, or who had been instructed to reduce or 
not in randomised controlled trials (RCTs). None of the 19 studies found that reduction was 
associated with a lower rate of future quitting, and 16 of the studies found that reduction was 
associated with higher rates of later quitting. A more recent review of 10 RCTs by Asfar et al. 
(2011) supports this. All included trials compared either a pharmacological, behavioural or 
combined smoking reduction intervention, in smokers not yet ready to quit, to at least one 
  CHAPTER 1: INTRODUCTION 
 
 
18 
control group, defined as placebo, no treatment, or minimal psychological intervention. Meta-
analysis results for the pharmacological and combined interventions showed that in both cases 
the reduction interventions increased the likelihood of long-term abstinence (six months or 
over).  However there was insufficient evidence available to reach a conclusion as to whether 
behavioural support for reduction alone enhanced future abstinence. 
 
Additionally, as well as the reasons cited earlier regarding manipulation of addiction 
pathways in the brain (Section 1.2.2), there are a number of psychological hypotheses for why 
reduction could help a smoker to stop smoking completely. Firstly, Michie (2009) proposed 
that reducing cigarette consumption provides a goal which is more in-line with the smoker’s 
current behaviour than complete abstinence. Therefore the eventual behavioural change may 
appear more achievable and desirable, encouraging more people to consider quitting in the 
first place. The second hypotheses concerns ’shaping’: a type of operant conditioning. 
Shaping involves making successive approximations of a target behaviour, which are 
positively reinforced, encouraging the desired final behaviour (Skinner 1953). In this case 
gradually quitting individual cigarettes would induce intermittent reinforcement, offering 
encouragement to, and increasing the likelihood of quitting altogether. This links to the final 
hypothesis, relating to the cognitive psychology principle of self-efficacy- a person’s belief in 
their ability to succeed. The positive reinforcement that smokers may experience when 
quitting individual cigarettes could increase their self-efficacy, as they can see that change is 
possible. Increases in self-efficacy such as this are thought to increase the likelihood that the 
final goal- in this case abstinence- will be achieved (Bandura 1977). 
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This evidence suggests that reduction could be a feasible alternative to abrupt quitting within 
treatment services. It could draw more people into the SSS by offering an option which 
appeals to a number of smokers (Section 1.4.1), who may not have had the opportunity to try 
this approach in a supportive context in the past. As a result, and despite scepticism (Section 
1.4.2) there seems to have been some revival in interest in this method and the Medicines and 
Healthcare Regulatory Authority (MHRA), in the UK, have now licensed NRT for use 
alongside smoking reduction regimes, following findings that this is both safe (Moore et al. 
2009) and cost-effective (Wang et al. 2008). 
 
1.5 Making treatment more effective 
1.5.1 The use of pharmacotherapies for smoking cessation 
Of the three types of smoking cessation pharmacotherapy available through the NHS SSS 
(NRT-in the form of gum, lozenge, transdermal patch, nasal spray, inhaler and sublingual 
tablet- varenicline and bupropion), NRT is the most popular (Table 1).  
 
Of smokers seeking assistance through the SSS between April and September 2010 
monitoring reports show 91% received some form of pharmacotherapy, mainly NRT (62%) 
(The NHS Information Centre 2011). Data from the STS assesses the use of medication in 
smokers quitting mainly without NHS SSS support (only 7% of attempts to quit were made 
with their support). Forty-seven percent of total quit attempts made use of pharmacotherapy, 
and this was again predominantly NRT (44%) (West 2008). 
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NRT used post-quit has been found to produce abstinence rates 58% higher than when using 
no medication (Risk Ratio (RR) = 1.58, 95% Confidence Intervals (CI) = 1.50, 1.66) (Stead et 
al. 2008). However if the use of NRT before quit day were also introduced, and had the 
effects hypothesised in Section 1.2.3, then there may be the potential to improve abstinence 
rates further. Nicotine preloading could be used either when quitting abruptly or when 
reducing first, and when using NRT, varenicline or bupropion post-quit.   
 
 
Table 1: The percentage of smokers using different types of pharmacotherapy to 
support their quit attempt: from a sample utilising NHS Stop Smoking Service support, 
and a sample quitting with and without behavioural support 
Type of 
pharmacotherapy  
used 
Smokers quitting 
through NHS SSS (The 
NHS Information 
Centre 2011) 
Smokers quitting 
predominantly  
without NHS SSS support  
(West 2008) 
No 
pharmacotherapy 
 
6% 
 
53% 
NRT   62% 44% (34% OTC, 10% Rx) 
Varenicline   26% 1% 
Bupropion     1% 3% 
NRT & varenicline     1% N/A 
 NRT & bupropion   <1% N/A 
Treatment 
unknown 
    
3% 
 
N/A 
NHS – National Health Service; SSS – Stop Smoking Service; NRT – Nicotine replacement therapy; OTC – over-
the-counter; Rx – on prescription; N/A – option not included in survey. 
 
Both bupropion (Electronic Medicines Compendium 2011a) and varenicline (Electronic 
Medicines Compendium 2011b) are licensed to be taken by smokers for up to two weeks 
before they quit, whilst still smoking.  Current NHS SSS practice is usually to ask smokers to 
begin taking either medication one week before their scheduled quit day; however when using 
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NRT clients start using their chosen application on quit day and do not smoke whilst doing so 
(NCSCT 2010b).  Historically there have been two reasons for this: 
 
1) Smoking just one puff after quit day can sabotage the maintenance of abstinence 
(Kenford et al. 1994), and 
2) Rose et al. (2006) notes that smoking whilst using NRT has been feared to lead to 
health problems. In particular, a telephone survey carried out in smokers in the US 
found this to be the case (Bansal et al. 2004). .  
 
1.5.2 The safety of concomitant smoking and use of NRT 
There has been no evidence of nicotine overdose when nicotine intake has been moderately 
increased (Stead et al. 2008; Moore et al. 2009), and a review by Fagerstrom & Hughes 
(2002), assessing the safety of using cigarettes and NRT concurrently found that although in 
some cases using nicotine patch and smoking raised nicotine concentrations to two to three 
times their usual level, this was accompanied by few and mild adverse effects. This 
favourable safety profile means NRT is now licensed for use whilst smoking, as part of harm 
reduction strategy. In 2010 the MHRA announced that it had extended the license of the 
nicotine inhalator, in response to a request, to include a harm reduction element (MHRA 
2009). Therefore the following is now included in the product information:  
 
 “Nicorette Inhalator relieves and/or prevents craving and nicotine withdrawal symptoms 
associated with tobacco dependence. It is indicated to aid smokers wishing to quit or reduce 
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prior to quitting, to assist smokers who are unwilling or unable to smoke, and as a safer 
alternative to smoking for smokers and those around them.” (MHRA 2009; p. 5) 
 
The Commission on Human Medicines Working Group, who made this decision, also 
recommended that this harm reduction element was appropriate for all the other authorised 
forms of NRT, suggesting that if the manufacturers were to request that the indications of 
their products be changed to include this then it would most likely be granted. Additionally, 
as previously mentioned in Section 1.4.3., the Summary of Product Characteristics’ (SPC) for 
all of the current forms of NRT (gum (Electronic Medicines Compendium 2010a), patch 
(Electronic Medicines Compendium 2010b), lozenge (Electronic Medicines Compendium 
2010c) inhalator (Electronic Medicines Compendium 2010d) and microtab (Electronic 
Medicines Compendium 2009a), apart from the nasal spray (Electronic Medicines 
Compendium 2009b), carry instructions on how to use the products, both when quitting 
abruptly or when quitting gradually. 
 
1.5.3 Preloading as aversion therapy 
As well as the possible motivations for preloading treatment referred to in Section 1.2.3, it has 
also been suggested that preloading could work by making smoking less attractive, with an 
aim to extinguish the behaviour (Hajek 2006).  Rapid smoking is an aversion technique that 
was used largely in studies in the 1970s and 1980s and involved asking participants to puff on 
a cigarette every 6-10 seconds. Smoking in this way leads to a rapid rise in blood nicotine 
concentration and generally results in unpleasant sensations, such as nausea, and participants 
were asked to concentrate on these (Hajek & Stead 2010).  It is possible that preloading could 
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invoke similar feelings and experiences as it could also substantially increase nicotine 
concentrations in the body (Fagerstrom & Hughes 2002).  A Cochrane Review investigated 
the effects of rapid smoking in comparison to a control of either inactive treatment matched 
for therapist contact, or active treatment of a different type or severity, and summarised that 
the positive results obtained could not be used to strongly conclude that rapid smoking was 
beneficial in smoking cessation, due to methodological flaws of the included studies (Hajek & 
Stead 2010). However the results were promising and further investigation is needed.  Using a 
method such as rapid smoking is unlikely to be very popular with health services at the 
current time. Firstly, because smoking in enclosed public places is illegal, and therefore 
asking smokers to smoke rapidly in a clinic is out of the question, and secondly, it would 
involve asking smokers to smoke more when we know that smoking is damaging to health. 
However it may be possible to implement this aversive principle in a legal and safe way, 
deemed more acceptable to the health service, using preloading.  
 
1.5.4 Acclimatisation to NRT 
A final reason why preloading may improve abstinence rates in smokers who wish to use 
NRT post-quit day is that it could acclimatise quitters to the use of NRT (Hajek 2006; 
Shiffman & Ferguson 2008; Bullen et al. 2010). This may mean that by the time they reach 
their quit day quitters will have have got used to the taste (in the case of acute NRT) and side 
effects of NRT, will have increased confidence in its effects, and so feel comfortable with 
using it and have ironed out any initial problems; therefore using it effectively to maximise 
success. If this is the case then even if previously mentioned theories as to why preloading 
could be successful (Section 1.2.3 & Section 1.5.3) are not supported then efficacy could be 
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increased indirectly by improving post-quit adherence to treatment.  However any benefit 
would most likely be greater in smokers who have not used NRT previously. Previous users 
are already likely to have at least an idea of how to use NRT and what works best for them 
from previous attempts. 
 
1.5.5 Preloading- evidence of efficacy 
Theories that preloading could make smoking less rewarding and less attractive are supported 
by evidence that smokers spontaneously reduce their smoking behaviour (Bolliger et al. 2000; 
Fagerstrom et al. 2000), and rate cigarettes as less rewarding when using NRT (Levin et al. 
1993; Rose at al. 1994; Rose & Behm 2004).  
 
Two meta-analyses have estimated the overall effect of nicotine preloading on abstinence 
rates in smokers trying to quit (Shiffman & Ferguson 2008; Stead et al. 2008). The studies 
included in both reviews compared smokers preloading with nicotine patches, for two to four 
weeks pre-quit, with smokers using a placebo pre-quit or starting NRT on their quit day.  
They both found a significant favourable effect of preloading with a nicotine patch. Shiffman 
and Ferguson’s (2008) analysis resulted in odds ratios (OR) of 1.96 (95% CI= 1.31, 2.93) for 
6 weeks abstinence, and of 2.17 (95% CI= 1.46, 3.22) for 6 months, and Stead et al.’s (2008) 
produced a RR of 1.79 (95% CI= 1.17, 2.72) for long-term abstinence (6 or 12 month). These 
results are promising, however both of the reviews failed to include an available study (Rose 
et al. 1994 in the case of Shiffman & Ferguson 2008; Rose et al. 2009- for which only short-
term data were available at the time of the review (Rose et al. 2007)- in the case of Stead et al. 
2008), and neither review included any studies that utilised acute forms of NRT for 
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preloading, such as gum or nasal spray, or investigated the possible mechanisms by which 
preloading may have its effects. Also since they were conducted further data has become 
available meaning these efficacy estimates are now outdated (Etter et al. 2009; Bullen et al. 
2010; Hughes et al. 2010). 
 
1.6  Plan of the thesis 
In order to achieve national targets for smoking prevalence it may be important to focus on 
two new strategies to increase rates of smoking cessation.  Neurobiological addiction theory 
and the way that associated neural pathways could be manipulated to aid and maintain 
cessation suggest that both smoking reduction to quit and nicotine preloading could improve 
abstinence; both directly as aids to cessation, and indirectly by drawing into treatment those 
who would not otherwise have used treatment services. As quit attempts through the SSS 
result in higher success rates, this could lead to higher population level quit rates.  
 
Anecdotal evidence suggests that some advisors within the NHS SSS already support clients 
to use these methods, and that smokers may be trying these things themselves outside of the 
service. Therefore we need to ascertain whether these approaches are beneficial or whether 
they may be less effective than the treatments already available.  As well as looking at quit 
rates, it is important to look at the experiences of smokers who use these methods to ascertain 
the optimal way to implement them and to show whether and how they would be used if 
provided. Using these experiences we may also be able to gain insights into the potential 
mechanisms of action of the methods. These are the objectives of this thesis. 
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Chapter 2 is the published research protocol (Lindson et al. 2009a; Appendix 1) for the Rapid 
Reduction Trial (RRT) - a non-inferiority RCT- developed to compare the success of a 
reduction to quit smoking method and abrupt quitting. Participants in the reduction arm of the 
study are able to choose one of three different ways to reduce their smoking, and participants 
in both arms use NRT for two weeks prior to their quit date.  This protocol was developed 
when there was strong evidence for the efficacy of preloading (Shiffman & Ferguson 2008; 
Stead et al. 2008), which is why the decision was made to implement preloading in both arms; 
however since then further evidence has to come to light on this subject, which is the topic of 
Chapter 4. Although the quantitative results of this trial are not the subject of this thesis, as 
these are not yet available, the results of the qualitative interviews conducted with trial 
participants are the subject of Chapter 5. Therefore the inclusion of Chapter 2 provides the 
context for these results. The interview element of the trial, and the resulting amendment to 
the trial protocol, was added after the initial publication of the protocol. This was as a result of 
my attendance at the UK Society for Behavioural Medicine (UKSBM) conference 2009, 
hosted by the University of Southampton, where a large emphasis was placed on the 
importance of user input in successful intervention development (for example Anderson 2009; 
Miller et al. 2009; Morrison et al. 2009). As noted in the acknowledgements of this thesis this 
Chapter was the result of collaborative work.  My role was to adapt the basic trial proposal- 
developed by Paul Aveyard- into a full trial protocol, suitable for submission to regulatory 
authorities and for publication. The sections describing the RRT interview study were the 
result of my own original idea. I also developed trial documents to support the protocol, and 
applied for and obtained regulatory approvals.   
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Chapter 3 outlines and implements further methods to investigate the efficacy of reduction to 
quit methods when compared to abrupt quitting; including a published systematic review of 
the literature (Lindson et al. 2010; Appendix 2) to identify all of the RCTs relevant for 
inclusion, and a meta-analysis to combine these data to estimate an overall treatment effect.  
The review was carried out on behalf of the Cochrane Collaboration and therefore conforms 
to the standards of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 
& Green 2009) and the Tobacco Addiction Group. This review was a collaborative work 
inspired by and building on the literature review carried out to develop the RRT protocol, 
reported in Chapter 2 (Section 2.1.1). My role was to develop the review protocol, identify 
and collect literature, conduct study eligibility assessment, extract data, assess risk of bias, 
conduct analyses and to draft the manuscript for publication. 
 
The published literature review and meta-analysis (Lindson & Aveyard 2011a; Appendix 3) 
reported in Chapter 4 utilises similar methodology to that used in Chapter 3. Quit rates 
achieved when nicotine preloading is used by smokers prior to a quit day is compared to 
placebo treatment or starting NRT use on the quit day. Due to the availability of substantial 
additional data this updates previous reviews of the literature (Shiffman & Ferguson 2008; 
Stead et al. 2008), that have found a significant positive effect of preloading, and also goes 
further than the existing reviews by separating the studies in terms of the type of NRT used, 
and by investigating the mechanisms by which preloading may have its effects. Chapter 4 also 
includes our response (Lindson & Aveyard 2011b; Appendix 4) to a Letter to the Editors 
(Rose 2011) inspired by our review. This review was carried out to update previous reviews, 
to support a funding application for a new trial of nicotine preloading commissioned by the 
NIHR.  My role was to develop a search strategy, identify and collect literature not included 
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in the original reviews, conduct study eligibility assessment, extract data, assess risk of bias, 
conduct analyses, draft the manuscript for publication, and draft the response to Rose’s (2011) 
letter. 
 
Chapter 5 builds on Chapters 3 and 4 by assessing the experiences of the RRT trial’s 
(described in Chapter 2) participants, when using the behavioural abrupt or reduction to quit 
methods, and preloading. I feel that it is important to gain insight into the perspectives of the 
individuals taking part in these interventions, as when deciding to implement an intervention 
it is important not only to take into account whether these are successful in controlled 
circumstances, but whether people would be likely to use and remain engaged with that 
intervention throughout the entire programme, if it were available. The efficacy of a treatment 
is irrelevant if people will not enrol onto the programme in the first instance. By asking 
participants directly it is possible to gain sometimes unexpected insights into why an 
intervention may or may not be successful beyond that which could be achieved through 
examining quantitative data. As mentioned above this collaborative work was the result of my 
idea outlined in Chapter 2. My role was to design the study, create study documents, identify, 
contact and interview participants, arrange transcription, carry out analyses, identify 
exemplary quotations, and draft the manuscript. 
 
Finally Chapter 6 discusses the findings presented in the previous Chapters, drawing them 
together and relating them back to the original objectives of the thesis. Based on this, 
conclusions are drawn about the potential impact of the results on future policy and practice in 
the field of smoking cessation, and how future research could be carried out to build on these. 
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The Chapters in this thesis are ordered chronologically, based on the emergence of research 
findings and resulting ideas over a period of time. It may seem logical that the description of 
the new RCT (RRT; Chapter 2) should come after the literature reviews and meta-analyses of 
the existing studies (Chapters 3 and 4); however when the protocol was developed the reviews 
had not been carried out, and so trial justification and design decisions were not based on 
these, but a more informal non-systematic review of the literature (Section 2.1.1).  
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CHAPTER 2: RAPID REDUCTION VERSUS ABRUPT 
QUITTING FOR SMOKERS WHO WANT TO STOP SOON: A 
RANDOMISED CONTROLLED NON-INFERIORITY TRIAL 
 
2.1 Background 
Without help, most smokers who try to stop smoking relapse within one week and only 4% of 
quit attempts sustain abstinence for one year (Hughes et al. 2004). The NHS SSS achieve 
around 15% one year abstinence (Ferguson et al. 2005), and NHS support in primary care 
achieves around 7% one year prolonged abstinence (Aveyard et al. 2007). Thus, while 
treatment improves substantially the number who achieve abstinence, whatever method of 
stopping is used, return to smoking is the norm for the majority, and even with treatment the 
majority of relapsers resume smoking during active treatment. Thus there are a cadre of 
patients who have been through treatment services many times. Currently, as addressed in 
Section 1.4, the NHS gives the same treatment on repeated attempts to stop as on the first 
attempt- abrupt quitting. Patients can choose different pharmacotherapies, but in other 
respects, the treatment is the same every time. As previously mentioned in Chapter 1 there are 
principles that suggest that reducing smoking before quitting might be as, if not more, 
effective than abrupt cessation, and could provide a new option for those who have failed to 
quit abruptly in the past. These include, setting a goal more in keeping with current behaviour, 
the cognitive psychology self-efficacy principle, decreasing the association between 
environmental cues and behaviour, and reducing biological dependence by lowering the dose 
of nicotine an individual receives.  In addition, smokers feel that cutting down is an 
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appropriate way to stop smoking. However, before a programme such as this is introduced it 
is important to ensure it is at least as effective as abrupt quitting, otherwise smokers may 
choose to reduce who would otherwise have quit abruptly, putting themselves at a 
disadvantage. 
 
2.1.1 Literature Review 
We conducted a search to find randomised trials comparing gradual to abrupt cessation using 
MEDLINE, Google Scholar, PsychINFO, Society for Research on Nicotine and Tobacco 
(SRNT) abstract search, a citation search, and contact with key authors.  
 
Identified trials (with relevant data) all resulted in RRs with CIs spanning one for 6 or 12 
month abstinence (Flaxman 1978; Cummings et al. 1988; Gunther et al, 1992; Cinciripini et 
al. 1995), suggesting that neither abrupt quitting or reducing smoking to quit resulted in 
superior quit rates in any of the studies. Cinciripini et al. (2006) have recently completed a 
three arm study with participants randomised to cutting down with nicotine patch, nicotine 
patch pre-cessation treatment without reduction, or usual post-cessation patch only. The 
results are unpublished, but preliminary data show improved cessation for the reduction arm 
at four weeks, with no evidence of difference at six months. The reduction arm had lower 
craving, fewer lapses, and less negative affect (personal communication). These studies are 
reviewed in more detail in Chapter 3. 
 
A second group of studies have led to a new use for NRT as an aid to gradual cessation in a 
programme called Cut Down Then Stop (CDTS). Critically, the CDTS trials enrolled smokers 
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who wanted to reduce their smoking but did not intend to stop it in the next one or six months. 
They were randomised to either NRT (used in acute and patch preparations) or placebo. The 
treatment programme gives NRT over six to nine months for reduction and for a further three 
months post-cessation. The CDTS NRT programme led to improvements in six month 
prolonged abstinence over placebo (7% versus 3%), with an RR (95% CI) of 2.06 (1.34, 3.15) 
(Wang et al. 2008). Six months prolonged abstinence is a standard accepted for evidence of 
effectiveness in smoking cessation (West et al. 2005). Half of those who sustain abstinence 
for six months remain abstinent for their whole lives (Etter & Stapleton 2006). These 
cessation rates are lower than those achieved by the NHS SSS (Ferguson et al. 2005); 
however the key point is that these were rates achieved in smokers who said that they did not 
intend or want to stop imminently (and who were on average highly addicted). It is possible 
that the differing intentions of smokers enrolled in CDTS trials and those that use the abrupt 
quitting method offered by the NHS explain the difference in prolonged abstinence rates. The 
CDTS studies demonstrate that reduction with NRT is more effective than without, but cannot 
show whether reduction or abrupt cessation is more effective. The positive effect of pre-quit 
nicotine patch found in the CDTS trials has also been discovered in trials utilising the abrupt 
method of cessation, as outlined in Section 1.5.5. However, two studies using nicotine gum 
pre-quit, for four days and four weeks respectively, have appeared to show less of an effect 
(Herrera et al. 1995; Etter et al. 2009).  
 
There is evidence that reduction should be much more rapid than used in the CDTS trials. In 
one CDTS trial (Haustein 2002) participants were randomised to rapid (four week) versus 
slow reduction (12 month). Despite enrolling people who said they did not intend to stop 
smoking in the next month, rapid reduction outperformed slow reduction at all follow-ups. In 
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addition, a pilot study randomised 31 smokers, ready to stop, to reduce over two weeks or 
three (Blalock et al. 2003). The quit rates were slightly higher in the two week group and 
qualitative data indicated that rapid reduction helped demarcate the boundary between 
reducing and quitting. Further detail about these trials can be found in Section 5.1.2.1. 
 
The studies comparing rapid reduction with abrupt quitting typically had small sample sizes 
and took place before a common standard had been introduced for both reporting RCTs in 
general (Moher et al. 2001), and carrying out and reporting the results of smoking cessation 
focused trials (West et al. 2005). Little consideration was given to the mechanisms by which 
these methods have their effects, which could provide insight into the best ways to implement 
them, and who they might benefit the most.  Therefore there is a need for a further correctly 
powered trial to compare rapid reduction and abrupt quitting, incorporating the use of pre-quit 
NRT, and investigating these mechanisms. 
 
2.1.2 Trial Objectives 
2.1.2.1 Aim 
To confirm or refute the non-inferiority of smoking reduction to quit in comparison to abrupt 
cessation, in smokers who wish to quit. 
 
2.1.2.2 Objectives 
1) To measure smoking abstinence at four week, eight week and six month follow-up, in 
smokers who wish to quit, in both the abrupt and reduction treatment arms. 
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2) To investigate possible mechanisms by which the behavioural advice to reduce prior 
to quit day achieves its effects in smokers who wish to quit. 
 
2.1.2.3 Hypothesis 
A behavioural intervention to reduce smoking before quitting completely will result in 
abstinence rates non-inferior to a behavioural intervention to quit smoking abruptly in 
smokers who want to quit. 
 
2.1.2.4 Null Hypothesis 
A behavioural intervention to reduce smoking before quitting completely will not result in 
abstinence rates non-inferior to a behavioural intervention to quit smoking abruptly in 
smokers who want to quit. 
 
 
2.2 Method 
All methods outlined below are in compliance with the Declaration of Helsinki (World 
Medical Association 2008) as approved by the National Research Ethics Service (Reference: 
08/H0408/213) 
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2.2.1 Why a non-inferiority trial? 
Given that reduction is both intuitive and appealing; it is likely to attract smokers who would 
have used abrupt quitting had reduction not been available. It is imperative to show that such 
smokers would not be worse off if they opted for a reduction programme rather than an abrupt 
quitting programme. Therefore we propose a non-inferiority, unblinded, pragmatic trial, large 
enough to show the non-inferiority these methods, to test this. Non-inferiority trials can show 
superiority but conventional superiority trials cannot show non-inferiority (Piaggio et al. 
2006).  
 
2.2.2 Inclusion criteria 
Participants must meet all of the following inclusion criteria to be eligible for enrolment into 
the trial:  
 
1. Male or female; 
2. 18 years or older; 
3. smokes at least 15 cigarettes, or 12.5 grams of loose tobacco daily as roll your own 
cigarettes, or blows 15 parts per million (ppm) or above on exhaled CO reading; 
4. willing to stop smoking completely in two weeks; 
5. able to understand and consent to all pertinent aspects of the study;  
6. willing to be randomised to either trial arm; 
7. willing and able to comply with all other study procedures. 
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2.2.3 Exclusion criteria 
Subjects presenting any of the following exclusion criteria will not be included in the trial: 
 
1. currently using NRT, bupropion, nortriptyline, mecamylamine, reserpine, or 
varenicline, or undergoing any treatment for tobacco dependence (e.g. acupuncture); 
2. unstable angina pectoris, myocardial infarction, or cerebrovascular accident during the 
last three weeks; 
3. severe cardiac arrhythmia; 
4. currently uncontrolled hyperthyroidism; 
5. active phaeocromocytoma; 
6. pregnancy, lactation or intended pregnancy; 
7. suspected alcohol or drug abuse; 
8. participation in other medicinal trials within the last three months and during study 
participation; 
9. previous severe skin reactions to nicotine patches, or severe eczema, or other skin 
diseases that make patch use hazardous or undesirable; 
10. a severe acute or chronic medical or psychiatric condition or previously diagnosed,      
clinically important renal or hepatic disease, that may increase the risk associated with 
study participation or may interfere with the interpretation of study results, and in the 
judgment of the investigator, would make the subject inappropriate for entry into this 
study. 
These exclusions were developed based on contra-indications to NRT use (2, 3, 4, 5, 6, 9, 10), 
to reduce the likelihood that observed effects may be due to a source other than those 
controlled in the trial (1, 8), or to limit the burden of quitting on smokers who may find 
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participation in the trial difficult, taking into account the intensity of data collection and visits 
(7, 10). 
 
2.2.4 Withdrawal criteria 
Trial Withdrawal: It is standard practice in smoking cessation trials to regard those who fail to 
attend for support and treatment as having relapsed, which is based on evidence (West et al. 
2005). Therefore, failure to attend will not count as withdrawal from the trial and the only 
withdrawals will be those where a patient asks to be withdrawn. Such patients will not be 
replaced and, unless s/he refuses permission, data available up to that point will be used. Such 
withdrawals are expected in fewer than 5% of participants.  
 
Treatment withdrawal: One of our exclusion criteria is previous adverse reactions to NRT. 
Given that many smokers have used NRT recently, the established safety profile of NRT and 
the evidence from trials of combination NRT (for example Bohadana et al. 2000), we do not 
expect any serious adverse events (SAE) due to the medication. Nevertheless, there will be a 
detailed work instruction for the trial that will detail the weekly assessment of side-effects, 
and the procedure for SAE and suspected unexpected serious adverse reactions (SUSAR). In 
the event of an SAE or SUSAR that is judged either possibly, probably, or definitely related 
to NRT, the prescription for NRT will be withdrawn and not re-instituted in that person. 
 
2.2.5 Participant Recruitment 
We will recruit participants through South Birmingham, Solihull, Heart of Birmingham and 
Warwickshire and Worcestershire Primary Care Trusts (PCTs) in the first instance; extension 
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to other sites will be considered if necessary. We will request that general practitioner's (GP) 
practices write to patients on their practice lists recorded as smokers and offer them treatment, 
using a provided RRT study template. We will also request that the NHS SSS write to people 
on their databases who have tried to stop and failed. The letters sent out will ask those 
individuals who wish to take part in the trial to respond to the research team. In our 
experience, 5–10% will respond. Following telephone screening for preliminary eligibility, 
potential participants will be booked in for an assessment visit and sent a participant 
information sheet (PIS), giving them more information about the study (Appendix 5). Written 
informed consent will be obtained from participants, using a consent form (Appendix 6), at 
the first assessment session before they have been randomised to a treatment arm.  
 
Participants in both treatment arms will be seen weekly for two weeks prior to quit day (visits 
-2 & -1), on quit day (visit 0), and weekly for four weeks post-quit (visit +1, +2, +3, +4). A 
further follow-up visit will take place eight weeks post-quit day (visit +8) and a final follow-
up phone call at six months post-quit. Therefore all participants will be enrolled in the trial for 
six months and two weeks.  
 
It is not unusual for people to delay their quit day, once committed, for a variety of reasons, 
e.g. death of a close family member or friend. In this situation we will allow participants to 
delay their quit attempt for a maximum of two weeks. They will be advised to carry on with 
their pre-quit NRT regime as prescribed and their actual quit date appointment will be 
recorded as their visit three appointment. Extra visits in between week two and week three 
will be recorded in the case record form (CRF; Appendix 7) and extra diaries and NRT will be 
issued to the participants to cover their delay period. Participants wishing to delay their quit 
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day by more than two weeks will be classified as abandoning this quit attempt, NRT will be 
ceased and the participant will be advised to contact their local NHS SSS (name and number 
will be provided) when they are ready to set a new quit date.  
 
2.2.6 Allocation to trial arms and treatments 
2.2.6.1 Randomisation 
Participants will be seen at an assessment session, similar to that used by the NHS SSS, where 
participants will be randomised 1:1 to reduction or abrupt cessation. We will use Stata 
software to accomplish stratified randomisation by therapist with blocking within each 
stratum to ensure balance. The blocks will be randomly ordered blocks of two, four, and six. 
Each therapist will open sealed numbered envelopes in turn after consent and initial 
procedures, to determine allocation to abrupt cessation or rapid reduction. 
 
Participants in the reduction arm will be offered a choice of three ways to reduce and asked to 
choose the method they feel is right for them. Those without strong preferences, who feel they 
can not choose between methods, will be randomised to one of the three reduction methods. 
We expect this to occur rarely, and will analyse those who choose their method and those 
randomised to it together (See Section 2.2.9.3). Again, we will use Stata to accomplish 
stratified randomisation by therapist with blocking within each stratum. Blocks will be 
randomly ordered blocks of three and six. The therapist will open sealed numbered envelopes 
in turn to determine allocation to reduction method.  
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It is quite likely that we will see couples, friends, or relatives who want to quit together and 
attend clinic as a group. In this situation they will be randomised together so they go into the 
same arm, and given the same study number, made individually identifiable by adding a letter, 
for example A or B. We hope that this will reduce the risk of contamination between 
behavioural methods. This has the potential to introduce cluster effects, however we expect 
joint randomisation to occur rarely and so to have little effect. Nevertheless we will bear this 
in mind when carrying out analysis and allow for clustering if it takes place. 
 
2.2.6.2 Behavioural intervention in the abrupt cessation (control) arm 
Participants randomised to abrupt cessation will have a brief discussion with the nurse about 
smoking and about the nicotine patch treatment. Participants will be informed that the 
rationale of wearing the patch is to divorce the cigarette smoking behaviour from its reward 
(the delivery of nicotine), as discussed previously (Section 1.2.3). We hope that this 
instruction will encourage the smoker not to reduce consumption at all, even if they feel like 
smoking fewer cigarettes, because this will work against the stated rationale (addressed in 
Section 2.2.7.1).  
 
At the first and second clinic visits patches will be provided for use until the next visit and 
homework given to identify critical cigarettes, which will provide the basis for the pre-quit 
session discussion, used in standard behavioural support. This will be followed by five 
weekly sessions on quit day and weekly thereafter, following the typical seven session UK 
withdrawal orientated therapy programme (Hajek 1989). Should a participant resume smoking 
during this treatment they will be allowed to renew their quit day following the new NHS 
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standards (Department of Health 2007). From quit day onwards participants in this arm will 
receive combination NRT, meaning patch plus top-up acute product of their choice (for 
example gum, inhalator). They will be advised to use generous doses of their acute NRT, 
because dose is related to outcome (Shiffman 2007), and combination treatment is more 
effective than patch alone (Stead et al. 2008). Combination NRT is standard in SSS clinics, 
and advised by NICE (2008) for dependent smokers.  
 
Participants will also be provided with diaries from week -2 to week 0. In weeks -2 and -1 
(Appendix 8) these will be used to record the number of cigarettes smoked per day, whether 
patches are being used, and any free-text comments. In week 0 this will be extended to 
include the amount of acute NRT product used per day. 
 
2.2.6.3 Behavioural intervention in the rapid reduction (intervention) arm 
The rapid reduction arm differs from the control arm only in the advice given in the pre-quit 
period- the two weeks before quit day.  Two of the three reduction methods offered (Section 
2.2.6.1) will focus on cpd, and aim to reduce consumption to less than 50% of baseline by the 
end of the first pre-quit week and less than 25% by quit day. The final method will focus on 
smoke-free periods (sfp), and aim to reduce the number of time periods when smoking takes 
place to less than 50% of baseline by the end of the first week and less than 25% by quit day. 
 
The three methods are as follows:  
a) Scheduled reduction (SR) method: A median ICI is calculated and then altered 
to achieve the gradual reduction in cpd. For example, if a person is typically 
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awake for 16 hours per day and smokes 16 cpd, then the median ICI is one 
hour. To achieve a 50% reduction, the ICI needs to increase to two hours. In 
this method, a person is advised to smoke every two hours whether or not they 
want to do so. If they cannot smoke, that cigarette is missed and the next 
opportunity takes place two hours later. At visits -2 and -1 each participant and 
their nurse will calculate their ICIs for the week, and record these on a 
smoking schedule (See Appendix 9 for an example of a completed SR 
schedule), which the participant can then refer to during the week. This method 
is potentially difficult in a country with smoke-free laws and for people with 
jobs where it is not possible to take cigarette breaks at the allotted times.  
b) Hierarchical reduction (HR): There are two variants of this approach- 
hierarchical reduction- difficult (HR-D) and hierarchical reduction- easy (HR-
E). Participants classify their usual cigarettes as either habitual cigarettes or 
particularly rewarding cigarettes. The HR-D method aims to get participants to 
reduce smoking by removing the most rewarding and therefore difficult 
cigarettes first. The rationale is that getting rid of the hardest ones is the most 
difficult and if this can be accomplished well before total abstinence, this will 
enhance confidence and reduce the chance of a slip. Using the HR-E method 
participants seek to avoid smoking habitual, less rewarding cigarettes that they 
judge easier to forgo first. The rationale is that this gives participants early 
initial success and allows them the confidence to tackle more difficult 
cigarettes later. If HR is allocated or chosen participants will be able to choose 
between HR-E and HR-D. Again participants will work with their nurse to 
create a reduction schedule (See Appendix 10 for an example of a completed 
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HR schedule) at visits -2 and -1, which will detail the cigarette(s) they should 
knock out each day. 
c) Smoke free periods (SFP): This method is different to the previous methods as 
it does not focus on cpd as the marker of reduction. Participants map out their 
typical day on a reduction schedule (see Appendix 11 for an example of a 
completed SFP schedule), marking the times they would usually smoke (their 
smoking periods). In a country with smoke free laws, smoking behaviour is 
generally concentrated into smoking breaks, except perhaps when at home. 
The SFP procedure will concentrate on reducing these smoking breaks over the 
reduction time. In a smoking period, participants will be able to smoke as 
much as they want, but they will be asked not to smoke outside of the smoking 
periods. The rationale for this is that anecdotally smokers typically report few 
urges to smoke in places where smoking is forbidden, but find not smoking 
when it is allowed more difficult. This method provides clear boundaries about 
when smoking is and is not allowed. It also focuses participants on what is 
being achieved- sfp- and not on what is being forgone- cigarettes not smoked.  
 
In methods that focus on cpd, participants will be asked to put aside the next day's cigarettes 
into a separate pack to encourage adherence to the target. Participants will be instructed to 
replace cigarettes missed with a type of acute NRT (for example nicotine gum) and 
encouraged to use this sufficiently to avoid smoking more cigarettes than the quota or 
smoking in a sfp. Reduction participants will also complete a diary from week -2 to week 0 
(Appendix 12), recording patches and acute NRT used, and the number of cigarettes smoked. 
In a current trial we find most participants complete the diary reliably. 
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2.2.7 Trial Medication 
The trial takes place within the context of NHS smoking cessation clinics, which provide 
behavioural support and medication to assist smoking cessation. The majority of smokers in 
these clinics use NRT as their medication to assist quitting (Section 1.5.1). This is the only 
pharmacotherapy that will be available to participants in this trial to ensure that any observed 
differences in efficacy are due to behavioural instructions, rather than medication choice.  
 
As previously mentioned (Section 2.2.6.2) current best practice is to use NRT in combination, 
which has been endorsed by the MHRA, and is recommended by NICE (2008). Therefore in 
this study, we propose using both nicotine patch and an acute form of NRT in combination 
(See Table 2). We will use Niquitin, Nicotinell, Wockhardt, and Nicorette NRT products, 
including 24 hour patches, which are also licensed for 16 hour use (there is no evidence that 
the effectiveness of 16 hour patches or 24 hour patches is different (Stead et al. 2008).  
 
Table 2: Daily medication regimes 
NRT – Nicotine Replacement Therapy; mg–milligram 
 
 Rapid reduction Abrupt cessation 
Pre-quit period (-2 weeks to 
quit day) 
21mg/24 hour patch, 
1mg of absorbed nicotine per 
cigarette forgone as a minimum 
from acute NRT. 
21mg/24 hour patch, 
No acute NRT. 
 
Quit day onward 21mg/24 hour patch, 
Minimum of 6mg of absorbed 
nicotine from acute NRT.  As 
much as needed to feel 
comfortable. 
21mg/24 hour patch, 
Minimum of 6mg of absorbed 
nicotine from acute NRT.  As 
much as needed to feel 
comfortable. 
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These patches provide about 1 milligram (mg) of nicotine per hour. Participants will be 
advised to wear the patch 24 hours per day, but will be advised to wear it only during day 
time should they experience sleep disturbance or vivid dreams. Although the medications 
provide the same amount of nicotine delivery with similar pharmacokinetics, the license 
dosing advice differs. Niquitin CQ recommend the 21mg patch for smokers who smoke 10 or 
more cpd, while Nicotinell recommend the 30cm2 (= 21mg) patch for smokers of 20 or more 
cpd. The evidence is that most smokers who smoke 10 or more cpd get less nicotine from 
their patch than they did from their cigarettes (Tonnesen et al. 1999; Johnstone et al. 2004). 
We have therefore chosen a cut-off of 15 cpd. In addition, all participants will be offered 
additional intra-nasal or oral nicotine replacement (gum, microtabs, lozenges, or inhalator), 
with the choice of delivery system left to personal preference. The dose of these products used 
will vary, but participants will be advised to take at least 1mg of absorbed nicotine for each 
cigarette forgone in the reduction phase, because each cigarette delivers about 1.2mg on 
average, though this is highly variable (Perez-Stable et al. 1998). A 2mg oral product, for 
example gum, delivers about 1mg available systemically, and a 10mg inhalator cartridge 
yields about 3mg of nicotine that is systemically available. In the cessation phase, participants 
in both arms will be given identical dosing instructions and advised to use at least 6mg of 
absorbed nicotine daily from acute NRT, which is the minimum dose associated with 
improved outcomes (Stead et al. 2008). 
 
2.2.7.1 Rationale of the pre-quit NRT in the abrupt and rapid reduction arms 
By utilising pre-quit NRT in both arms of the trial we will ensure that any effect is caused by 
the difference in reduction rather than differences in nicotine intake. Smoking and using a 
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patch gives higher concentrations of nicotine than just smoking, whereas smoking and using 
an acute form of NRT does not (Fagerstrom & Hughes 2002). As explained in more detail in 
Section 1.2.3, it is thought that high levels of nicotine dissociate the cigarette from its reward 
and this is responsible for the effectiveness of nicotine pre-treatment (Hajek 2006), which 
does not appear to occur when only acute forms of NRT are used (Herrera et al. 1995; Etter et 
al. 2009). Consequently, we have chosen a nicotine patch for both study arms. However, 
gradual reduction could undermine the nicotine preloading effect so we will attempt to keep 
nicotine levels high by replacing foregone cigarettes with acute NRT, alongside the patch. 
 
2.2.7.2 Duration of medication use and discontinuation 
At the time of writing, the license for NRT allows continued use for up to nine months, 
however patch use will be phased out using the step down doses between two and three 
months after quit day. For participants who are still lapsing but showing determination to stop 
smoking, the patch will be phased out more slowly, providing no signs of overdose are 
evident. The dose reduction regimes vary in the SPCs and in any case the dose reduction is 
individual, based upon confidence in reducing the patch dose and occurrence of urges to 
smoke. Oral NRT is commonly continued for several months in abstinent smokers (Hajek et 
al. 1988; Hughes et al. 1991; Sutherland et al. 1992; Hajek et al. 2007) and there are reasons 
to assume this is beneficial; again we will apply clinical judgement in deciding on length of 
treatment of oral/intranasal NRT. The advice on patch duration and oral NRT discontinuation 
will be the same in both arms. At week +8 participants will be given a months supply of NRT 
and advised to contact either their GP or local SSS should they need further support and/or 
prescriptions beyond week +12. 
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2.2.7.3 Stopping rules/modification of medication regime 
The following stopping rules or modifications to the medication regime will be exercised: 
 
• Participants who have problems with insomnia or difficulties with vivid dreams will 
use the patch for 16 hours daily, not 24 hours; 
• Participants who have skin reactions to the patch that are not controlled by switching 
preparations, emollient and hydrocortisone cream will switch to acute NRT only; 
• Participants who become pregnant may have their dose adjusted in line with NICE 
(2008) guidance, and in accord with the wishes of the participant; 
• Participants who show symptoms of overdose will have their dose reduced; 
• Participants who do not quit or give up on their quit attempt will cease using NRT. 
 
2.2.7.4 Evidence of the safety of concomitant smoking and NRT use 
The safety of using transdermal NRT whilst smoking was investigated in reviews by 
Fagerstrom & Hughes (2002) - summarised in Table 3- and Wang et al. (2008). Wang et al. 
(2008) systematically reviewed the CDTS studies mentioned in the literature review (Section 
2.1.1), and also conducted a meta-analysis of adverse events in people smoking and using 
NRT versus those smoking and using placebo NRT. Overall, 1384 predominantly middle- 
aged smokers were treated with NRT for 6 to 18 months, while 1383 were treated with 
placebo. Four deaths occurred in those randomised to NRT and four in those randomised to 
placebo (OR=1.00, 95% CI=0.25, 4.02). SAEs occurred in fewer than 8% of participants in 
both arms (OR=1.09, 95% CI=0.79, 1.50). In no cases were these judged likely to have been 
due to treatment. Discontinuation of treatment due to adverse events was rare with 1.7% and 
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Table 3: Summary of Fagerstrom & Hughes (2002) review of the safety of smoking and 
concomitant NRT use 
 
cpd – cigarettes per day; mg – milligrams; TP – transdermal patch; ng/ml – nanograms per millilitre; hrs–hours 
 
1.3% in the NRT and placebo groups respectively (OR=1.27, 95% CI=0.64, 2.51). Nausea 
was selected as an index symptom to indicate possible nicotine overdose. It was slightly and 
significantly more common in the NRT group with 8.6% versus 5.3% on placebo 
experiencing nausea (OR=1.69, 95% CI=1.21, 2.36). 
 
Study reviewed Nicotine intake Blood nicotine 
concentrations 
Safety conclusions 
Foulds et al. 
(1992) 
16+ cpd & 15mg TP 
over 16hrs 
Baseline: 37ng/ml,  
Placebo: 36ng/ml,  
15mg TP: 44ng/ml.  
Participants experienced 
almost no subjective 
toxic effects whilst 
wearing the patch 
Pickworth et al. 
(1994) 
13+ cpd & 22mg, 44mg 
TP over 24hrs 
Baseline: 30ng/ml,  
Placebo: 19ng/ml,          
22 mg TP: 39ng/ml,       
44 mg TP: 63ng/ml. 
No adverse subjective 
experiences were 
reported. 
Mahmarian et 
al. (1997) 
8+ cpd & 14mg, 21mg 
TP over 24hrs 
Baseline 16ng/ml,  
14mg TP: 24ng/ml,  
21mg TP: 30ng/ml.  
Only adverse effects 
noted were nausea & 
vomiting in 2 patients. 
Zevin et al. 
(1998) 
Smoking ad libitum & 
21mg, 42mg, 63mg 
patch over 8hrs 
Placebo: 20ng/ml,   
63mg TP: 60ng/ml.  
No additional 
haemodynamic effects 
of TP on heart rate, 
blood pressure, 
noradrenaline, white 
blood cell count, 
fibrinogen, haematocrit, 
cortisol, or lipids.  No 
adverse reactions. 
Carpenter et al. 
(2000) 
11+ cpd & TP, gum or 
inhaler 
Lower than 22mg TP: 
54% increase,    
Higher than 22mg TP: 
190% increase.  
Not applicable 
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2.2.7.5 Lifestyle advice 
There is no special dietary or life-style advice warranted for NRT use, and the associated 
regimes proposed in the protocol. However, participants using oral NRT will be advised to 
avoid acidic drinks 15 minutes prior to using oral NRT, as acidic conditions in the mouth 
have been found to hinder nicotine absorption (Henningfield et al. 1990). 
 
2.2.8 Concomitant Medication 
All medications will be permitted for use concurrently, except those that are proven to help 
smoking cessation (bupropion, nortriptyline, mecamylamine, reserpine, varenicline), and 
medications that are unlicensed, for which no interaction data with NRT are available. No 
rescue therapies will be permitted in treatment, in accordance with NICE (2008) guidance on 
smoking cessation pharmacotherapy. The NRT itself is aimed at the relief of symptoms of 
nicotine withdrawal. Should adverse skin reactions occur with the use of the patch, advice 
will be given on the use of OTC emollients and 1% hydrocortisone cream, as is standard. Data 
on all concomitant medications will be recorded. 
 
2.2.9 Trial Outcomes 
2.2.9.1 Primary trial outcome 
• Abstinence at four weeks, measured according to the Russell standard for clinical 
practice, outlined in the NHS SSS Service and Monitoring Guidance (Department of 
Health 2007). The Russell standard definition of abstinence allows a two week grace 
period from quit day for slips, and is CO validated. 
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2.2.9.2 Secondary trial outcomes 
• Point prevalence abstinence at each follow-up and prolonged abstinence at eight 
weeks and six months. Half of those sustaining abstinence for six months sustain it for 
life- the goal of treatment (Stapleton 1998; Etter & Stapleton 2006). 
• Urges to smoke and nicotine withdrawal symptoms will be measured after cessation. 
Urges to smoke are an important proxy of return to smoking (Doherty et al. 1995; 
Killen & Fortmann 1997). 
 
2.2.9.3 Other trial outcomes (non-efficacy) 
• Exhaled CO, using CO monitors. This is a measure of smoke exposure, which we will 
compare before quit day between study arms. 
 
• Cotinine levels- to show whether nicotine intake rises from normal when smoking in 
both arms, as we expect, and whether the rise in cotinine relates to the success of 
treatment. We propose measuring cotinine at baseline, week -1, quit day, and at week 
+1 in all participants to examine whether reduction leads to higher self-medication 
with nicotine. It could be that reduction treatment gets people used to using high doses 
of NRT and therefore some of the effect of treatment could be explained by post-
quitting NRT dose. These data will also provide valuable evidence on nicotine 
consumption while smoking and using NRT. 
 
• Participant rating of the reward from their cigarette while smoking using the modified 
Cigarette Evaluation Questionnaire (mCEQ) (Westman et al. 1992; Capelleri et al. 
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2007). The mCEQ measures satisfaction, taste, mood, and cognitive and sensory 
sensations to smoking particular cigarettes. Twice each week, prior to quitting, we will 
ask participants to rate satisfaction from smoking, for the first cigarette of the day and 
one other key cigarette. We will routinely ask participants to rate cigarette satisfaction 
in one specimen day so as to anticipate danger periods for lapsing after cessation. For 
example, typical rewarding cigarettes are after dinner. Additionally, participants will 
be asked to rate a cigarette smoked in a negative affect situation. It is possible that the 
mechanism of benefit may be the reward from smoking, and this study will allow 
investigation of this. We will also rate satisfaction from smoking after cessation, 
should slips occur. 
 
• Confidence in quitting- self-efficacy- is a predictor of abstinence (McIntyre et al. 
1983), which may be modified by reduction, and so will be used in mediation analysis. 
This will be measured by the single question: 
 
How high would you rate your chances of giving up smoking for good at this attempt? 
(Circle one response): 
 
Extremely high 
Very high 
Quite high 
Not very high 
Low 
Very low 
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• Smoking stereotypy is a measure of the degree to which smoking is prompted by cues 
to smoke (Shiffman et al. 2004). Reduction may work by disrupting stimulus control, 
as hypothesised in Section 1.2.2, and the stereotypy scale could measure this. Only 
two questions from this scale will be used to measure smoking stereotypy because the 
other questions are either forced to change with reduction, or could not be assessed 
over a short period.  
 
There are no specific outcomes proposed when comparing methods of reduction, hence why 
randomisation to method of reduction was not obligatory. Participants who chose their 
method of reduction and those randomised to it shall be analysed together. This analysis will 
focus on the above measures and is exploratory. See Table 4 for a breakdown of which 
outcomes are to be measured at specific time-points.  
 
2.2.10 Trial Statistics 
2.2.10.1 Power calculation 
We propose a non-inferiority trial, following the Consolidated Standards of Reporting Trials 
(CONSORT) statement for such trials (Piaggio et al. 2006). A one-sided alpha of 0.05 will 
have 80% power to detect inferiority of 9.5% in the quit rate at four weeks, if 343 participants 
are enrolled in each arm, assuming 50% four week abstinence. This is roughly the percentage 
of people who achieve four week abstinence when quitting through the NHS SSS (The NHS 
Information Centre 2011).  Therefore the trial sample size shall be N = 700. Analyses will be 
carried out on an intention-to-treat (ITT) basis, according to the Russell Standard, where 
participants lost to follow up are assumed to be smokers (West et al. 2005). Arguably,  
  CHAPTER 2: RRT PROTOCOL 
 
 
53 
Table 4: Schedule of trial measures 
 
Follow-up Trial measures 
Baseline  
(wk -2) 
-Smoking history, demographics, nicotine dependence using FTND (Heatherton 
et al. 1991), urges and withdrawal using MPSS (West & Hajek 2004), 
confidence in quitting, smoking stereotypy (Shiffman et al. 2004), cigarette 
satisfaction (Cappelleri et al. 2007), exhaled CO, salivary cotinine.  
-Give out diaries. 
Pre-quit visit  
(wk -1) 
-CO, cotinine, MPSS, confidence, smoking stereotypy, cigarette satisfaction, 
adverse events. 
-Collect diaries with daily smoking, NRT use, the two urge to smoke questions 
from the MPSS, and once a week cigarette satisfaction.  
-Give out diaries. 
Extra pre-quit 
visit   
(wk -1a) 
Only applicable if delays quit date by 1 week 
-CO, MPSS, confidence, smoking stereotypy, cigarette satisfaction, adverse 
events. 
-Collect diaries with daily smoking, NRT use, the two urge to smoke questions 
from the MPSS, and once a week cigarette satisfaction.  
-Give out diaries. 
Extra pre-quit 
visit  
(wk -1b) 
Only applicable if delays quit date by 2 weeks 
-CO, MPSS, confidence, smoking stereotypy, cigarette satisfaction, adverse 
events. 
-Collect diaries with daily smoking, NRT use, the two urge to smoke questions 
from the MPSS, and once a week cigarette satisfaction.  
-Give out diaries. 
Quit day 
(wk 0) 
-CO, cotinine, MPSS, confidence, smoking stereotypy, cigarette satisfaction, 
adverse events. 
-Collect diaries with daily smoking, NRT use, the two urge to smoke questions 
from the MPSS, and once a week cigarette satisfaction.  
-Give out diaries 
One week after 
quit day (wk +1) 
-CO, cotinine, MPSS, confidence, cigarette satisfaction if lapsed, adverse events 
-Collect diaries with daily smoking, NRT use, the two urge to smoke questions 
from the MPSS, and once a week cigarette satisfaction.  
Post-quit visits 
(wks +2, +3, +4) 
-Smoking in past week, CO, MPSS, confidence, cigarette satisfaction if lapsed, 
NRT use, adverse events 
+8 wk visit -Smoking in past 4 weeks, CO, MPSS, cigarette satisfaction if lapsed, 
confidence, NRT use, adverse events 
6 month 
telephone call 
-Smoking status over past 5 months, NRT use, SAEs. Those claiming 7-day 
abstinence will be invited to a validation visit for exhaled CO.  
FTND - Fagerstrom Test for Nicotine Dependence, MPSS – Mood and Physical Symptoms Scale, CO – carbon 
monoxide, NRT – nicotine replacement therapy, SAEs - serious adverse events. 
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differences of 5% at four weeks would be worthwhile detecting (West 2007), but a trial would 
need to enrol 2500 participants for this, which would make it impractical and unlikely to be 
funded. If the reduction arm produced abstinence rates not worse than 9.5% less than the 
abrupt arm at four weeks, then it would still result in an abstinence rate of at least 40% at 4 
weeks. This is almost twice as effective as basic support for smoking cessation in primary 
care, measured at 4 week follow-up (22%; Aveyard et al. 2007) and therefore, in the 
judgement of the authors, is probably sufficient for NHS SSS to implement the programme. 
 
This trial is powered to make a comparison between the abrupt quitting and reduction to quit 
arms of the study, and not to make comparisons between reduction methods. This will be kept 
in mind during analysis, and any comparison made between reduction methods will be purely 
exploratory. 
 
2.2.10.2 Analysis 
The analysis will compare the proportions stopping smoking, calculating the RR and CIs.  If 
the upper and lower limits of the CIs lie above the non-inferiority margin (0.9) then reducing 
smoking to quit will be judged non-inferior to quitting abruptly, in accord with Piaggio et al. 
(2006). We will calculate differences in withdrawal scores using regression, controlling for 
baseline differences, as is standard using the Mood and Physical Symptoms Scale (MPSS) 
(West & Hajek 2004). We will investigate possible mechanisms of action (NRT dose, 
cigarette satisfaction, withdrawal, self-efficacy) using mediation analysis within a regression 
framework. Mediation analysis is outlined in more detail by the Research in Prevention Lab 
(RIPL) research group at the Arizona State University (RIPL 2008). 
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In comparing methods of reduction, we have no specified hypotheses. We will compare 
changes in confidence, stereotypy, and urges to smoke, calculating differences in mean 
changes and confidence intervals for the difference. We will compare the proportion 
abstinent, using point prevalence and prolonged abstinence as in the comparison between 
reduction and abrupt cessation. The primary analysis of abrupt cessation versus reduction will 
not be adjusted by method of reduction used. 
 
2.2.11 Qualitative Interviews 
Qualitative interviews will be conducted during the trial to investigate participants’ 
experiences and opinions about the methods they used to make their quit attempt. These 
views could be used in the future to refine quitting methods, and to provide insight into how 
the methods may work.  Interviews will be conducted over the phone for a maximum of 30 
minutes per participant, and not necessitate a further visit in order to encourage participants to 
take part. Interviews will be carried out by a researcher (NL), using a semi-structured 
interview schedule consisting of open questions (Appendix 13). As this research is largely 
exploratory there are no pre-conceived ideas of the answers that participants may provide. 
The semi-structured schedule means we will be able to ask participants to elaborate on topics 
which arise and appear to be of interest. All of the interviews will be digitally recorded and 
then transcribed, and analysed as the interviews progress. These recordings and transcripts 
will be filed with no identifying information and so will be anonymous. We will carry out 
interviews with consenting patients (in all arms) until no new themes emerge and we have 
deemed theoretical saturation to have been reached. Analysis of interview transcripts shall be 
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carried out using principles of the framework approach (indexing, charting, mapping and 
interpretation), developed and outlined by Ritchie & Spencer (1994). 
 
At the first visit when the research nurse explains the study participants will be given 
information about these interviews. There will be an option included on the consent forms 
(Appendix 6), which will allow participants to opt out of taking part if they wish. If 
participants agree to take part they will be asked to provide a phone number and convenient 
times to contact them, so that we can call them to conduct the interviews around week +5. 
They will also be provided with a sheet providing information about the interviews and the 
topics that they will be asked about (Appendix 14). There will be room for participants to 
make notes on these topics as they proceed through the study, so that these can be used as 
prompts for participants whilst they are being interviewed.  Hopefully this will encourage 
participants to think about their method of quitting throughout the study, so that they can 
provide richer data when interviewed.  
 
2.2.12  Trial schedule 
With two full-time nurses who will also act as trial co-ordinators and liaise with practices, and 
do follow ups, and the support of a PhD student, we can see the 700 participants in 24 months 
(bearing in mind that clinical contacts span 10 weeks). 
 
2.2.12.1  Definition of end of trial 
End of trial is defined as the final six month patient follow-up, measuring CO level of the last 
participant undergoing the trial. 
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2.2.13  Safety Reporting 
2.2.13.1 Assessment of safety 
Potential participants' safety will be ensured by screening for eligibility using a structured 
form (included in the CRF- Appendix 7), completed by the trial nurse. This will record 
evidence of eligibility and exclusion criteria. In addition, the nurse will take a general medical 
history to assess for other complicating diseases. Any queries remaining as a result of this 
process will be resolved by discussion between the trial nurse, principal investigator (PI) and 
the relevant physicians providing routine medical care (usually the participant's GP). Such 
concerns are not rare and typically arise from a participant's hazy knowledge or understanding 
of their past medical history, but can usually be readily resolved. No blood or further medical 
testing will be necessary to ensure safety.  
 
NRT has been investigated in several hundred previous clinical trials and is widely prescribed 
worldwide. It is subject to safety monitoring, and is replacing a product- nicotine- which the 
participants are already consuming, and will most likely have consumed for many years in 
cigarettes. Thus, there is every reason to expect that treatment in this trial will be safe. 
Participants will be warned about the side-effects of NRT and advised not to stop taking the 
medication without consulting with an NHS professional; preferably the trial team. To this 
end, all participants will be given a credit card-sized card including the trial team's contact 
details that will allow participants to receive advice on medication or to report perceived 
SAEs as required. Participants will record the occurrence of side-effects of medication, as 
specified on the SPC for relevant NRT preparations, by completing a checklist. The checklist 
will be given to the trial nurse and the nurse will enquire about recorded adverse events, so as 
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to determine the severity of any adverse event and ensure that appropriate advice is given for 
its management (such as rotating the patch site or use of emollients for skin reactions). For 
each known side-effect listed in the SPC, the trial nurse will have a definition of clinical 
severity. For example, a mild skin site reaction to the patch will be defined as burning 
sensation that does not interfere with normal activities, redness or swelling at the site of 
application, or mild blistering. Any reaction beyond that will be classified as potentially 
moderate or severe and will be reported to and discussed with the PI. A decision on stopping 
therapy will then be made with the participant, attending clinician, PI, and other relevant 
parties as appropriate. Nicotine has a short half-life (two hours), meaning that the blood 
concentration will not build up during the course of treatment, so that new side-effects are not 
expected after the first few weeks. In addition, with reactions relating to local use, such as 
skin discomfort from patches, or bad taste from oral use, either treatment will have been 
switched or people will have become accustomed to the side-effects within a short time of 
using the preparation. At their last clinic visit (week +8 of the quit attempt) participants will 
be advised to phone the provided trial contact number to report any side-effects that occur 
after this. The advice given will depend upon the severity of the reported reaction, and those 
with moderate reactions will be invited to an ad hoc consultation.  
 
Participants will also complete a schedule of nicotine overdose symptoms at each visit. On 
completion of this questionnaire, the schedule will be handed to the nurse and thus any 
symptoms of overdose will be assessed. Based on this enquiry the nurse will make an 
assessment of whether the NRT dose is too high or not, and then take appropriate action, such 
as continue with prescribed dose, or direct the participant to use a lower dose, which will be 
recorded.  
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The SPC for the relevant NRT products contain no warnings about serious adverse reactions, 
except rare allergic reactions, such as angioedema, and cardiac arrhythmias- occurring in less 
than 1/1000 users. This and the long history of NRT use in and outside of trials means that no 
or very few SUSARs are expected in this trial. On the reverse of the trial card providing the 
contact number for advice on side-effect management, there will be instructions for the 
reporting of SAEs. Therefore, we expect to become aware of these through direct contact with 
the participant or their attending physician. If any member of the trial team becomes aware 
they will inform the PI within 24 hours. The PI will then assess the seriousness, causality, 
expectedness and severity of the adverse effects. An immediate decision will be made on the 
interim use of medication for that participant. If an event is judged severe, it will be reported 
to the trial sponsor, who will report the event to the Research Ethics Committee and MHRA. 
Participants will be asked weekly to report inter-current illnesses and the response recorded. If 
any of these inter-current illnesses contraindicates NRT, this will be immediately reported to 
the PI and a decision made about continued use of the NRT product. The reporting procedures 
and definitions for adverse events are presented in Appendix 15. 
 
2.2.13.2 Monitoring and audit 
The progress of the trial will be monitored by a quarterly review of records. This will ensure 
that consent is being obtained and the inclusion and exclusion criteria are adhered to. The 
medication dispensed and the instructions for using it will also be assessed.  
 
Data cleaning will take place by a series of logical checks on the electronic data. (For 
example, a person cannot be recorded as prolonged abstinent smoker at six months if they 
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were not in such a state at eight weeks). Discrepant records will be checked with the source 
documents, and the database amended if necessary.  
 
The trial will be potentially subject to audit by the appropriate regulatory authorities and 
therefore participants will be asked to consent to allow their records to be viewed. 
 
2.2.14  Data management 
The trial is being run as part of the portfolio of trials in the Primary Care Clinical Research 
and Trials Unit (PCCRTU), a National Institute for Health Research (NIHR) recognised trials 
unit in Primary Care Clinical Sciences at the University of Birmingham. The data 
management will be run in accord with the standard operating procedures, which are fully 
compliant with the Data Protection Act (Great Britain 1998) and International Conference on 
Harmonisation (ICH) Good Clinical Practice (GCP) guidance (European Medicines Agency 
2002). The source documents for the trial will be the CRFs, which will be stored in the trials 
unit, in a locked cabinet, in a locked office, in a locked department. The trial database will be 
securely held and maintained by the PCCRTU. On completion of the trial and data checking, 
the CRFs will be transferred to Modern Records, a secure archiving facility at the University 
of Birmingham, where they will be held for 15 years and then destroyed. The database will be 
anonymised and a secure compact disc containing the link between identification number and 
patient identifiable information will also be stored in Modern Records. 
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2.2.14.1 Data protection and confidentiality 
Data will be kept in accordance with the Data Protection Act (Great Britain 1998), and the 
trial registered with the Data Protection Act website at the University of Birmingham. The 
standard operating procedures of the PCCRTU will be followed, which are designed to 
protect patient confidentiality. Patient identifiable data will be shared only within the clinical 
team on a need-to-know basis, to provide good and appropriate clinical care and follow-up. 
Patient identifiable data will also be shared with GPs, and approved auditors from the 
Research Ethics Committee, NHS Research and Development, or the MHRA. Otherwise, 
confidentiality will be maintained and no one outside the trial team will have access to either 
the CRFs or the database. 
 
2.2.15  Ethics and Research Governance 
We will conduct the trial in compliance with the principles of the Declaration of Helsinki 
(World Medical Association 2008), the principles of ICH-GCP (European Medicines Agency 
2002), including recommendations for the reporting of adverse events, SAEs and SUSARs, in 
accord with the EU Clinical Trials Directive (The European Parliament and the Council of the 
European Union 2001), and all of the applicable regulatory requirements. The study protocol 
and other documentation have been reviewed and approved by the National Research Ethics 
Committee (08/H0408/213), the MHRA (2008-006433-28), and local NHS Research & 
Development offices. Any subsequent protocol amendments will be submitted to the Research 
Ethics Committee for approval, and the other bodies if necessary. In addition the Research 
Ethics Committee will be provided with progress reports as well as a copy of the Final Study 
Report. 
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2.2.16  Finance 
The study will be funded by the British Heart Foundation and service support costs will be 
claimed via the Comprehensive Clinical Research Network. 
 
2.2.17  Publication 
The trial is registered with www.controlled-trials.com, and results will be written up for 
submission to a peer reviewed journal. No data relating to individuals will be identified in 
these publications.
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CHAPTER 3: A COCHRANE REVIEW OF REDUCTION 
VERSUS ABRUPT CESSATION IN SMOKERS WHO WANT 
TO QUIT 
 
3.1 Background 
As previously described in Section 1.4.2, surveys carried out across England and Wales (West 
& Fidler 2011) and the UK, US, Canada and Australia (Cheong et al. 2007) have investigated 
the success of quit attempts, and found that abrupt quitting was almost twice as successful as 
quitting gradually (by reducing first), in those sampled. However, there is reason to believe 
that this may not be the case when support is provided, as the provision of increased structure 
may benefit quitters who reduce more than those who quit abruptly (Cheong et al. 2007). 
Therefore with a goal to establish the relative efficacy of abrupt and reduction to quit services 
(Section 2.1), it is important that an attempt is made to compare these approaches when 
support is available to the quitters using them.  
 
Although British (NICE 2008) and American (Fiore et al. 2008) national guidelines for 
smoking cessation services do not recommend reducing smoking before quitting, both 
conclude that further research is needed into whether it could be used as a successful 
intervention to help those who have tried unsuccessfully to quit in the past. The RRT 
described in Chapter 2 is one attempt to do this, and this review is another. It builds on the 
narrative review in Section 2.1.1, by carrying out a systematic search and amalgamating the 
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existing data from RCTs, to come up with an overall conclusion about the relative efficacy of 
the two approaches. 
 
3.2 Objectives 
• To compare the success of smoking cessation interventions that instruct the smoker to 
reduce the amount they smoke before quitting with interventions that instruct the 
smoker to stop smoking abruptly, in smokers who want to quit soon. 
• To compare adverse events by intervention type (reduction to quit versus abrupt 
quitting), stratified by whether they use pharmacotherapy. 
 
3.3 Methods 
All methods were carried out as specified in the protocol for this review (Lindson et al. 
2009b). 
3.3.1 Criteria for considering studies for this review 
3.3.1.1 Types of studies 
Randomised controlled trials (RCTs). We included one trial where allocation to treatment 
arms was cluster randomised, and carried out a sensitivity analysis to adjust for this 
clustering. To meet the second objective we examined adverse events, only in those trials 
which had a reduction arm utilising pre-quit pharmacotherapy, and an abrupt quitting arm that 
did not utilise pre-quit pharmacotherapy (the only trials for which adverse events data was 
available). 
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3.3.1.2 Types of participants 
Cigarette smokers of any age who intended to stop smoking soon. Participants demonstrated 
their commitment to quitting by enrolling in a smoking cessation programme. Trials that 
enrolled smokers who did not intend to quit soon were excluded, as they are covered by the 
Cochrane review of harm reduction (Stead & Lancaster 2007). 
 
3.3.1.3 Types of interventions 
We compared any instruction to participants to reduce the amount of cigarettes smoked before 
quitting, with any instruction to stop smoking abruptly without prior reduction. We did not 
include trials with arms where participants spontaneously reduced before quitting without 
being advised to do so, versus arms where participants stopped abruptly.  
 
Interventions included anything from no behavioural support to extensive behavioural 
support, but studies were excluded if behavioural support differed substantially in type or 
duration between arms. Behavioural support pre- and post-quit could vary between the 
reduction and abrupt quit arms as long as overall contact was roughly equal. Trials could also 
include concomitant pharmacotherapy to support cessation, as long as it was equivalent in all 
trial arms after cessation. Pharmacotherapy used prior to quit day could vary as a necessary 
component of the intervention i.e. to support smoking reduction. 
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3.3.2 Types of outcome measures 
3.3.2.1 Primary outcomes 
The primary outcome was abstinence from smoking at least six months after the quit day. We 
excluded trials with a follow-up of less than six months.  
 
In trials with more than one measure of abstinence, we preferred the measure with the strictest 
criteria. We used prolonged or continuous abstinence over point prevalence abstinence, and 
preferred biochemically validated abstinence, such as exhaled CO, over self-report. 
 
3.3.2.2 Secondary outcomes 
The secondary outcome was the type and number of adverse events recorded. 
 
3.3.3 Search methods for identification of studies 
We searched the Cochrane Tobacco Addiction Review Group specialised register, which has 
been developed from electronic searches of MEDLINE, EMBASE and PsycINFO, together 
with hand searching of specialist journals, conference proceedings and reference lists of 
previous trials and overviews. We also searched MEDLINE, EMBASE, PsycINFO and the 
reference lists of relevant trials for possible trials to include in the review. Where necessary 
we contacted the authors of ongoing trials.  
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We searched MEDLINE (Ovid, 1966 to 5th November 2009), EMBASE (Ovid, 1980 to 2009 
week 44) and PsycINFO (Ovid, 1967 to 23rd November 2009) using the following topic-
specific terms: 
 
• cold turkey.mp 
• (schedul* adj3 smok*).mp 
• (cut* down or cut-down).mp 
• (({Gradual* or abrupt*}) adj3 (reduction or reduce* or quit* or stop* or abstin* or 
abstain* or cessat*)).mp 
• fading.mp 
• taper*.mp 
• (controlled adj smoking).mp 
 
[mp=title, original title, abstract, name of substance word, subject heading word] 
 
combined with the standard terms used to identify trials of tobacco addiction interventions for 
the Tobacco Addiction Review Group specialised register. Full strategies are shown in 
Appendix 16. We also searched the specialised register in November 2009 using the 
following terms: Cold turkey or schedul* or Cut* down or cut-down or Gradual* or abrupt* 
or fading or reduction or reduce* or taper* or controlled smoking. 
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3.3.4 Data collection and analysis 
3.3.4.1 Selection of studies 
One author (NL) checked the titles and abstracts of studies identified by the search strategy 
for relevance, and obtained copies of papers reporting relevant trials. Two authors (NL & PA) 
then independently assessed the reduced trials list for inclusion in the review. Any 
disagreements were resolved through discussion with the remaining review author (JH). We 
based eligibility decisions on the following questions: 
 
1. Is the study described as randomised or quasi- randomised? 
2. Were the participants cigarette smokers who wanted to quit? 
3. Did the study include at least two groups, i.e. one group advised to reduce their 
smoking before quitting and one advised to quit abruptly on their quit day? 
4. If the intervention includes behavioural support with or without pharmacotherapy, is 
the intensity of overall contact for behavioural support (throughout the intervention), 
and post-quit pharmacotherapy, similar between groups? 
5. Is the intervention an instruction to reduce the number of cigarettes smoked, rather 
than an instruction to reduce harm, e.g. smoking cigarettes with lower levels of 
nicotine? 
6. Does the study report smoking abstinence at least six months after the quit date? 
 
If the answer to any of the above questions was ’No’ then the trial was not included in the 
review. Study eligibility, as well as the data extraction outlined below, was piloted on one 
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study initially, to establish the suitability of our criteria, before full eligibility assessment and 
extraction took place.  
 
3.3.4.2 Data extraction and management 
Only one non-English language article met the inclusion criteria and this was translated from 
Spanish for this review (Roales-Nieto & Fernández Parra 1992). For each included trial one 
author (NL) extracted the data and another author checked them (PA). The following 
information was extracted: 
 
Methods: 
• The design of the trial, for example randomised or quasi-randomised 
• Country and setting 
• Method by which participants were selected 
• The definition of a smoker used 
• Duration of the study 
• Time to follow up(s) 
 
Participants: 
• The number of participants randomised to each intervention group 
• Demographics of participants (age, gender, ethnicity) 
• The average number of cpd, and number of past quit attempts 
• Average Fagerstrom Test for Nicotine Dependence (FTND) or equivalent score 
• Preference for abrupt or gradual cessation 
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Interventions: 
• The method of rapid reduction intervention used 
• The method of abrupt quitting intervention used 
• Whether pharmacotherapy was used as part of the intervention, and if so details of use 
• Details of any behavioural support provided 
• Duration of reduction period 
• Who delivered the intervention? 
 
Outcomes: 
• Did the trial examine whether the reduction arm reduced as instructed, and that the 
abrupt arm did not reduce? 
• Outcomes measured 
• The strictest definition of abstinence used 
• Whether abstinence was biochemically verified, and if so, how? 
• Whether data was available for an intention-to-treat analysis 
• The proportion of quitters in each intervention arm 
• The number of adverse events in each arm 
• Amount of reduction in cpd in each arm (self report and/or chemical biomarkers) 
• Additional outcome results 
• Drop-out rates 
• Information about withdrawals 
• Further information about adverse events 
• Missing data in both arms 
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3.3.4.3 Assessment of risk of bias in included studies 
Risk of bias for each trial was assessed within the domains of sequence generation, allocation 
concealment and incomplete outcome data, using the risk of bias table, as outlined in the 
Cochrane Collaboration Handbook (Higgins & Green 2009). Blinding of participants and 
investigators was not assessed, as it is not possible to keep these concealed when 
administering behavioural interventions, as was the case in the included trials. Selective 
reporting was also unlikely to be a problem as in smoking cessation trials abstinence is 
generally the main outcome, and therefore unlikely not to be reported. However during the 
risk of bias analysis we kept an open mind as to potential sources of bias outside of the tool, 
and reported those that were apparent (Section 3.4.4). 
 
3.3.4.4 Measures of treatment effect  
All quantitative analysis of abstinence data was carried out using the  RevMan 5.1 computer 
programme, developed by the Cochrane Collaboration to carry out systematic reviews and 
meta-analyses. We compared quit rates between the abrupt cessation and reduction groups, 
calculated on an ITT basis, including all participants originally randomised to a trial arm. Any 
participants lost to follow-up were treated as relapsed, excluding any deaths. We used RR as 
the summary statistic in all meta-analyses, using the Mantel-Haenszel fixed-effect model for 
pooling results, checking for no significant heterogeneity. Had heterogeneity been detected 
we would have considered the use of a random-effects model.  
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We also compared the number of adverse events between arms; however no meta-analysis 
was carried out for this outcome as data was sparse and not consistently measured across 
studies. 
 
3.3.4.5 Assessment of heterogeneity 
Any inconsistency across study results was identified and assessed by examining forest plots 
for poor overlap of confidence intervals, and by examining the I-squared statistic. 
 
3.3.4.6 Sub-group analyses  
We conducted a sub-group analysis comparing trials which used pharmacotherapy as part of 
the interventions with those that did not. We also grouped interventions by whether or not the 
instruction on how to quit smoking was given alongside behavioural support or self-help 
methods. 
 
3.3.4.7 Sensitivity analyses 
We  investigated the sensitivity of the main effect, when adjusting for the only cluster 
randomised trial eligible for inclusion in the meta-analysis. This adjustment to Jerome , Behar 
et al. (1999)  used an intra-class correlation of 0.0105 (as recommended by Martinson et al. 
(1999) for an outcome of percentage quit in the work place) and an average number of people 
per group of 18.3 (design effect = 1.18). We also carried out a sensitivity analysis to see 
whether the exclusion of studies where non-validated, self-report data were used influenced 
the outcome of the meta-analysis. 
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3.4 Results 
3.4.1 Description of studies 
3.4.1.1 Results of the search 
The searches of the Cochrane Specialised Register, MEDLINE, EMBASE and PsycINFO 
resulted in 543 unduplicated references (See Appendix 17 for study inclusion flow diagram). 
Additionally, at the time of writing, a co-author of this review (JH) has just completed a study 
comparing reduction to abrupt quitting, and written a study report (Hughes et al. 2010) citing 
two further studies possibly relevant for inclusion. These 546 references were screened for 
eligibility based on their titles and abstracts, resulting in a reduced total of 30 studies. These 
studies were then independently assessed by two authors (NL & PA) for eligibility, based on 
the questions specified in Section 3.3.4.1. We found 10 studies which were relevant for 
inclusion in the review based on these criteria (further detail available in Appendix 18); seven 
of these took place within the USA (Flaxman 1978; Cummings et al. 1988; Curry et al. 1988; 
Cinciripini et al. 1995; Jerome, Behar et al.1999; Riley et al. 2005; Hughes et al. 2010), and 
the remaining three were situated in Austria (Gunther et al. 1992), Switzerland (Etter et al. 
2009) and Spain (Roales-Nieto & Fernández Parra 1992). We also discovered three ongoing 
studies (Riley et al. 2001; Cinciripini et al. 2006; Lindson et al. 2009a) which, when 
completed, may also be relevant for inclusion (further details available in Appendix 19). The 
authors of eight of the aforementioned studies (Cummings et al. 1988; Curry et al. 1988; 
Jerome, Behar et al.1999; Riley et al. 2001; Riley et al. 2005; Roales-Nieto & Fernández 
Parra 1992; Cinciripini et al. 2006; Etter et al. 2009) provided additional information when 
contacted. 
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The inclusion of Hughes et al. (2010) may be deemed a potential source of selection bias, as 
the study was yet to be published when the searches were carried out, and results were 
obtained through one of the review authors.  In addition one of the ongoing studies is being 
carried out by two of the review authors (Lindson et al. 2009). However every attempt was 
also made to identify studies eligible for inclusion in the review, published or not, from 
authors outside of the review team  (identified through conference proceedings  included in 
the Cochrane Tobacco Addiction Review Group specialised register). This is evidenced by the 
fact that neither of the trial reports for Jerome, Behar et al. (1999) or Riley et al. (2005) had 
been published, and were obtained through contact with the authors. We also tried to obtain 
unpublished data from Riley et al. 2001 and Cinciripini et al. 2006, however this is not yet 
available, and so these studies are classed as ongoing. Therefore we feel that we made every 
effort to obtain relevant and available data. As Cochrane Reviews are updated every two 
years, emerging data will be periodically incorporated into the review. 
 
3.4.1.2 Included studies 
3.4.1.2.1 Characteristics of participants 
The 10 included studies all recruited adult cigarette smokers with an aim to quit. Seven 
studies recruited participants from the community using advertisements (Flaxman 1978; 
Cummings et al. 1988; Curry et al. 1988; Cinciripini et al. 1995; Riley et al. 2005; Etter et al. 
2009; Hughes et al. 2010). One study recruited work-sites to take part, and then recruited their 
employees by posting advertisements and internal memos (Jerome, Behar et al.1999). Another 
recruited students using advertisements at a university (Roales-Nieto & Fernández Parra 
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1992), and another recruited patients consulting a hospital based, smoking counselling service 
(Gunther et al. 1992).  
 
In one study these participants were then randomised in clusters (work-sites) to study arms 
(Jerome, Behar et al.1999), however for all other included studies participants were 
individually randomised. In the eight studies where participant gender was reported 
participants were on average evenly split between males and females, and the average 
reported age of participants (averaged across seven studies) was 42.8 years. Eight studies 
reported average baseline cpd in all participants, and this ranged from 23 to 28 cpd, with an 
average of 25.4. 
 
3.4.1.2.2 Sample sizes 
The total sample size across the 10 included studies ranged from 23 to 1895, with a mean 
sample size of 487. However not all study arms in all of the trials were used in the meta-
analysis. When only the conditions relevant to this review were taken into account, sample 
sizes ranged from 14 to 1277, with a mean of 376. In five of the included studies all 
conditions randomised were relevant to the current review and were therefore included in the 
meta-analysis, however five of the studies randomised participants to interventions which 
were not relevant. Cummings et al. (1988); Jerome, Behar et al. (1999) and Hughes et al. 
(2010) all included a control condition, which did not provide specific advice on how to quit, 
but provided information about the health implications of smoking, praise for quitting, and 
material emphasising the importance of a general programme of physical health (including 
quitting smoking) respectively. Flaxman (1978) included an immediate quit condition where 
participants were asked to quit the day after enrolling in the study and received substantially 
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less behavioural support than the other conditions. Roales-Nieto & Fernández Parra (1992) 
included two conditions where the participants’ goal was to reduce their smoking and control 
it rather than to reduce and quit completely. All of these conditions were deemed not relevant 
to this review and were excluded from any meta-analyses. 
 
3.4.1.2.3 Interventions 
All of the included studies had at least one group of participants who were instructed to 
reduce the amount they smoked before they quit, and at least one group instructed to quit 
smoking abruptly. In four of the studies, participants were advised on either abrupt or gradual 
cessation by self-help manuals or a handheld computer programme (Cummings et al. 1988; 
Jerome, Behar et al.1999; Riley et al. 2005; Etter et al. 2009). Participants in another five 
studies were given face-to-face (Flaxman 1978; Gunther et al. 1992; Roales-Nieto & 
Fernández Parra 1992; Cinciripini et al. 1995) or telephone based (Hughes et al. 2010) 
behavioural support as a means to assist either reduction or abrupt cessation. In the remaining 
study one reduction arm and one abrupt arm consisted of self-help therapy, and participants in 
the other reduction and abrupt arms were provided with behavioural support (Curry et al. 
1988). The behavioural support varied in terms of the overall length of time for which support 
was provided, the length of support sessions, number of support sessions, whether these were 
provided to individuals or groups, and who provided the support; however they all included 
pre-quit sessions where participants were taught strategies to help them avoid smoking when 
tempted, such as strategies to maximise self-control, and post-quit sessions focusing on 
relapse prevention. Most of the self-help interventions consisted of information booklets, 
some of which provided the participants with written activities. However for the reduction 
interventions in Jerome, Behar et al. (1999) and Riley et al. (2005) participants were given the 
  CHAPTER 3: ABRUPT ‘VS’ REDUCTION COCHRANE REVIEW 
 
 
77 
LifeSign handheld computer (PICS Inc). LifeSign structures a gradual reduction schedule, 
prompts users to smoke and allows them to record each cigarette they smoke. In the Jerome, 
Behar et al. (1999) study this computer was provided, with a 48 page manual, which consisted 
of instructions on how to use the computer and information about behaviour modification 
strategies and relapse prevention. In the Riley et al. (2005) study participants only received 
brief instructions on how to use the device and no further information. This was designed as a 
minimal contact intervention, which matched the minimal instructions provided to the abrupt 
quitting intervention group members, who received a calendar log to record their smoking. 
 
The abrupt quitting method advised for participants did not vary much across the ten studies. 
Participants were either given a quit date or asked to choose one themselves, and then asked 
to smoke as normal and quit abruptly on this date, with no prior cutting down. Quit dates 
ranged from zero to five weeks following baseline assessment. The smoking reduction 
methods all culminated in a quit day but varied considerably across studies as follows: 
 
• Cummings et al. (1988) gave participants unspecific advice on how to quit; they were 
simply advised to reduce the amount smoked over two weeks before quitting. 
Suggestions were provided on how they could reduce, such as setting daily goals, 
switching brands, changing habits and delaying the first cigarette; but ultimately it 
was left to participants to choose by how much to reduce and which, if any, strategies 
to use to achieve this. 
• Three studies asked participants to reduce cpd by a certain quota over a set time 
interval without providing participants with any particular strategy to do so. Etter et 
al. (2009) asked participants to reduce their smoking to 50% of baseline over four 
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weeks and then quit completely. Gunther et al. (1992) asked participants to reduce 
their smoking by five to ten cigarettes per week (depending on how much they were 
smoking at baseline), over five weeks until they were not smoking at all. Roales-Nieto 
& Fernández Parra (1992) instructed participants to reduce by 25% of baseline in 
week one, 50% in week two, 75% in week three and to quit completely in week four. 
• In the Cinciripini et al. (1995) study two groups of participants were asked to reduce 
their smoking; one of the groups reduced smoking by a set quota but did not use a 
specific technique to achieve this, as in the three studies above. Participants cut down 
to 66% of their baseline smoking rate in the first week of reduction, to 33% of 
baseline in the second week, and to 22% of baseline in the third week, until they 
reached two to four cpd. The second reduction group reduced by the same quota of 
cigarettes, but this was structured. Each week the advised smoking rate was divided 
by the number of hours in the participants’ waking day, to calculate an ICI. 
Participants were then able to smoke only in the first five minutes of each interval, 
and any missed cigarettes could not be accumulated for later use. Both groups quit in 
the week following the third week of reduction, and were combined for the purposes 
of our meta-analysis. 
• Jerome, Behar et al. (1999) and Riley et al. (2005) also used ICIs to reduce smoking to 
zero. They implemented this using a handheld computer called LifeSign, which 
developed a smoking reduction schedule, lasting between 10 to 28 days, depending on 
each individual’s baseline smoking rate and progress through the programme. The 
machine beeped and put a reminder on its screen to prompt participants to smoke. 
• Hughes et al. (2010) advised participants to reduce their smoking by 25% of baseline 
in week one, 50% in week two and 75% in week three, before quitting completely. 
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They were also provided with three structured ways to do this, which they could 
choose between. The first was scheduled reduction where participants were advised to 
gradually increase the time between cigarettes (the ICI). The second asked 
participants to rate each cigarette of the day in terms of how difficult it would be to 
give up and then eliminate each in turn starting with the most difficult first. The third 
was the same as the second but participants started with the easiest first. Abstinence 
results did not appear to differ across the methods and so the data was pooled. 
• Flaxman (1978) differed from the previous approaches as participants were not asked 
to reduce by a certain quota of cigarettes, but to identify situations that caused them to 
smoke. They were then asked to rate these situations in terms of how difficult it would 
be to abstain from smoking, and then to eliminate smoking in one situation every 
three days, starting with the easiest situation and proceeding to the most difficult. In 
one reduction group participants continued this until they were not smoking at all and 
in the other they reduced until they were smoking in 50% of their baseline smoking 
situations, and then quit abruptly. These two reduction groups were combined into an 
overall reduction group for our meta-analysis. 
• One study gave very limited information as to how reduction took place (Curry et al. 
1988); the method was described as cigarette tapering and a gradual acquisition of 
coping skills. The authors confirmed that this was a reduction method relevant for 
inclusion in this review, however no further detail could be provided. 
 
3.4.1.2.4 Pharmacotherapy 
Three of the studies included in this review gave participants pharmacotherapy as a part of 
their interventions. In all cases this was in the form of NRT; one study used gum (Etter et al. 
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2009), another lozenges (Hughes et al. 2010) and the third nasal spray (Riley et al. 2005). In 
the reduction arm of each study participants used the NRT both pre- and post- quit, and in the 
abrupt quitting arm post-quit only. In the pre-quit period Etter et al. (2009) advised 
participants to use at least 10 pieces of 4mg nicotine gum per day, Hughes et al. (2010) 
requested that participants replace each cigarette missed with a 2mg or 4mg lozenge (4mg for 
those who smoked within 30 minutes of waking and 2mg for others). Riley et al. (2005) 
signalled when participants should use the nasal spray using the same LifeSign handheld 
computer as was used to signal smoking. The appropriate nasal spray dosage was determined 
for each individual user depending on their recorded baseline smoking rate. 
 
3.4.1.2.5 Outcomes 
Nine of the 10 studies reported smoking abstinence as an outcome at either six month follow-
up (Flaxman 1978; Cummings et al. 1988; Hughes et al. 2010), 12 month follow-up (Gunther 
et al. 1992; Curry et al. 1988; Etter et al. 2009) or both (Cinciripini et al. 1995; Jerome, Behar 
et al. 1999; Riley et al. 2005). The remaining study (Roales-Nieto & Fernández Parra 1992) 
reported cpd over seven days at six month, nine month and 12 month follow-ups for 
individual participants; so it was possible to calculate abstinence rates from this information. 
Where abstinence was measured at 6 and 12 month follow-ups the 12 month rates were used 
in the meta-analysis. In three studies smoking abstinence was reported as point prevalence 
(Roales-Nieto & Fernández Parra 1992; Jerome, Behar et al. 1999; Riley et al. 2005) and in 
six studies as prolonged/continuous (Cummings et al. 1988; Curry et al. 1988; Gunther et al. 
1992; Cinciripini et al. 1995; Etter et al. 2009; Hughes et al. 2010). Flaxman (1978) did not 
report how abstinence was defined. Abstinence was verified in eight of the included studies, 
by either expired carbon monoxide (Jerome, Behar et al. 1999; Riley et al. 2005; Etter et al. 
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2009; Hughes et al. 2010), saliva cotinine (Cinciripini et al. 1995; Etter et al. 2009), saliva 
thiocyanate (Curry et al. 1988), or asking a relative or friend to confirm the participant had 
stopped smoking (Cummings et al. 1988; Roales-Nieto & Fernández Parra 1992). However 
for the purposes of this review verified data were not used for one of the studies (Cummings 
et al. 1988), as there were problems with the naming of a friend or relative to verify 
participants’ self report. If participants did not name a person to verify their self-report, or if 
their self-report contradicted their friend’s/relative’s then they were classed as smoking; 
however 20% of those claiming abstinence did not provide a friend/relative. Participants who 
lived alone were four times more likely not to name a person for verification than those who 
lived with others.  
 
All of the study reports either reported ITT analysis or provided sufficient information to 
allow calculation of this, apart from Cummings et al. (1988) where the authors provided this 
information when contacted. Only two studies (Etter et al. 2009; Hughes et al. 2010) reported 
information about adverse events. Further information was obtained from these authors, and 
some limited information about adverse events was also obtained from the authors of Riley et 
al. (2005). Reporting was not consistent across studies and so it was not possible to carry out 
a meta-analysis; therefore these data are synthesised qualitatively. 
 
3.4.1.3 Excluded studies 
Studies which were identified as potentially relevant but later excluded are listed, with 
reasons for exclusion, in the characteristics of excluded studies tables (Appendix 20). The 
primary reasons for exclusion fell into one of three categories: 1) The goal of the intervention 
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was to reduce smoking and control it, rather than quit (Hatsukami et al. 1988; Bolliger 2000- 
Rosette trial); 2) the main outcome was smoking rates, and it was not possible to calculate 
abstinence rates from the data presented, or to get these from the authors (Marston & McFall 
1971); or 3) both of the trial arms quit in the same way (Bernard & Efran 1972; Glasgow et al. 
1989; Cinciripini et al. 1994; Herrera et al. 1995; Daughton et al. 1998; Jerome, Fiero et al. 
1999; Rose et al. 1998; Bolliger 2000- CEASE trial; Schuurmans et al. 2004; Rose et al. 
2006; Rezaishiraz et al. 2007; Bullen et al. 2010; Rose et al. 2009; Shiffman et al. 2009). Five 
of the excluded studies examined pre-treatment with NRT versus placebo prior to the quit 
date, and did not instruct smokers to reduce pre-quit (Rose et al. 1998; Schuurmans et al. 
2004; Rose et al. 2006; Rose et al. 2009; Bullen et al. 2010). These studies are included in the 
meta-analysis of nicotine preloading treatment, reported in Chapter 4. Three of these reported 
that participants spontaneously reduced whilst using the NRT (Rose et al. 1998; Rose et al. 
2006; Rose et al. 2009), two of which found that participants who reduced their smoking the 
most were more likely to achieve abstinence (Rose et al. 2006; Rose et al. 2009). However, as 
none of the studies instructed participants to reduce their smoking during the pre-cessation 
phase of the treatment, this success cannot be attributed to an instruction to reduce and so the 
studies were excluded from this review. 
 
3.4.2 Effects of interventions 
3.4.2.1 Abstinence Outcome 
The main meta-analysis included 10 trials with a total of 3760 participants. There was 
evidence that reduction produced similar quit rates to abrupt cessation and that any difference 
in effectiveness was small. The overall RR for abstinence, for reduction versus abrupt 
  CHAPTER 3: ABRUPT ‘VS’ REDUCTION COCHRANE REVIEW 
 
 
83 
cessation was 0.94 (95% CI= 0.79, 1.13) (Figure 4). There was low heterogeneity (I² = 14%), 
suggesting that the effect of reduction relative to abrupt cessation did not differ across trials. 
For all studies CIs spanned one, indicating no study achieved statistically significant 
superiority of either gradual or abrupt cessation. We have not reported pooled quit rates 
because studies varied on a number of factors, such as definition of abstinence (point 
prevalence or prolonged), length of abstinence (6 months or 12 months), whether or not 
behavioural support was provided, and whether pharmacotherapy was provided, meaning that 
average rates would not be useful. 
 
  
Study or Subgroup
Flaxman 1978
Hughes et al. 2010
Jerome, Behar et al. 1999
Gunther et al. 1992
Riley et al. 2005
Curry et al. 1988
Etter et al. 2009
Cinciripini et al. 1995
Cummings et al. 1988
Roales-Nieto et al. 1992
Total (95% CI)
Total events
Heterogeneity: Chi² = 10.41, df = 9 (P = 0.32); I² = 14%
Test for overall effect: Z = 0.65 (P = 0.51)
Events
9
12
43
12
21
16
32
20
35
2
202
Total
32
297
415
55
227
65
154
65
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7
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9
21
39
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19
19
31
17
23
0
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Total
16
299
296
55
196
74
160
63
615
7
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5.9%
10.3%
22.5%
6.9%
10.1%
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15.0%
8.5%
11.8%
0.2%
100.0%
M-H, Fixed, 95% CI
0.50 [0.25, 1.01]
0.58 [0.29, 1.15]
0.79 [0.52, 1.18]
0.86 [0.44, 1.68]
0.95 [0.53, 1.72]
0.96 [0.54, 1.70]
1.07 [0.69, 1.67]
1.14 [0.66, 1.97]
1.41 [0.85, 2.36]
5.00 [0.28, 88.53]
0.94 [0.79, 1.13]
Reduction to quit Abrupt quitting Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours abrupt quitting Favours reduction to quit
 
 
Figure 4: A forest plot illustrating the outcome of the reduction to quit versus abrupt 
quitting meta-analysis (abstinence outcome) 
 
3.4.2.2 The effect of gradual versus abrupt cessation in participants using 
pharmacotherapy 
The studies were split into two sub-groups to assess whether the effect of gradual cessation 
depended on whether people used smoking cessation pharmacotherapy or not. One sub-group 
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included studies that didn’t use any pharmacotherapy as part of the interventions (Flaxman 
1978; Cummings et al. 1988; Curry et al. 1988; Gunther et al. 1992; Roales-Nieto & 
Fernández Parra 1992; Cinciripini et al. 1995; Jerome, Behar et al. 1999). The other sub-
group included the remaining studies (Riley et al. 2005; Etter et al. 2009; Hughes et al. 2010), 
which utilised NRT pre- and post-quit in the reduction interventions and post-quit in the 
abrupt interventions. There was no evidence of the superiority of either gradual or abrupt 
cessation whether NRT was used (RR= 0.89, 95% CI= 0.65, 1.22), or not (RR= 0.97, 95% 
CI= 0.78, 1.21), and neither was there evidence that pharmacotherapy modified the effect of 
reduction versus abrupt cessation (Figure 5). 
 
Study or Subgroup
1.2.1 Pharmacotherapy (NRT) used
Etter et al. 2009
Hughes et al. 2010
Riley et al. 2005
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 2.26, df = 2 (P = 0.32); I² = 12%
Test for overall effect: Z = 0.70 (P = 0.48)
1.2.2 No pharmacotherapy used
Cinciripini et al. 1995
Cummings et al. 1988
Curry et al. 1988
Flaxman 1978
Gunther et al. 1992
Jerome, Behar et al. 1999
Roales-Nieto et al. 1992
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 8.21, df = 6 (P = 0.22); I² = 27%
Test for overall effect: Z = 0.29 (P = 0.77)
Total (95% CI)
Total events
Heterogeneity: Chi² = 10.41, df = 9 (P = 0.32); I² = 14%
Test for overall effect: Z = 0.65 (P = 0.51)
Test for subgroup differences: Not applicable
Events
32
12
21
65
20
35
16
9
12
43
2
137
202
Total
154
297
227
678
65
662
65
32
55
415
7
1301
1979
Events
31
21
19
71
17
23
19
9
14
39
0
121
192
Total
160
299
196
655
63
615
74
16
55
296
7
1126
1781
Weight
15.0%
10.3%
10.1%
35.4%
8.5%
11.8%
8.8%
5.9%
6.9%
22.5%
0.2%
64.6%
100.0%
M-H, Fixed, 95% CI
1.07 [0.69, 1.67]
0.58 [0.29, 1.15]
0.95 [0.53, 1.72]
0.89 [0.65, 1.22]
1.14 [0.66, 1.97]
1.41 [0.85, 2.36]
0.96 [0.54, 1.70]
0.50 [0.25, 1.01]
0.86 [0.44, 1.68]
0.79 [0.52, 1.18]
5.00 [0.28, 88.53]
0.97 [0.78, 1.21]
0.94 [0.79, 1.13]
Reduction to quit Abrupt quitting Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours abrupt quitting Favours reduction to quit  
Figure 5: Forest plots illustrating the outcome of the sub-group analysis investigating 
the impact of pharmacotherapy use on the reduction to quit versus abrupt quitting 
meta-analysis (abstinence outcome) 
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3.4.2.3 The effect of the type of behavioural support utilised 
We also conducted a sub-group analysis, splitting studies based on the type of therapy 
provided. Some of the included studies used self-help therapy (Cummings et al. 1988; Jerome, 
Behar et al. 1999; Riley et al. 2005; Etter et al. 2009), and some behavioural support 
(Flaxman 1978; Gunther et al. 1992; Roales-Nieto & Fernández Parra 1992; Cinciripini et al. 
1995; Hughes et al. 2010). Curry et al. (1988) included study arms that were self-help and 
others that were behavioural, so these were split accordingly for the sake of this analysis. 
Again the risk estimates were similar whether the instruction of how to quit and support for 
achieving this was given by self-help (RR= 0.98, 95% CI= 0.78, 1.23) or by behavioural 
support (RR= 0.87, 95% CI= 0.64, 1.17), and neither reduction nor abrupt quitting resulted in 
superior quit rates in either case (Figure 6). 
 
3.4.3 Adverse Events Outcomes 
The secondary objective of this review was to compare adverse events between arms, 
however no attempt has been made to do this quantitatively as there was a lot of variation in 
the nature and depth of reporting. The seven studies that did not utilise pharmacotherapy did 
not report information about adverse events. Of the three studies using pharmacotherapy,  
Riley et al. (2005) reported no information on adverse events in the study report, but the 
authors kindly supplied further information for this review. Etter et al. (2009) and Hughes et 
al. (2010) also provided additional information, as well as data reported in the publications. 
Etter et al. (2009) and Riley et al. (2005) reported that no participants experienced SAEs. 
Etter et al. (2009) also provided data obtained in response to the question: “If you experienced 
undesirable effects due to the nicotine gum, please describe them” (open ended 
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Study or Subgroup
1.3.1 Self-help therapy
Cummings et al. 1988
Curry et al. 1988
Etter et al. 2009
Jerome, Behar et al. 1999
Riley et al. 2005
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 4.15, df = 4 (P = 0.39); I² = 4%
Test for overall effect: Z = 0.17 (P = 0.86)
1.3.2 Behavioural support
Cinciripini et al. 1995
Curry et al. 1988
Flaxman 1978
Gunther et al. 1992
Hughes et al. 2010
Roales-Nieto et al. 1992
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 7.65, df = 5 (P = 0.18); I² = 35%
Test for overall effect: Z = 0.95 (P = 0.34)
Total (95% CI)
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Heterogeneity: Chi² = 12.25, df = 10 (P = 0.27); I² = 18%
Test for overall effect: Z = 0.67 (P = 0.50)
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7
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9
9
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12
2
64
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24
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297
7
480
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13
31
39
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6
9
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0
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160
296
196
1317
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24
16
55
299
7
464
1781
Weight
11.8%
5.8%
15.0%
22.5%
10.1%
65.1%
8.5%
3.0%
5.9%
6.9%
10.3%
0.2%
34.9%
100.0%
M-H, Fixed, 95% CI
1.41 [0.85, 2.36]
0.66 [0.29, 1.49]
1.07 [0.69, 1.67]
0.79 [0.52, 1.18]
0.95 [0.53, 1.72]
0.98 [0.78, 1.23]
1.14 [0.66, 1.97]
1.50 [0.63, 3.56]
0.50 [0.25, 1.01]
0.86 [0.44, 1.68]
0.58 [0.29, 1.15]
5.00 [0.28, 88.53]
0.87 [0.64, 1.17]
0.94 [0.78, 1.13]
Reduction to quit Abrupt quitting Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours abrupt quitting Favours reduction to quit  
 
Figure 6: Forest plots illustrating the outcome of the sub-group analysis investigating 
the impact of type of support provided on the reduction to quit versus abrupt quitting 
meta-analysis (abstinence outcome) 
 
question), asked two months after target quit day. Overall the most commonly reported 
symptoms were mouth pain/dry mouth/throat burns, hiccups, stomach pain/heartburn- the 
most common side-effects from oral NRT. Nine of the total symptoms reported occurred 
more frequently in the reduction group (mouth pain/dry mouth/throat burns, hiccups, stomach 
pain/heartburn, pain/cramp in jaws, mouth ulcers, headache, eructation, heart palpitations, 
cough), four in the abrupt group (nausea, bad taste, insomnia, vomiting), and three were 
reported as frequently in both groups (malaise, constipation, diarrhoea). Hughes et al. (2010) 
reported that the incidence of adverse events rated severe was small and similar across 
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conditions. 3% of participants randomised to the reduction to quit group reported severe 
adverse events and 5% of the abrupt quit group; the incidence of discontinuation was 1% for 
both groups. 
 
3.4.4 Risk of bias  
We extracted information from each study to assess the risk of biased randomisation, whether 
allocation concealment took place, and whether incomplete outcome data was addressed. This 
was assessed as either likely to cause bias, unlikely to cause bias, or unclear, if insufficient 
information was present to make a judgement (Figure 7). 
 
 Randomisation sequence generation. Five studies reported adequate information on 
sequence generation, to be classified as having minimal chance of bias in this regard.                                     
Five of the studies (Flaxman 1978; Roales-Nieto & Fernández Parra 1992; Cinciripini 
et al. 1995; Jerome, Behar et al. 1999; Riley et al. 2005) did not describe the method 
of randomisation used, and so were classified as unclear in this category. All of the 
studies randomised individual participants, apart from Jerome, Behar et al. (1999) who 
randomised work-sites to trial arms. Trials that randomise clusters to treatment arms 
can be given a higher weighting than they should if data on individuals are entered 
into the meta-analysis. This is because the analysis assumes there is no connection 
between individuals in the same group, in the likelihood of them stopping smoking 
successfully. However, when an analysis was carried out to adjust for the clustering in 
Jerome, Behar et al. (1999), although the study weighting decreased from 22% to  
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     +    Yes/unlikely to cause bias;      -    No/likely to cause bias;       ?   unclear 
 
Figure 7: Risk of bias: a summary of judgements made about methodological quality for 
each study included in the reduction to quit versus abrupt quitting meta-analysis 
 
 
17%, the main result was not sensitive to the adjustment; RR = 0.93, 95% CI= 0.78, 
1.12 (Figure 8). 
 
 Allocation concealment. When rated in terms of concealing allocation from clinicians 
enrolling participants into studies, four studies (Cummings et al. 1988; Jerome, Behar 
  CHAPTER 3: ABRUPT ‘VS’ REDUCTION COCHRANE REVIEW 
 
 
89 
et al. 1999; Riley et al. 2005; Etter et al. 2009) were rated as unlikely to cause bias, as 
all interventions consisted of self-help therapy and there was either no or minimal 
contact with investigators/enrolling clinicians. Consequently, participants’ enrolment 
in the studies could not depend on knowledge of the allocation sequence, as there was 
no clinician deciding on whether to enrol, or which treatment to give. Hughes et al. 
(2010) was also rated as unlikely to cause bias in this category, as a statistician 
generated a concealed allocation sequence. The five remaining studies did not report 
on allocation concealment and were therefore classed as unclear. 
 
     
  
Study or Subgroup
Cinciripini 1995
Cummings 1988
Curry 1988
Etter 2009
Flaxman 1978
Gunther 1992
Hughes 2010
Jerome 1999
Riley 2005
Roales-Nieto 1992
Total (95% CI)
Heterogeneity: Chi² = 10.27, df = 9 (P = 0.33); I² = 12%
Test for overall effect: Z = 0.75 (P = 0.45)
log[Risk Ratio]
0.1313
0.3462
-0.042
0.07
-0.693
-0.154
-0.553
-0.24
-0.047
1.60943791
SE
0.2785
0.26251305
0.2937
0.2253
0.3584
0.3441
0.3525
0.2257
0.3012
1.4663
Weight
11.3%
12.7%
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17.3%
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IV, Fixed, 95% CI
1.14 [0.66, 1.97]
1.41 [0.85, 2.36]
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0.50 [0.25, 1.01]
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0.93 [0.78, 1.12]
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0.01 0.1 1 10 100
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Figure 8: A forest plot illustrating the cluster randomisation sensitivity analysis, for the 
reduction to quit versus abrupt quitting meta-analysis (abstinence outcome) 
 
 
 
 Incomplete outcome data. In the category of incomplete outcome data six studies were 
classed as unlikely to cause bias, as participant attrition was reported as similar in all 
trial arms. The four remaining studies were classed as unclear; three of the studies 
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(Flaxman 1978; Cinciripini et al. 1995; Riley et al. 2005) did not provide any 
information about participant attrition or missing data, and the abstinence rates table in 
the Cummings et al. (1988) report appeared to leave 18 participants unaccounted for. 
Due to the length of time since the study had been completed the authors could not 
clarify why this was the case, but did provide further information so that an ITT 
analysis could be carried out, in which the missing participants were classified as not 
abstinent. Participants’ attrition in general was similar across arms, however the study 
was classified as unclear, as the allocation of the missing participants and whether this 
was similar across arms was unknown. 
 
Two of the included studies (Flaxman 1978; Cinciripini et al. 1995) were rated as unclear for 
all three of the above bias categories and another two were rated as unclear for two (Roales-
Nieto & Fernández Parra 1992; Riley et al. 2005). We carried out a sensitivity analysis to 
establish whether the main result was sensitive to the exclusion of these four studies and 
found that it was not (RR= 0.94, 95% CI= 0.76, 1.16; Figure 9). 
   
Other potential sources of bias were failure to verify smoking abstinence by biochemical 
means and whether participants conformed to their allocated intervention. 
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Study or Subgroup
Hughes 2010
Jerome 1999
Gunther 1992
Curry 1988
Etter 2009
Cummings 1988
Total (95% CI)
Total events
Heterogeneity: Chi² = 5.51, df = 5 (P = 0.36); I² = 9%
Test for overall effect: Z = 0.58 (P = 0.56)
Events
12
43
12
16
32
35
150
Total
297
415
55
65
154
662
1648
Events
21
39
14
19
31
23
147
Total
299
296
55
74
160
615
1499
Weight
13.7%
29.9%
9.2%
11.7%
19.9%
15.6%
100.0%
M-H, Fixed, 95% CI
0.58 [0.29, 1.15]
0.79 [0.52, 1.18]
0.86 [0.44, 1.68]
0.96 [0.54, 1.70]
1.07 [0.69, 1.67]
1.41 [0.85, 2.36]
0.94 [0.76, 1.16]
Reduction to quit Abrupt quitting Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours abrupt quitting Favours reduction to quit
 
Figure 9: A forest plot illustrating the risk of bias sensitivity analysis, for the reduction 
to quit versus abrupt quitting meta-analysis (abstinence outcome) 
 
 Biochemical verification. Studies that did not validate self reports of abstinence 
(Flaxman 1978; Gunther et al. 1992), or where validation was potentially flawed, and 
therefore not used in this review (Cummings et al. 1988) could potentially over-
estimate abstinence. However we would not expect this to differ between arms, and a 
sensitivity analysis (Figure 10) confirmed that the main findings were not sensitive to 
the exclusion of studies where abstinence was not validated (RR= 0.91, 95% CI= 0.74, 
1.12). The SRNT Subcommittee on Biochemical Verification (2002) concluded that 
population based studies with limited face to face contact, and where data collection is 
optimally by mail, telephone, or on the Internet are unlikely to benefit from 
biochemical verification. Population studies have much higher biochemical 
verification refusal rates than clinic based studies, if all participants who refused were 
classed as smoking then this would be likely to overestimate smoking rates. In reality 
the extent that self-reports inflate abstinence rates is small and rarely differs across 
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conditions. Also, in studies where there is very little contact with an investigator or 
therapist this reduces demand characteristics, meaning there is little incentive to lie. 
 
 
Study or Subgroup
Hughes 2010
Jerome 1999
Riley 2005
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Cinciripini 1995
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Test for overall effect: Z = 0.88 (P = 0.38)
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65
7
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0
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296
196
74
160
63
7
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13.3%
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0.3%
100.0%
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0.58 [0.29, 1.15]
0.79 [0.52, 1.18]
0.95 [0.53, 1.72]
0.96 [0.54, 1.70]
1.07 [0.69, 1.67]
1.14 [0.66, 1.97]
5.00 [0.28, 88.53]
0.91 [0.74, 1.12]
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0.01 0.1 1 10 100
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Figure 10: A forest plot illustrating the non-validated abstinence sensitivity analysis, for 
the reduction to quit versus abrupt quitting meta-analysis (abstinence outcome) 
 
 
 Adherence to method of quitting allocated. Six of the 10 studies assessed whether 
participants followed the instructions they had been given on how to quit i.e. to reduce 
or quit abruptly without prior reduction. Three of these studies (Roales-Nieto & 
Fernández Parra 1992; Etter et al. 2009; Hughes et al. 2010) found that participants 
followed instructions; the participants in the reduction group reduced before quitting 
and the participants in the abrupt group quit abruptly with no prior reduction. 
Cinciripini et al. (1995) found that the reduction group complied well with their 
instructions but the abrupt group also reduced by seven to eight cpd before quitting. 
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However the reduction group smoked significantly fewer cigarettes than the abrupt 
group before quit day. The two remaining studies to report on adherence to the 
intervention allocation found that participants did not abide by intervention 
instructions. In Flaxman (1978) the group which reduced until they were not smoking 
at all reduced by a mean of 6 cpd, and the group who reduced to 50% of baseline then 
quit reduced by a mean of 3.5 cpd. However the abrupt quit group also reduced by an 
average of 3.4 cpd before they quit, meaning there was little difference between 
reduction in the partial reduction group and the abrupt quit group. Cummings et al. 
(1988) asked participants after quit day whether they had quit abruptly- 39% of 
participants in the abrupt group quit abruptly and 40% of the reduction group also quit 
abruptly- therefore there appeared to be little difference between the arms in the 
methods of quitting that were actually used. As is the case with all ITT analyses, it is 
only ever possible to examine the effect of allocation to a quitting method, not the 
effectiveness of actually following it. 
 
3.5 Discussion 
The 10 studies included in this review compared interventions that instructed participants to 
quit smoking gradually, by reducing the amount they smoked, with interventions that 
instructed participants to quit smoking abruptly without prior reduction, in smokers who 
wanted to quit. The results provide evidence that reduction to quit results in similar quit rates 
to abrupt quitting, with no evidence that one method is significantly superior to the other, in 
adults trying to quit smoking. This applies whether therapy is self-help or includes 
behavioural support, and whether the quit attempt uses NRT or not. The similarity of the 
result in the NRT sub-group and the non NRT sub-group suggests that the success of the 
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reduction interventions, relative to the abrupt quit interventions, is not due to the use of pre-
quit NRT. We were unable to combine data on absolute quit rates as studies varied on a 
number of factors expected to influence quit rates, for example length of follow-up, and so 
cannot provide meaningful estimates of average quit rates as a result of reduction to quit and 
abrupt quit interventions.  
 
We were unable to combine the adverse events data statistically, and therefore could not 
determine whether adverse events differed significantly between the intervention groups that 
reduced and used NRT pre- and post-quit, and the intervention groups where participants quit 
abruptly and used NRT post-quit. However a recent review conducted a meta-analysis (Moore 
et al. 2009) of seven placebo controlled RCTs, which used NRT to assist reduction to stop 
smoking, and found that there were no significant differences in deaths (OR= 1.00, 95% CI= 
0.25, 4.02), SAEs (OR= 1.16, 95% CI= 0.79, 1.50), and discontinuation due to adverse events 
(OR= 1.25, 95% CI= 0.64, 2.51), between the placebo and NRT interventions. The only 
adverse event that was more common in the NRT interventions was nausea (OR= 1.69, 95% 
CI= 1.21, 2.36), which is a common side effect of NRT. Taken with other safety data on 
concurrent smoking and use of NRT (Fagerstrom & Hughes 2002), there appears to be no 
reason to recommend against the practice of gradual reduction assisted by NRT. At least one 
trial shows that among smokers trying to quit smoking by gradual reduction, using NRT is 
more effective than use of placebo in supporting abstinence (Shiffman & Ferguson 2008), and 
a Cochrane Review of smoking harm reduction (Stead & Lancaster 2007) found that people 
who did not originally want to quit smoking were more likely to be abstinent from cigarettes 
at long-term follow-up when NRT was used as an aid to reduction than when a placebo was 
used (OR= 1.90, 95% CI= 1.46, 2.47). On this basis, if reduction is to be used as a means of 
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quitting, use of NRT or other pharmacotherapy appears desirable. NRT is licensed for use in 
this way in the UK and Australia, however at the time of writing the US Medicines Regulator, 
along with other pharmaceutical regulators have not yet licensed NRT for this purpose.  
 
An important limitation of any meta-analysis is that methods vary across studies and the 
underlying assumption that the meta-analysis is trying to estimate a single true rate ratio 
might not hold. In this instance patient populations, outcome definitions, provision of 
pharmacotherapy and the behavioural support provided varied across the included trials. 
Despite this, the measure of heterogeneity was low, suggesting that heterogeneity of these 
elements did not translate into heterogeneity of effectiveness of reduction. One of the studies 
also varied because it used cluster randomisation, but sensitivity analysis suggested that 
allowing for this or not had little influence on the result of the meta-analysis. Four of the 
studies included in the meta-analysis (Flaxman 1978; Cummings et al. 1988; Curry et al. 
1988; Cinciripini et al. 1995) had more than one intervention that qualified as reduction 
and/or abrupt quitting, and these were combined to create one reduction arm and one abrupt 
quit arm per study. We considered entering data from each trial arm separately to see if this 
would give us any more detailed information about the relative success of different reduction 
methods, however the methods used differed in each study (scheduled, non scheduled, group 
behavioural support, individual behavioural support, reduction to zero cigarettes before quit, 
reduction to 50% of baseline before quit etc), so they could not be pooled for a sub-group 
analysis, and therefore would be no more informative than the original studies. There is 
however some evidence that structured methods of reduction are more effective than simple 
advice to cut-down without following specific methods (Levinson et al. 1971; Cinciripini et 
al. 1995).  
  CHAPTER 3: ABRUPT ‘VS’ REDUCTION COCHRANE REVIEW 
 
 
96 
 
Two of the 10 included studies (Etter et al. 2009; Hughes et al. 2010) were assessed as 
unlikely to cause bias for all three of the Cochrane risk of bias categories assessed. These 
studies were the most recent of the 10 studies, which may suggest that their increased 
reporting, relative to the other eight studies, is due to awareness of the revised CONSORT 
reporting guidelines (Moher et al. 2001), which were published in 2001, and advise reporting 
methods of sequence generation and allocation concealment, and a flow diagram illustrating 
the flow of participants through the study. Seven of the studies rated in at least one bias 
category as ‘No’ or ’Unclear’ were published before 2001, and the remaining study was not 
written up for publication. Therefore lack of reporting may be for these reasons rather than 
because bias is present. This may also explain why the reporting of adverse events was only 
present in the most recent studies. The main results of the two most recent studies do not 
differ much from the main results of the eight older studies; therefore there is no evidence that 
studies reporting better randomisation procedures produced different results. Many of the 
older studies did not propose a hypothesis that favoured either a reduction or an abrupt 
quitting intervention (Flaxman 1978; Curry et al. 1988; Gunther et al. 1992; Roales-Nieto & 
Fernández Parra 1992; Cinciripini et al. 1995), so in the cases where allocation concealment 
was not reported, and so may not have occurred, there is no reason why allocation would have 
been carried out to favour any particular arm.  
 
Whilst assessing studies for eligibility there were two studies (Curry et al. 1988; Jerome, 
Behar et al. 1999) where uncertainty arose about whether the intervention methods were 
abrupt or reduction to quit. Curry et al. (1988) reported that one method of quitting used in the 
study was “cold turkey” and that the other was “tapering and nicotine fading”. There is no 
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further detail given on these methods so we contacted the authors who confirmed that one of 
these methods was an abrupt quit method and the other was a reduction to quit method, which 
met the inclusion criteria. Jerome, Behar et al. (1999) consisted of a study arm where 
participants reduced and then quit using a handheld computer, and an arm where participants 
were provided with an American Lung Association self-help booklet called “Freedom From 
Smoking For You and Your Family”. The study report did not specify whether this booklet 
advised an abrupt quitting method or a reduction to quit method, and the authors and the 
American Lung Association were unable to provide additional information. However Davis et 
al. (1992) includes a table comparing the content of three self-help guides including this one, 
which reported that the topic of cutting down smoking is not covered. We therefore believe 
that including these studies in the review is appropriate. The failure of studies to clarify 
methods used to achieve abstinence does raise the possibility that studies could have been 
missed because authors described them in terms that were not expected. We followed-up 
included studies’ reference lists to check for other studies that may not have come up in the 
search, and no other studies were found. Nevertheless, we could have failed to include all 
extant studies, but there is no reason why publication bias or failure to find less clearly 
described or less prominent studies would be expected to bias the results towards reduction or 
abrupt cessation methods. 
 
Surveys carried out in the general population (Cheong et al. 2007; West & Fidler 2011) have 
found that gradual quitting isn’t as effective as abrupt quitting, however these differ from the 
RCTs included in this meta-analysis in ways that may explain the difference in outcomes. The 
participants quitting gradually in the RCTs (whether support was behavioural or self-help) 
were all provided with some instructions as to how to quit, which included setting quotas of 
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cigarettes to reduce by, and setting time intervals at which participants could smoke. All of 
the included studies also appeared to require participants to set a target quit day, providing 
them with a goal to work toward. However, the participants included in the observational 
studies will have quit using a number of methods of gradual reduction, and it is likely that 
these will vary in their levels of success. The UK and US national guidelines do not 
recommend cutting down before quitting and therefore services such as the UK NHS SSS 
only offer abrupt quitting as a cessation method. This means that those participants who 
choose gradual cessation in the general population are less likely to have benefited from any 
kind of support whilst quitting (although this wasn’t the case in the Cheong et al. 2007 and 
West & Fidler 2011 studies, where behavioural support was not used or used rarely 
respectively), which in the case of the NHS SSS has been found to increase quit rates by up to 
four times (Hughes et al. 2004; Ferguson et al. 2005). Therefore quitters choosing gradual 
reduction are automatically put at a disadvantage. A person who quits without support may 
also be more likely to use an unstructured method, with no reduction goals, no particular 
method of reducing, and no target quit day. Cinciripini et al. (1995) found that those 
participants that quit using unstructured reduction were less successful than those who used a 
more structured method.  
 
Two previous meta-analyses (Law & Tang 1995; Fiore et al. 2008) have looked at nicotine 
fading as a smoking cessation intervention. These, however, differ from the current analysis, 
because as well as including studies where participants were asked to reduce nicotine intake 
by reducing the number of cigarettes they smoked, they also included studies where 
participants were asked to use graduated filters to remove progressively more nicotine from 
inhaled smoke, and studies where participants changed brands to cigarettes of successively 
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lower nicotine yield. We chose not to combine all of these approaches in the current analysis 
as there is reason to believe that the different methods do not all work by the same 
mechanisms. For example, one of the ways reducing cigarettes smoked may work is by 
weakening links between environmental cues (e.g. socialising) and smoking a cigarette 
(Section 1.2.2). This wouldn’t be applicable to using nicotine filters as the person is still 
smoking in all of the same situations, and therefore still associates smoking with the same 
environmental cues. One of the reviews (Law & Tang 1995) compared the gradual quitting 
interventions with sudden or abrupt cessation, as in this review, however the second (Fiore et 
al. 2008) compared nicotine fading with untreated control conditions, and therefore the 
relative effectiveness of reducing nicotine intake and abrupt quitting was not reported. Fiore 
et al. (2008) found that there was no effect of using nicotine fading techniques when 
compared to no treatment, however Law & Tang (1995) found that gradual cessation was 5% 
(95% CI=  2% to 11%) more effective than abrupt quitting, although this difference was not 
significant (p>0.10). Therefore, as in this analysis neither abrupt quitting nor reducing to quit 
provided superior quit rates.  
 
The result of this analysis suggests that public health messages on cessation and cessation 
services supporting individuals who smoke could advocate or offer reduction as a way to quit 
for people who intend to quit soon. They can be confident that if people choose to quit by 
reducing before stopping entirely, this would not put them at a disadvantage compared with 
those who choose to smoke as normal and then quit abruptly. Reduction to quit might help 
those who have tried to quit a number of times without success and are disillusioned with the 
abrupt quit method. Having a new way to quit could give renewed hope, especially as many 
smokers see reduction as an intuitive first step toward stopping smoking completely (Hughes 
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et al. 2006; West 2008). Offering reduction to quit may also appeal to those who would 
otherwise not seek behavioural support and pharmacotherapy because they want to pursue 
gradual cessation, and this is not currently supported. This would then enhance the proportion 
of the population that make assisted quit attempts and boost population cessation rates. The 
increase in success rates achieved when behavioural support is provided (Section 1.3) 
suggests that efforts should be made to encourage as many people as possible to use cessation 
services. Our sub-group analysis, however, suggests that reduction is as successful as abrupt 
quitting whether the intervention consists of behavioural support or is self-help. Therefore this 
result could also benefit people who want to quit smoking on their own, without behavioural 
support. If people who smoke are aware of an additional effective quitting method then this 
could also encourage more of those, who want to quit independently, to do so.  
 
Although the statistical heterogeneity in this review was not significant reduction versus 
abrupt quitting RRs did vary to some extent across the studies included in this meta-analysis 
(from Flaxman (1978): RR= 0.50, 95% CI= 0.25, 1.01 to Roales-Nieto & Fernández Parra 
(1992): RR= 5.00, 95% CI= 0.28, 88.53). We may expect the effect of the abrupt 
interventions to be constant across studies as quit instructions did not vary, suggesting that 
there may be a difference in the success rates of different reduction methods. This is 
supported by the fact that gradual reduction has been found to be less successful than abrupt 
quitting in observational studies, but as successful in RCTs. The studies included in this 
review used a number of different methods, including scheduled reduction, non-scheduled 
reduction, reducing to zero cigarettes before quitting, and reducing to 50% of baseline before 
quitting. However a calculation of the ‘risk’ of quitting when quitting abruptly in each study 
suggests that this does vary to some extent across studies (Range = 0.04-0.56), and more so 
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than when quitting by reducing smoking first (Range = 0.04-0.33). Therefore this variation 
could be due to variation in study characteristics rather than the interventions used.  
 
Nevertheless, there are conceivably many ways that people could reduce before going on to 
quit completely. Trials that have been carried out so far to compare different reduction 
methods are small and often participants aim to reduce rather than to quit completely. 
Therefore, further work is needed to identify the most effective reduction methods in those 
wanting to quit. Ideally this would be a review which amalgamates existing evidence and 
identifies literature gaps, leading to large-scale RCTs that directly compare different methods. 
In turn, this could inform policy and service development as to the most successful reduction 
to quit method or methods. If there are marginal differences in the effects of different 
reduction methods then quitters could choose from a number of options. However, if there are 
methods shown to be significantly less effective quitters should not be advised to use them, as 
this might put them at a disadvantage. It may prove useful to establish whether different 
quitting methods benefit different groups of smokers; for example, a particular method may 
benefit a highly addicted smoker more than a less addicted one. If so, then a person could use 
a quitting method tailored to their individual profile, to produce the optimal likelihood of 
abstinence. Further research also needs to be carried out to investigate the methods of gradual 
reduction that smokers in the general population are using, and whether they are using any 
type of support alongside. This could establish whether this accounts for the difference in 
results between observational studies and RCTs. 
 
Finally, so far there has been no assessment of the cost-effectiveness of a reduction to quit 
cessation method. This is likely to be influenced by the intensity of the behavioural support 
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for the reduction method used, whether pharmacotherapy is used alongside behavioural 
support, and the length of the reduction period before the quit day. Now that there is efficacy 
evidence to suggest that reduction could be used alongside abrupt quitting economic data 
would also be useful to aid health care commissioners in their decision making. If reduction to 
quit is as cost-effective as abrupt quitting this would give further support for its use in the 
NHS. 
 
In summary, we believe that the methods used in this review allow us to draw robust 
conclusions about the relative effectiveness of the two cessation methods compared. As with 
any meta-analysis there are concerns that a single rate ratio may not hold, however the 
heterogeneity in this meta-analysis was low, reducing this possibility. Despite the fact that 
some studies do not report interventions used clearly we are confident that we have identified 
existing studies, due to the fact that the literature review was systematic and that the reference 
lists of relevant studies were also searched. We believe another strength of this review to be 
that a thorough quality assessment and sensitivity analyses, where necessary, were carried out 
of included studies, to assess the risk of bias and allow the reader to make their own 
decisions. In all cases methods have been reported transparently allowing for replication and 
update of the review where necessary.  
 
We found no big differences in effect when advising people who smoke, and want to quit, to 
quit abruptly or advising them to reduce cigarette consumption prior to quit day, i.e. gradual 
quitting. These results apply to gradual quitting methods that all employed a definite quit day, 
and it is not clear whether telling people to cut down and quit when they are ready would 
achieve the same results. Given these findings, it seems reasonable to offer smokers a choice 
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of whether to cut down in preparation for quitting or to continue to smoke as normal and quit 
abruptly. 
 
3.6 Conclusions 
3.6.1 Implications for research 
• Further research should focus on methods of reduction that smokers in the general 
population use to quit, and whether they utilise behavioural or self-help support 
alongside these. 
• A review of the existing literature on methods of smoking reduction is needed, and 
RCTs should be developed to determine which methods of reduction are the most 
effective. 
• Research is needed to try and establish people who may benefit most from the abrupt 
and gradual approaches to quitting smoking, in order to tailor smoking cessation to 
individuals. 
• Future research into reduction methods should include assessment of cost-
effectiveness. 
 
3.6.2 Implications for practice 
• Smokers could be given a choice to quit smoking either by reducing cigarettes smoked 
before quitting or by quitting abruptly with no prior reduction. 
• Reduction to quit could be implemented via self-help therapy or with the aid of 
behavioural support. 
• NRT could be used to aid pre-quit reduction.
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CHAPTER 4: AN UPDATED META-ANALYSIS OF NICOTINE 
PRELOADING FOR SMOKING CESSATION, IN SMOKERS 
WHO WANT TO QUIT: INVESTIGATING MEDIATORS OF 
THE EFFECT 
 
4.1 Background 
Nicotine preloading means using NRT prior to quitting smoking. As mentioned previously 
(Section 1.5.5) two meta-analyses of nicotine patch preloading, in comparison to no 
preloading or placebo patch preloading, reported very positive results. Shiffman and Ferguson 
(2008) gave an OR of 1.96 (95% CI= 1.31, 2.93) for six weeks abstinence, and an OR of 2.17 
(95% CI= 1.46, 3.22) for six months, and a Cochrane review (Stead et al. 2008) a RR of 1.79 
(95% CI= 1.17, 2.72) for long-term abstinence (6 or 12 month). Since these reviews were 
published the results of three more trials have become available (Etter et al. 2009; Bullen et 
al. 2010; Hughes et al. 2010), as well as six month quit rates from a study by Rose et al. 
(2009), which is cited as Rose et al. (2007) in Shiffman and Ferguson's (2008) review.  
 
Neither previous review (Shiffman and Ferguson 2008; Stead et al. 2008) investigated 
possible mediators of the efficacy of preloading. However knowing the mechanisms of action 
could have clinical implications. For example, preloading could reduce the reward from 
smoking, help extinguish the learned need to smoke, and lead to reduced withdrawal intensity 
after cessation of smoking (Section 1.2.3). One hypothesis that flows from this is that 
lengthening the preloading period might enhance efficacy. Furthermore, a clinician could 
  CHAPTER 4: UPDATED PRELOADING REVIEW 
 
 
105 
measure reward from smoking and lengthen preloading or advise quitting depending upon 
responses of individual patients.  
 
We developed three mediational hypotheses to test in this review. The first is that preloading 
reduces reward from smoking which facilitates the extinction of learned associations between 
cues to smoke and smoking, as outlined in Section 1.2.3. This would lead to reduced 
dependence, reduced withdrawal symptoms and craving on stopping smoking, and enhance 
the likelihood of cessation success. If this mechanism holds, we would expect nicotine 
patches to be more effective than short-acting forms of NRT. This is because nicotine patches 
used concurrently with smoking lead to supra-normal blood nicotine concentrations 
(Fagerstrom and Hughes 2002), that we expect would blunt reward, reduce the need to smoke 
to avoid withdrawal, and hence undermine the learned basis of tobacco addiction. Short-
acting NRT, such as gum, used concurrently with smoking produces blood nicotine 
concentrations similar to those while smoking only (Fagerstrom and Hughes 2002). We 
expect in this situation that the natural fall in blood nicotine concentrations will mean that 
smoking is more rewarding than on a patch and that preloading with a short-acting form of 
NRT will be less effective. It follows from this that higher blood nicotine concentrations 
(usually measured by cotinine) will be associated with greater cessation efficacy. It also 
follows that we would expect reduced exhaled CO concentrations, as preloading reduces 
smoking intensity due to reduced reward.  
 
The second mediational hypothesis is that preloading accustoms smokers to using NRT, 
which leads to greater use of NRT after quit day. Greater use of NRT after quit day is 
associated with increased likelihood of abstinence (Shiffman 2007; Stead et al. 2008). If this 
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hypothesis holds we would expect to see higher use of NRT in the intervention arm than the 
control arm. However, NRT use after quit day is contingent on participants' intentions. Once a 
participant decides continuing to quit is futile or no longer desired, s/he usually stops NRT. A 
trial showing higher abstinence in one arm than another could show higher use of NRT for 
this reason alone, so we need to account for this.  
 
Our third mediational hypothesis is that smoking while using NRT leads to reduced cigarette 
consumption, based on findings reported in Section 1.5.5, which will increase a person's 
confidence that he or she can stop smoking. Confidence or self-efficacy is associated with 
increased likelihood of cessation (Gwaltney et al. 2009).  
 
In addition to these mediational hypotheses, we also examined the evidence that behavioural 
support modifies the effectiveness of preloading. Until recently, smokers were warned even 
by the package inserts that smoking while wearing the nicotine patch was dangerous, and 
there is no intuitive reason for people to assume that smoking while using a patch would help. 
Behavioural support is assumed to be effective partly by enhancing adherence to medication, 
as users are able to voice their doubts and be directly reassured by therapists. If this is the 
case, we hypothesise that more intensive pre-quit behavioural support would be associated 
with better adherence in the pre-quit period. However, if adherence is high during preloading, 
even without behavioural support, we would expect behavioural support not to modify the 
effectiveness of preloading.   
 
Finally, we also assessed evidence of any additional moderation in trial reports. 
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4.2 Method 
4.2.1 Inclusion criteria 
Studies were included if they were RCTs, if participants were cigarette smokers attempting to 
quit, if the intervention was a smoking cessation intervention with a pre-quit phase during 
which participants were randomised to receive active NRT daily for at least a week or a 
control of either placebo or no NRT, if the nicotine content of cigarettes smoked pre-quit were 
comparable across conditions, if post-quit NRT and overall behavioural support was 
comparable across conditions, and if abstinence was reported at six month follow-up or later.  
 
4.2.2 Search strategy 
Studies relevant for inclusion were sought from already published reviews of preloading, and 
from the MEDLINE, EMBASE and PsycINFO databases, using the following topic-specific 
terms: nicotine or NRT, combined with any of the following: pre-cessation, precessation, pre 
cessation, pre-loading, preloading, pre loading, pre-treatment, pretreatment, pre treatment, 
pre-quit, prequit, pre quit, before treat*, before quit*, before cessation (See Appendix 21 for 
complete search strategies).  
 
4.2.3 Study eligibility assessment  
The titles and abstracts generated from the search strategy, as well as the reference lists of 
relevant papers, were checked for relevance using the inclusion criteria above (see Appendix 
22 for the study eligibility form used to do this).  
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4.2.4 Data extraction 
Data on the following were then extracted from each relevant paper: study design, setting of 
study, method of participant recruitment, type of NRT, type of support/participant contact, 
follow-up point, number of participants randomised to each group, participant characteristics 
at baseline, definition of abstinence, whether abstinence was biochemically verified, the 
number of quitters in each arm, and secondary outcomes. 
 
4.2.5 Outcomes 
Primary outcomes were both short-term abstinence and long-term abstinence at least six 
months after quit day. In trials with more than one measure of abstinence, we preferred the 
measure with the strictest criteria. We used prolonged or continuous abstinence over point 
prevalence abstinence, and biochemically validated abstinence over self-report, for both short-
term outcomes and abstinence at least six months from quit date. We also extracted data on 
the possible mediators and moderators of the effect of preloading. 
 
4.2.6 Quality assessment 
The quality of each included study was assessed within the domains of randomisation 
sequence generation, concealment of allocation to study arm, blinding to study arm allocation, 
and incomplete outcome data. This assessment was carried out according to procedure 
outlined in the Cochrane Collaboration Handbook (Higgins and Green 2009). Whether studies 
validated self-reported abstinence was also considered. A sub-group analysis was used to 
compare the effect of preloading in double-blinded studies using placebo NRT in the control 
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groups, with studies that were unblinded. We also examined funnel plots to investigate 
possible publication bias. 
 
4.2.7 Analysis 
With an aim to establish the efficacy of preloading we compared both short- and long-term 
quit rates between treatment arms using pre-quit NRT and the arms using placebo/no pre-quit 
NRT, calculated on an ITT basis. Participants lost to follow-up were classified as smokers.  
This meta-analysis was carried out using the RevMan 5.1 computer programme developed by 
the Cochrane Collaboration. RR was used as the summary statistic in all meta-analyses, using 
the Mantel–Haenszel fixed-effect model. We checked for heterogeneity by examining forest 
plots for poor overlap of confidence intervals and using the I² and the chi-squared Q statistics.  
 
In order to establish how preloading may work and in which circumstances it may be most 
effective we tested our hypotheses, by carrying out the following a priori analyses. Where 
analysis is qualitative this is because insufficient quantitative data was provided to conduct 
meta-analyses. 
 
4.2.7.1 Hypothesis 1. Efficacy is mediated through reduced reward and hence 
reduced dependence 
We synthesised the data qualitatively to examine the effects of preloading on reward, negative 
reinforcement, cigarette smoking, and post-quit withdrawal intensity. Furthermore, we split 
the studies into those providing two and four weeks preloading, and those using patch and 
gum consistent with the hypotheses reported in Section 4.1, using meta-analyses. 
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4.2.7.2 Hypothesis 2. Efficacy is mediated through increased post-quit 
adherence 
We synthesised the data qualitatively to examine whether post-quitting adherence was higher, 
in participants who continued to try to quit, in those who had carried out preloading in 
comparison to those who had not. 
 
4.2.7.3 Hypothesis 3. Efficacy is mediated through increased confidence 
We examined qualitatively whether confidence before quitting increased more in the 
preloading groups relative to the control groups. 
 
4.2.7.4 Hypothesis 4. Behavioural support modifies the effect of preloading 
We qualitatively examined whether the degree of behavioural support provided was 
associated with enhanced adherence to pre-quit NRT. We also investigated whether studies 
that provided less support in the pre-quit period were associated with reduced smoking 
cessation efficacy, using meta-analysis. 
 
Finally we examined baseline individual differences, as potential moderators of the effect of 
preloading on abstinence, and synthesised the available data. 
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4.3 Results 
4.3.1 Included studies and participants 
Our database searches retrieved 129 references and after title and abstract searches we were 
left with 15 full-text papers (See Appendix 23 for study inclusion flow diagram). After 
checking the full-text against the inclusion criteria, we found eight studies relevant for 
inclusion (Rose et al. 1994; Rose et al. 1998; Schuurmans et al. 2004; Rose et al. 2006; Etter 
et al. 2009; Rose et al. 2009; Bullen et al. 2010; Hughes et al. 2010) (Table 5). Four of these 
were included in Stead et al.'s (2008) review (Rose et al. 1994; Rose et al. 1998; Schuurmans 
et al. 2004; Rose et al. 2006), and four were included in Shiffman and Ferguson's (2008) 
review (Rose et al. 1998; Schuurmans et al. 2004; Rose et al. 2006; Rose et al. 2009). We 
found three studies published since these reviews were conducted (Etter et al. 2009; Bullen et 
al. 2010; Hughes et al. 2010). The total sample size in the preloading arms was 1,403 across 
the eight studies, ranging from 24 to 549 in individual studies. In the control arms total 
sample size was 1,410, ranging from 24 to 551 across studies. All of the studies recruited 
participants attempting to quit smoking. On average participants were evenly split between 
males and females, their mean age was 42 years, average cpd ranged from 19 to 30 across 
studies, with a median of 24 cpd, and a median FTND of 6. In all but one of the studies 
(Hughes et al. 2010) all trial arms were relevant and included in the analyses; however 
Hughes et al. (2010) included a third arm where participants were randomised to a minimal 
treatment condition. As this trial arm received a different level of behavioural support to the 
preloading condition this could impact on the resulting effect, and so it was not included in 
the analyses. 
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Table 5: Characteristics of studies included in the preloading meta-analyses 
FTND- Fagerstrom Test for Nicotine Dependence, cpd- cigarettes per day, NRT- nicotine replacement therapy, CO- carbon monoxide, mg- milligram, hr- hour, N- 
number of participants
Study ID Total 
N 
Preloading 
N 
Control 
N 
Mean age % female Mean 
baseline 
FTND 
Mean 
baseline cpd 
Length of 
preloading 
(weeks) 
Pre-quit 
NRT 
Preloading 
smoking 
instructions 
Measure of 
short-term 
abstinence  
Measure of long-
term abstinence  
Bullen et al. 
(2010) 
1100 549 551 40 60 6 19 2 Patch 
+/or gum 
Smoke 
freely 
12 week self-
reported, 
continuous  
6-month self-
reported, 
continuous  
Etter et al. 
(2009) 
314 154 160 Preloading = 
42 
Control= 44 
Preloading = 
35 
Control= 47 
Preloading = 
5.5 
Control= 5.4 
Preloading = 
24 
Control= 23.4 
4 4mg gum Reduce 8 week self-
reported 
continuous 
12 month, 
cotinine & CO 
verified, 4 week 
prolonged 
Hughes et al. 
(2010) 
596 297 299 48 54 5.9 23 3-5 2 or 4mg 
lozenge 
Reduce 12 week self-
reported, 
prolonged  
6 month CO 
verified, 
prolonged 
Rose et al. 
(1994) 
48 24 24 34 60 6 28 2 21mg/24
hr 
patches 
Smoke 
freely 
7 week CO 
verified, 
continuous 
12 month CO 
verified, 
continuous 
Rose et al. 
(1998) 
80 40 40 41 49 6.4 29.9 4 21mg/24
hr 
patches 
Smoke 
freely 
6 week CO 
verified, 
continuous 
6 month CO 
verified, 
continuous 
Rose et al. 
(2006) 
96 48 48 45 53 6.5 28.6 2 21mg/24
hr 
patches 
Smoke 
freely 
4 week CO 
verified, 
continuous 
6 month CO 
verified, 7-day 
point prevalence 
Rose et al. 
(2009) 
379 191 188 42 57 5.9 23.1 2 21mg/24
hr 
patches 
Smoke 
freely 
6 week CO 
verified, 
continuous 
6 month CO 
verified, 
continuous 
Schuurmans et 
al. (2004) 
200 100 100 44 44 6.1 24.8 2 15mg/16
hr 
patches 
Smoke as 
normal 
6 week, CO 
verified, 
continuous 
6month, CO 
verified, 
continuous 
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4.3.2 Excluded studies 
The seven studies that were excluded at this stage were excluded for the following reasons: 
participants were not asked to preload as defined for the purposes of this review (Powell et al. 
2004; Chan & Davenport 2010); the nicotine content of cigarettes was varied across study 
arms pre-quit (Rezaishiraz et al. 2007); the NRT treatment was not comparable across study 
arms post-quit (Becker et al. 2008; Shiffman et al. 2009); participants were not asked to 
preload as part of a smoking cessation intervention (Braur et al. 1999); and finally Herrera et 
al. (1995) was excluded as a small sub-group of the participants were allocated to preloading 
as defined here, however the quit rate data was not available at long-term follow-up for this 
group. 
 
4.3.3 Interventions 
All studies included at least one group randomised to receive NRT before quitting smoking; 
three included another group who received a preloading placebo pre-quit (Schuurmans et al. 
2004; Rose et al. 2006; Rose et al. 2009), and five studies included a group who received no 
placebo preloading intervention, and so were unblinded (Rose et al. 1994; Rose et al. 1998; 
Etter et al. 2009; Bullen et al. 2010; Hughes et al. 2010). Preloading was carried out for two 
weeks in five studies (Rose et al. 1994; Schuurmans et al. 2004; Rose et al. 2006; Rose et al. 
2009; Bullen et al. 2010), four weeks in two studies (Rose et al. 1998; Etter et al. 2009), and 
three to five weeks in the remaining study (Hughes et al. 2010). Four studies provided 
participants with 21mg/24hr patches pre-quit (Rose et al. 1994; Rose et al. 1998; Rose et al. 
2006; Rose et al. 2009), one with 15mg/16hr patches (Schuurmans et al. 2004), and Bullen et 
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al. (2010) gave participants a choice of nicotine patch only, patch and gum, or gum only, 
where the dose depended on the advisor's assessment. Another study provided participants 
with 4mg gum pre-quit (Etter et al. 2009), and the final study (Hughes et al. 2010) sent 
participants 2 or 4mg lozenges depending on how soon they smoked their first cigarette on 
waking. Post-quit day NRT was provided for 4-12 weeks, varying across studies.  
 
In addition to NRT treatment three included studies provided participants with mecamylamine 
(a nicotinic antagonist) or placebo either pre and post-quit (Rose et al. 1994; Rose et al. 1998) 
or post-quit only (Rose et al. 2006), and two studies provided participants with cigarettes with 
manipulated nicotine content (Rose et al. 2006; Rose et al. 2009). Five studies asked 
participants to smoke freely whilst preloading (Rose et al. 1994; Rose et al. 1998; Rose et al. 
2006; Rose et al. 2009; Bullen et al. 2010), one asked participants to smoke as they normally 
did (Schuurmans et al. 2004), and two asked participants to reduce their smoking in the 
preloading arm and quit abruptly in the control arm (Etter et al. 2009; Hughes et al. 2010). 
 
4.3.4 Outcomes 
The follow-up point for short-term abstinence varied across studies from 4 to 12 weeks, with 
a median of 6.5 weeks. Seven of the eight studies reported short-term continuous abstinence: 
two as self-report only (Etter et al. 2009; Bullen et al. 2010) and five studies using CO 
validation to confirm self-report (Rose et al. 1994; Rose et al. 1998; Schuurmans et al. 2004; 
Rose et al. 2006; Rose et al. 2009). The eighth study (Hughes et al. 2010) defined short-term 
abstinence as self-reported prolonged abstinence.  
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Six studies reported long-term abstinence at six month follow-up (Rose et al. 1998; 
Schuurmans et al. 2004; Rose et al. 2006; Rose et al. 2009; Bullen et al. 2010; Hughes et al. 
2010), one at 12 month follow-up (Etter et al. 2009), and the remaining study reported 
abstinence at both 6 and 12 month follow-up (Rose et al. 1994); in this case 12 month 
abstinence was used. Four of the included studies supplied continuous abstinence rates, 
verified by either CO and/or cotinine (Rose et al. 1994; Rose et al. 1998; Schuurmans et al. 
2004; Rose et al. 2009), one prolonged CO-verified rates (Hughes et al. 2010) and another 
defined abstinence as seven day point prevalence at six months, verified by CO measurement 
(Rose et al. 2006). Etter et al. (2009) provided four week prolonged abstinence rates verified 
by cotinine and CO, as well as continuous self-reported rates at 12 month follow-up. In this 
case the verified rates were used as these were most stringent. Bullen et al. (2010) only 
attempted cotinine verification in a sample of participants, for point prevalence rates. For this 
study self-reported continuous abstinence was used. 
 
4.3.5 Effect of preloading on abstinence 
There was a very weak positive effect of preloading on short-term abstinence (RR=1.05, 95% 
CI= 0.92, 1.19), however the effect was not significant (p=0.49) (Figure 11). There was 
marked heterogeneity with an I2 of 69%, p=0.002. The effect on long-term abstinence gave a 
slightly larger RR of 1.16 (95% CI= 0.97, 1.38) (Figure 12), and there was less heterogeneity 
with an I2 of 39%, p=0.12. However, again the effect was non-significant. Based on the large 
amount of heterogeneity in the short-term analysis we re-ran the analyses using random-
effects models; however the results were similar to the fixed-effect models for both short- and 
long-term abstinence (Appendix 24). 
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Study or Subgroup
Hughes 2010
Bullen 2010
Etter 2009
Rose 1998
Schuurmans 2004
Rose 1994
Rose 2009
Rose 2006
Total (95% CI)
Total events
Heterogeneity: Chi² = 22.66, df = 7 (P = 0.002); I² = 69%
Test for overall effect: Z = 0.69 (P = 0.49)
Events
39
132
61
16
29
10
44
24
355
Total
297
549
154
40
100
24
191
48
1403
Events
60
143
65
14
19
6
24
11
342
Total
299
551
160
40
100
24
188
48
1410
Weight
17.6%
41.9%
18.7%
4.1%
5.6%
1.8%
7.1%
3.2%
100.0%
M-H, Fixed, 95% CI
0.65 [0.45, 0.95]
0.93 [0.75, 1.14]
0.98 [0.74, 1.28]
1.14 [0.65, 2.02]
1.53 [0.92, 2.54]
1.67 [0.72, 3.86]
1.80 [1.15, 2.84]
2.18 [1.21, 3.94]
1.05 [0.92, 1.19]
Pre-quit NRT Control Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.5 0.7 1 1.5 2
Favours control Favours pre-quit NRT
 
Figure 11: A forest plot illustrating the effect of NRT preloading on short-term 
abstinence 
 
 
  
Study or Subgroup
Hughes 2010
Bullen 2010
Etter 2009
Rose 1994
Rose 2006
Schuurmans 2004
Rose 2009
Rose 1998
Total (95% CI)
Total events
Heterogeneity: Chi² = 11.50, df = 7 (P = 0.12); I² = 39%
Test for overall effect: Z = 1.63 (P = 0.10)
Events
12
99
32
6
10
22
28
12
221
Total
297
549
154
24
48
100
191
40
1403
Events
21
97
31
4
6
12
15
6
192
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299
551
160
24
48
100
188
40
1410
Weight
10.9%
50.6%
15.9%
2.1%
3.1%
6.3%
7.9%
3.1%
100.0%
M-H, Fixed, 95% CI
0.58 [0.29, 1.15]
1.02 [0.79, 1.32]
1.07 [0.69, 1.67]
1.50 [0.48, 4.65]
1.67 [0.66, 4.22]
1.83 [0.96, 3.50]
1.84 [1.01, 3.33]
2.00 [0.83, 4.81]
1.16 [0.97, 1.38]
Pre-quit NRT Control Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.2 0.5 1 2 5
Favours control Favours pre-quit NRT
 
Figure 12: A forest plot illustrating the effect of NRT preloading on long-term 
abstinence 
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4.3.5.1 Hypothesis 1. Efficacy is mediated through reduced reward and hence 
reduced dependence 
Two studies measured reward, satisfaction or enjoyment from smoking during preloading 
(Rose et al. 1994; Rose et al. 1998). Rose et al. (1994) reported that preloading significantly 
reduced smoking satisfaction, good taste of cigarettes, and the calming effect of smoking 
relative to control, but there was no main effect of preloading on enjoyment of respiratory 
tract sensations when smoking. It was not possible to calculate effect sizes from the report. 
Rose et al. (1998) reported that nicotine preloading did not affect the reward from cigarettes 
pre-quit, with almost identical reductions in reward in both active and placebo groups. Taken 
together, there is little evidence that preloading influences the positive reward from smoking. 
 
Four studies reported data on the effect of preloading on variables relevant to negative 
reinforcement from smoking, during the pre-quit period (Rose et al. 1994; Rose et al. 1998; 
Schuurmans et al. 2004; Rose et al. 2006). Rose et al. (1994) reported some evidence that 
nicotine patch treatment reduced negative affect in smokers with high baseline ratings, but 
effect sizes were not calculable. Rose et al. (1998) reported that negative affect increased in 
nicotine treatment compared to placebo during the first week only of four weeks preloading, 
but again no effect size was calculable. Rose et al. (2006) measured negative affect pre-
quitting but results presented do not enable the reader to determine whether there was an 
effect of nicotine preloading. Schuurmans et al. (2004) reported no effect of preloading on a 
composite (Wisconsin) scale of withdrawal symptoms. Overall we found no evidence that 
preloading influenced negative reinforcement.  
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Reduced positive or negative reinforcement from smoking should reduce cravings during the 
pre-quit period and four studies had data. Rose et al. (1994) and Rose et al. (1998) found no 
effect of preloading on craving. However, Rose et al. (2006) reported an approximate 20% 
reduction in craving during preloading, and Hughes et al. (2010) a 10% reduction, whereas 
very little difference was observed in the control groups of both studies. Therefore the effect 
on pre-quit cravings is small if it exists.  
 
Our hypothesis was that reduced craving would be associated with reduced dependence scores 
and lower cigarette consumption (cpd, CO, and cotinine) during preloading. In five studies 
participants were advised to smoke as they chose (Rose et al. 1994; Rose et al. 1998; Rose et 
al. 2006; Rose et al. 2009; Bullen et al. 2010). Rose et al. (1994) found that participants 
reduced cigarette consumption by more than half in the nicotine preloading condition, 
whereas there was little change in the placebo group. Rose et al. (1998) showed an 
approximate one third reduction in cpd in the active patch condition compared with placebo, 
where there was little reduction pre-quit. There was no apparent reduction in CO but plasma 
nicotine derived from smoking fell by around 20% in the nicotine treated group and was 
steady in the placebo group. Rose et al. (2006) showed an approximate 20% reduction in daily 
cigarette consumption in the nicotine preloading group, versus 10% reduction without 
preloading. CO levels declined by about 10% in the active group and did not change in the 
non-nicotine group. Bullen et al. (2010) found the preloading group reduced daily cigarette 
consumption by 63% and the no preloading group reduced by 16%. Schuurmans et al. (2004) 
reported almost no reduction in cpd in both active and placebo groups, and CO declined little 
(12% versus 3%), but the investigators had asked participants not to change their smoking 
behaviour. Etter et al. (2009) and Hughes et al. (2010) both asked the preloading group to 
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reduce their smoking. Etter et al. (2009) reported a 48% reduction in consumption and 9% in 
the group who received no preloading. Hughes et al. (2010) found that cpd reduced by 54% 
(13 cpd), as well as CO levels by 21% (6 ppm), in the preloading condition, in comparison to 
a 1% (0.3 cpd) reduction in cpd and a 0% (0 ppm) reduction in CO in the control group. Only 
one study reported on cotinine concentration while smoking (Rose et al. 2006). Cotinine 
concentration rose by about 60% during preloading with patch, compared with almost no 
change using placebo. Taken together the data indicate that preloading reduces smoking 
consumption moderately and variably across studies, but this seems partly related to the 
instructions given on how to smoke. Reduction in smoke intake measured by CO is less 
affected than cpd. 
 
Only two studies reported change in dependence over the pre-quit period (Rose et al. 2006; 
Hughes et al. 2010). Hughes et al. (2010) reported that participants in the preloading condition 
decreased their dependence, by increasing the time to first cigarette after waking from 15 to 
28 minutes, whereas this measure of dependence did not change in the control group. They 
also reported that similar outcomes occurred when dependence was measured using self-rated 
addiction and the FTND; the change in scores is not specified, however the difference 
between the preloading condition and control was significant in both cases (p< 0.0001). 
Hughes et al. (2010) also reported that the regularity of smoking (stereotypy) decreased in the 
preloading condition by 10%, but stayed the same in the control condition during the pre-quit 
period. Rose et al. (2006) showed a decline of about two FTND points (20%) in the group 
receiving nicotine preloading and one point in the group on placebo. In both of these studies 
cigarette consumption declined on average and this contributes to FTND score, so in the case 
of FTND, it is not possible to know whether other indices of dependence declined, or whether 
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these changes were accounted for by reduction in consumption. However the decline in other 
measures of dependence (self-rated addiction and stereotypy), that do not depend on cigarette 
consumption, in Hughes et al. (2010) support the theory that dependence was reduced by 
preloading.  
 
We hypothesised that reduced positive or negative reward from smoking would manifest as 
reduced pre-quit consumption, reduced dependence, and hence reduced intensity of 
withdrawal after quitting. Rose et al. (1994) showed similar levels of craving after cessation 
in nicotine preloading and placebo groups. Rose et al. (1998) showed an approximate 10% 
reduction in craving after cessation in both the active and placebo groups. Bullen et al. (2010) 
reported that craving was 0.24 units (3% of the whole scale) lower in the preloading group 
than the no preloading group. Etter et al. (2009) reported similar craving levels in smokers 
receiving preloading compared to those who did not. Overall withdrawal scores were 
measured by Schuurmans et al. (2004) and Etter et al. (2009), both showing almost no 
difference in active or comparator groups. Some studies (Rose et al. 1994; Rose et al. 1998; 
Rose et al. 2006; Etter et al. 2009) reported scores for individual withdrawal symptoms. These 
indicated no large differences and when these were compared statistically (Etter et al. 2009) 
the differences were not significant. Overall there appears to be reasonable evidence that 
nicotine preloading does not reduce post-quit smoking withdrawal. 
 
A subsidiary hypothesis arising from this proposed mechanism is that patch, which leads to 
supra-normal nicotine blood concentrations when smoking, would be more effective than 
short-acting NRT, in which nicotine concentration is typical of smoking alone (Fagerstrom 
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and Hughes 2002). We tested this by carrying out a sub-group analysis, splitting the studies in 
terms of whether they used gum/lozenge (Etter et al. 2009; Hughes et al. 2010) or patch 
(Rose et al. 1994; Rose et al. 1998; Schuurmans et al. 2004; Rose et al. 2006; Rose et al. 
2009; Bullen et al. 2010) pre-quit. Bullen et al.’s (2010) study included participants that used 
patch and participants that used gum only, but did not present results split this way for the 
continuous cessation outcome. As only 9% used nicotine gum, for the purposes of this 
analysis, we included all participants in the patch category. For short-term abstinence the RR 
for the patch group was 1.17 (95% CI= 1.00, 1.37) and for gum/lozenge was 0.82 (95% CI= 
0.66, 1.02), p=0.009 for the difference in RRs (Figure 13). Splitting the studies in this way for 
short-term outcomes did not remove heterogeneity which was still 66% for the patch sub-
group and 67% for the gum/lozenge sub-group. For long-term cessation, the nicotine patch 
also appeared somewhat more effective than gum with a RR of 1.26 (95% CI= 1.03, 1.55), 
compared to a RR of 0.87 (95% CI= 0.60, 1.26), although the difference between the sub-
groups was not statistically significant (p=0.08). Heterogeneity was still present, with an I2 of 
28% in the patch group and 55% in the gum/lozenge group (Figure 14). This supports the 
hypothesis that preloading using nicotine patch is more successful than preloading with short-
acting NRT only, and that there is no benefit to preloading using short-acting NRT, although 
these conclusions are clouded by unexplained heterogeneity.  
 
A second subsidiary hypothesis is that longer preloading would lead to better cessation rates. 
Five studies that used patches had a preloading period of two weeks (Rose et al. 1994; 
Schuurmans et al. 2004; Rose et al. 2006; Rose et al. 2009; Bullen et al. 2010) and one of four 
weeks (Rose et al. 1998). 
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Figure 13: A forest plot illustrating the type of NRT sub-group analysis , for the 
preloading meta-analysis (short-term abstinence rates) 
 
          
Study or Subgroup
1.4.1 Patch
Bullen 2010
Rose 1994
Rose 2006
Schuurmans 2004
Rose 2009
Rose 1998
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 6.91, df = 5 (P = 0.23); I² = 28%
Test for overall effect: Z = 2.27 (P = 0.02)
1.4.2 Gum/Lozenge
Hughes 2010
Etter 2009
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 2.24, df = 1 (P = 0.13); I² = 55%
Test for overall effect: Z = 0.74 (P = 0.46)
Total (95% CI)
Total events
Heterogeneity: Chi² = 11.50, df = 7 (P = 0.12); I² = 39%
Test for overall effect: Z = 1.63 (P = 0.10)
Test for subgroup differences: Chi² = 3.03, df = 1 (P = 0.08), I² = 66.9%
Events
99
6
10
22
28
12
177
12
32
44
221
Total
549
24
48
100
191
40
952
297
154
451
1403
Events
97
4
6
12
15
6
140
21
31
52
192
Total
551
24
48
100
188
40
951
299
160
459
1410
Weight
50.6%
2.1%
3.1%
6.3%
7.9%
3.1%
73.2%
10.9%
15.9%
26.8%
100.0%
M-H, Fixed, 95% CI
1.02 [0.79, 1.32]
1.50 [0.48, 4.65]
1.67 [0.66, 4.22]
1.83 [0.96, 3.50]
1.84 [1.01, 3.33]
2.00 [0.83, 4.81]
1.26 [1.03, 1.55]
0.58 [0.29, 1.15]
1.07 [0.69, 1.67]
0.87 [0.60, 1.26]
1.16 [0.97, 1.38]
Pre-quit NRT Control Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.2 0.5 1 2 5
Favours control Favours pre-quit NRT 
Figure 14: A forest plot illustrating the type of NRT sub-group analysis, for the 
preloading meta-analysis (long-term abstinence rates) 
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For short-term outcome (Figure 15) the RRs of the two groups were similar, with a two week 
RR of 1.18 (95% CI= 1.00, 1.39), and four week RR of 1.14 (95% CI= 0.65, 2.02). For long-
term cessation (Figure 16) the RRs were 1.23 (95% CI= 1.00, 1.52) and 2.00 (95% CI= 0.83, 
4.81), but in neither case was the test for difference in sub-groups significant (p=0.92 and 
p=0.29 respectively). The wide confidence intervals show the data are insufficient to examine 
the effect of length of preloading. 
 
4.3.5.2 Hypothesis 2. Efficacy is mediated through increased post-quit 
adherence 
In all included trials, participants were randomised to NRT or placebo/no NRT pre-quit, but 
all participants used active NRT after quit day. Our hypothesis was that preloading would 
enhance post-quit adherence to NRT relative to control. Adherence to NRT treatment was 
measured using a variety of measures in all eight of the studies, however only four of these 
studies made between-group, post-quit comparisons (Schuurmans et al. 2004; Etter et al. 
2009; Rose et al. 2009; Hughes et al. 2010). Two studies used placebo patch pre-quit as a 
control (Schuurmans et al. 2004; Rose et al. 2009), therefore we would expect that adherence 
would be similar across the groups, which was the case. Rose et al. (2009) found that overall 
adherence was high post-quit and that there was no difference between groups. Schuurmans et 
al. (2004) found that at quit day, two, six and 10 weeks follow-up 95%, 79%, 58% and 38% 
of participants in the active patch group complied with nicotine treatment respectively, and in 
the placebo patch group 87%, 77%, 57% and 39%. In Etter et al. (2009) and Hughes et al. 
(2010)- the only studies to compare preloading with no preloading (without placebo) and 
report post-quit adherence between groups- there was no significant differences in adherence  
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Figure 15: A forest plot illustrating the length of preloading sub-group analysis, for the 
preloading meta-analysis (short-term abstinence rates) 
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Figure 16: A forest plot illustrating the length of preloading sub-group analysis, for the 
preloading meta-analysis (long-term abstinence rates) 
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post-quit. Etter et al. (2009) found that at eight weeks follow-up preloading participants had 
used gum for 68%, and control participants for 67%, of the past 60 days (p=0.80), 41% of the  
preloading condition and 40% of the control condition (p=0.45) were still using nicotine gum 
daily, and preloading participants had used NRT for an average of 6.5 days of the week, and 
the control condition for 6.2 days of the week. The available evidence on adherence does not 
support the hypothesis that preloading achieves efficacy by enhancing adherence to post-quit 
NRT. 
 
4.3.5.3 Hypothesis 3. Efficacy is mediated through increased confidence 
We hypothesised that if preloading reduces cpd pre-quit then this will increase confidence in 
quitting. Only Etter et al. (2009) and Hughes et al. (2010) reported on confidence in quitting. 
Etter et al. (2009) showed that the preloading group reduced consumption by 48% compared 
with 9% in the group who received no preloading. However, confidence ratings were not 
affected, with scores measured on a 0–100 scale three days after quitting, reported as 73 in 
both groups (p=0.88). Hughes et al. (2010) found that the preloading group reduced cigarette 
consumption by 54% and the control group by 1%. This corresponded to an increase in self-
efficacy (measured using the nine-item form of Velicer’s scale) in the preloading group from 
18 at baseline to 23 pre-quit, out of a possible 45 (an 11% increase), with minimal change in 
the control (data for the control condition alone were not provided). A similar effect occurred 
when confidence was measured using the five-point confidence in quitting scale, however 
data were not reported. Therefore there was contrasting and inconclusive evidence that 
reduced smoking enhanced confidence in ability to quit. 
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4.3.5.4 Hypothesis 4. Behavioural support modifies the effect of preloading 
Our fourth hypothesis was that the intensity of behavioural support provided pre-quit 
moderates the effect of preloading, through increased pre-quit adherence. Providing support 
during preloading could increase adherence, and in turn the efficacy of preloading, because 
participants can raise any misunderstandings, worries and/or problems with the regimen. To 
investigate this we carried out a sub-group analysis to assess cessation outcomes, by splitting 
the studies into two sub-groups based on whether or not behavioural support was provided 
during the pre-quit period. All included studies provided participants with behavioural 
support, which varied from minimal with no in-person support to moderate intensity. The 
studies offering clinic visits (Rose et al. 1994; Rose et al. 1998; Schuurmans et al. 2004; Rose 
et al. 2006; Rose et al. 2009) all included support part-way through the preloading period bar 
one (Schuurmans et al. 2004), which provided support at baseline and one to two days before 
quit day. One trial provided telephone support (Bullen et al. 2010), but not during the pre-quit 
period (Bullen et al. 2008). Hughes et al. (2010) provided telephone support three times for 10 
minutes each during the pre-quit period, in addition to a session at baseline. The remaining 
study was a self-help study (Etter et al. 2009) with support only by a booklet and/or website. 
The mid pre-quit support group therefore included five studies (Rose et al. 1994; Rose et al. 
1998; Rose et al. 2006; Rose et al. 2009; Hughes et al. 2010) and the no mid pre-quit support 
group contained three studies (Schuurmans et al. 2004; Etter et al. 2009; Bullen et al. 2010) 
(Table 6). For short-term abstinence, splitting by the type of behavioural support (mid pre-
quit support versus no mid pre-quit support) resulted in a RR of 1.15 (95% CI= 0.93, 1.44) for 
mid pre-quit support, and an RR of 0.99 (95% CI= 0.85, 1.16) for no mid pre-quit support; 
p=0.27 for sub-group difference (Figure 17). Heterogeneity was lowered to 38% in the no mid 
pre-quit support group, but was high in the other group at 78%. The result was similar using
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Table 6: Details of support provided as part of studies included in the preloading meta-analyses 
NRT- nicotine replacement therapy, wk- week
Study ID Method of contact Support facilitator Pre-quit support contacts Minutes per contact Content of contact 
Bullen et al. 
(2010) 
Established telephone quit-line  Trained advisors Control condition quit immediately. 
Preloading condition received pre-quit 
support at baseline only (Bullen et al. 
2008) 
Not specified Not specified 
Etter et al. (2009) Mailed NRT & booklet. 
Smoking cessation website  
No person contact Could use booklet & website as required Not applicable Booklet included instructions to 
participants (no further details). 
Website: www.stop-tabac.ch 
Hughes et al. 
(2010) 
Telephone & US National 
Cancer Institute’s ‘Clearing the 
Air’ booklet. 
Counsellors with a 
bachelor’s degree in 
psychology or counselling 
Control condition: Baseline, 2 days pre-
quit. Preloading condition: Baseline, 1 
week after baseline, 2 weeks after 
baseline, 2 days pre-quit. 
All participants received 70-90 
minutes in total. Preloading 
received at least 1 hour pre-
quit. 
Manuals used by counsellors can be 
found at: 
http://www.uvm.edu/~hbpl/?Page=dat
a.html 
Rose et al.  
(1994) 
Clinic visits & self-help 
booklet  
Research assistant Baseline, mid-way through pre-quit (wk 
1), quit day 
15 Participants interviewed about 
difficulties & offered encouragement 
& behaviour change strategies. 
Booklet advised on quitting strategies 
Rose et al. (1998) Clinic visits & self-help 
booklet  
Research assistant Baseline, wk 1, wk 2 & wk 3 pre-quit, quit 
day 
10-15 Participants interviewed about 
difficulties & offered encouragement 
& behaviour change strategies. 
Booklet advised on quitting strategies 
Rose et al. (2006) Clinic visits 
 
Not specified Baseline, mid-way through pre-quit (wk 
1), quit day 
5-10 Brief supportive counselling. Booklet 
advised on quitting strategies & 
quitting benefits 
Rose et al. (2009) Clinic visits  Not specified Baseline, mid-way through pre-quit (wk 
1), day before quit day 
Not specified Not specified  
Schuurmans et al. 
(2004) 
Clinic visits  Experienced nurse Baseline, 1-2 days before quit day 20 Counselling given. (No further details 
specified) 
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long-term abstinence rates, where the RR was 1.30 (95% CI= 0.93, 1.83) for the mid pre-quit 
support group and 1.10 (95% CI= 0.90, 1.36) for no mid pre-quit support; p=0.42 for sub-
group difference (Figure 18). Again this analysis did not eliminate heterogeneity (49% mid 
pre-quit support, 26% no mid pre-quit support). Given the imprecision of these estimates, the 
data are insufficient to conclude whether pre-quit support enhances the effectiveness of 
preloading, though there is very modest support for this hypothesis.  
 
The evidence that behavioural support enhances effectiveness would be supported by data 
showing that such support enhanced adherence to preloading. All studies that offered support 
part-way through the pre-quit period (Rose et al. 1994; Rose et al. 1998; Rose et al. 2006; 
Rose et al. 2009; Hughes et al. 2010) reported that pre-quit NRT use was high, ranging from 
90–100% of patches applied in the Rose studies, and 93% of participants using lozenges on a 
median of 83% of days, and on average using four to five lozenges (18.6mg) per day in 
Hughes et al. (2010). The three studies providing no mid pre-quit support reported mixed 
adherence. Bullen et al. (2010) reported that 61% of participants used all of their NRT in the 
preloading arm pre-quit. However, both Etter et al. (2009) and Schuurmans et al. (2004) also 
reported adherence was high. In Etter et al. (2009) participants used 7.9 gums per day on 
average pre-quit. Schuurmans et al. (2004) reported 95% of participants were using 
preloading active or placebo patches at quit day. This suggests that participants generally 
adhered to treatment well in the preloading arms, and so the addition of support during 
preloading did not enhance adherence, and in turn the effectiveness of preloading. 
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Study or Subgroup
1.2.1 Personal contact mid pre-quit period
Hughes 2010
Rose 1998
Rose 1994
Rose 2009
Rose 2006
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 17.95, df = 4 (P = 0.001); I² = 78%
Test for overall effect: Z = 1.28 (P = 0.20)
1.2.2 No personal contact mid pre-quit period
Bullen 2010
Etter 2009
Schuurmans 2004
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 3.21, df = 2 (P = 0.20); I² = 38%
Test for overall effect: Z = 0.12 (P = 0.91)
Total (95% CI)
Total events
Heterogeneity: Chi² = 22.66, df = 7 (P = 0.002); I² = 69%
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Chi² = 1.23, df = 1 (P = 0.27), I² = 18.9%
Events
39
16
10
44
24
133
132
61
29
222
355
Total
297
40
24
191
48
600
549
154
100
803
1403
Events
60
14
6
24
11
115
143
65
19
227
342
Total
299
40
24
188
48
599
551
160
100
811
1410
Weight
17.6%
4.1%
1.8%
7.1%
3.2%
33.8%
41.9%
18.7%
5.6%
66.2%
100.0%
M-H, Fixed, 95% CI
0.65 [0.45, 0.95]
1.14 [0.65, 2.02]
1.67 [0.72, 3.86]
1.80 [1.15, 2.84]
2.18 [1.21, 3.94]
1.15 [0.93, 1.44]
0.93 [0.75, 1.14]
0.98 [0.74, 1.28]
1.53 [0.92, 2.54]
0.99 [0.85, 1.16]
1.05 [0.92, 1.19]
Pre-quit NRT Control Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.5 0.7 1 1.5 2
Favours experimental Favours control  
Figure 17: A forest plot illustrating the type of behavioural support sub-group analysis, 
for the preloading meta-analysis (short-term abstinence rates) 
                    
Study or Subgroup
1.5.1 Personal contact mid pre-quit period
Hughes 2010
Rose 1994
Rose 2006
Rose 2009
Rose 1998
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 7.91, df = 4 (P = 0.09); I² = 49%
Test for overall effect: Z = 1.53 (P = 0.13)
1.5.2 No personal contact mid pre-quit period
Bullen 2010
Etter 2009
Schuurmans 2004
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 2.72, df = 2 (P = 0.26); I² = 26%
Test for overall effect: Z = 0.94 (P = 0.35)
Total (95% CI)
Total events
Heterogeneity: Chi² = 11.50, df = 7 (P = 0.12); I² = 39%
Test for overall effect: Z = 1.63 (P = 0.10)
Test for subgroup differences: Chi² = 0.66, df = 1 (P = 0.42), I² = 0%
Events
12
6
10
28
12
68
99
32
22
153
221
Total
297
24
48
191
40
600
549
154
100
803
1403
Events
21
4
6
15
6
52
97
31
12
140
192
Total
299
24
48
188
40
599
551
160
100
811
1410
Weight
10.9%
2.1%
3.1%
7.9%
3.1%
27.2%
50.6%
15.9%
6.3%
72.8%
100.0%
M-H, Fixed, 95% CI
0.58 [0.29, 1.15]
1.50 [0.48, 4.65]
1.67 [0.66, 4.22]
1.84 [1.01, 3.33]
2.00 [0.83, 4.81]
1.30 [0.93, 1.83]
1.02 [0.79, 1.32]
1.07 [0.69, 1.67]
1.83 [0.96, 3.50]
1.10 [0.90, 1.36]
1.16 [0.97, 1.38]
Pre-quit NRT Control Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.2 0.5 1 2 5
Favours control Favours pre-quit NRT 
Figure 18: A forest plot illustrating the type of behavioural support sub-group analysis, 
for the preloading meta-analysis (long-term abstinence rates) 
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4.3.6 Additional moderators of the preloading effect 
We also extracted any available results from the included studies, of analyses investigating 
whether differences in participants' characteristics at baseline were associated with differences 
in the effect of preloading on abstinence. Five included studies carried out this type of 
analysis. Bullen et al. (2010) conducted sub-group analyses splitting participants by ethnic 
group (Maori/non-Maori), age group (<40 years old/≥40 years old), sex (male/female), and 
social economic group (left school below year 12 or with no qualification/attained year 12 and 
above), and found that there was no significant differences in the effect of preloading on 
abstinence for any of these distinctions. Hughes et al. (2010) investigated the interaction of 
baseline age, sex, race, cpd, FTND, self-rated addiction, confidence in ability to quit, 
intention to quit, confidence could quit gradually/abruptly, quitting method preference, self-
efficacy and regularity of smoking on abstinence, and found no interaction between any of the 
moderators and either point prevalence or prolonged abstinence. Rose et al. (2006) also found 
that age and FTND at baseline did not interact with the effect of preloading on abstinence. 
However, Rose et al. (2009) did find that baseline FTND interacted with 10-week continuous 
abstinence rates (p=0.03), with NRT preloading showing a greater effect for those with scores 
less than six, compared with those with six or higher. Thirty-four percent of smokers with 
lower FTND scores achieved abstinence in the preloading arm and 9% in the control arm, 
14% of smokers with high FTND scores achieved abstinence with preloading, compared with 
11% in the control arm. Rose et al. (2009) also specified that they would investigate an 
interaction for age, sex, withdrawal, smoking satisfaction, cigarettes per day, CO and cotinine 
levels at baseline, however the results of these analyses were not reported, which might imply 
none were significant. Finally, Schuurmans et al. (2004) reported that smokers of fewer than 
16 cpd who received preloading had similar rates of abstinence whether or not they received 
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active or placebo patches. However, among heavier smokers, active patch users were 
significantly more successful (p=0.01) than placebo users. This cut-off was based on an 
exploratory technique and therefore no test for sub-group differences was appropriate or 
performed. The data from Schuurmans et al. (2004) and Rose et al. (2009) are somewhat 
contradictory and therefore there is no strong evidence that any characteristics discernable at 
the start of treatment identify participants who might benefit more than others from 
preloading. 
 
4.3.7 Quality assessment 
Each included study was rated on whether they might cause bias in terms of randomisation 
sequence generation, concealment of the allocation sequence, blinding to study arm 
allocation, and incomplete outcome data. For each criteria a study was rated as ‘Yes’ if 
unlikely to cause bias, ‘No’ if they may cause bias, and ‘Unclear’ if there was insufficient 
information to make a judgment (for more detail see Appendix 25). In terms of sequence 
generation all studies claimed to be randomised; three of these reported acceptable sequence 
generation methods (Etter et al. 2009; Bullen et al. 2010; Hughes et al. 2010). The remainder 
did not specify the method used to generate the randomisation sequence, so were rated 
‘Unclear’ (Rose et al. 1994; Rose et al. 1998; Schuurmans et al. 2004; Rose et al. 2006; Rose 
et al. 2009). Although Schuurmans et al. (2004) did specify that randomisation was performed 
with a computer generated list, in order to have allocated exactly 100 participants to each arm 
it is likely that a special system would need to have been used, which was not described.  
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When rated in terms of concealment of participant allocation from researchers, the same four 
studies were rated as unlikely to cause bias, as they specified that allocation was concealed 
(Schuurmans et al. 2004; Bullen et al. 2010; Hughes et al. 2010) or they involved no therapist 
contact (Etter et al. 2009). The remaining four studies did not report on allocation 
concealment and thus were rated as ‘Unclear’ (Rose et al. 1994; Rose et al. 1998; Rose et al. 
2006; Rose et al. 2009).  
 
In the blinding category three studies were classified as unlikely to cause bias (Schuurmans et 
al. 2004; Rose et al. 2006; Rose et al. 2009). They were all double-blinded, using placebo 
nicotine patches in the control arm, so that participants and researchers were unaware of who 
was receiving active treatment. None of the remaining studies (Rose et al. 1994; Rose et al. 
1998; Etter et al. 2009; Bullen et al. 2010; Hughes et al. 2010) used placebos, therefore it was 
impossible to conceal treatment arm after allocation had occurred. As a result these studies 
may have caused bias in this respect. To investigate this possibility we conducted a sub-group 
analysis on the main meta-analysis, comparing the effect of preloading in the double-blinded 
studies with the effect of preloading in the unblinded studies. For short-term outcome there 
was a significant sub-group difference (p<0.001) with an RR of 1.78 (95% CI= 1.33, 2.39) for 
the double-blind studies and an RR of 0.91 (95% CI= 0.79, 1.05) for the unblinded studies 
(Figure 19). The difference was smaller but still significant (p=0.01) for the long-term 
outcome with an RR of 1.80 (95% CI= 1.21, 2.68) in the blinded studies and an RR of 1.02 
(95% CI= 0.84, 1.25) in the unblinded studies (Figure 20).  
 
When rated in terms of incomplete outcome data five studies were classified as unlikely to 
cause bias for the meta-analysis (Rose et al. 1994; Schuurmans et al. 2004; Etter et al. 2009;  
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Study or Subgroup
1.10.1 Blinded
Schuurmans 2004
Rose 2009
Rose 2006
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 0.81, df = 2 (P = 0.67); I² = 0%
Test for overall effect: Z = 3.86 (P = 0.0001)
1.10.2 Unblinded
Hughes 2010
Bullen 2010
Etter 2009
Rose 1998
Rose 1994
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 5.97, df = 4 (P = 0.20); I² = 33%
Test for overall effect: Z = 1.35 (P = 0.18)
Total (95% CI)
Total events
Heterogeneity: Chi² = 22.66, df = 7 (P = 0.002); I² = 69%
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Chi² = 16.47, df = 1 (P < 0.0001), I² = 93.9%
Events
29
44
24
97
39
132
61
16
10
258
355
Total
100
191
48
339
297
549
154
40
24
1064
1403
Events
19
24
11
54
60
143
65
14
6
288
342
Total
100
188
48
336
299
551
160
40
24
1074
1410
Weight
5.6%
7.1%
3.2%
15.9%
17.6%
41.9%
18.7%
4.1%
1.8%
84.1%
100.0%
M-H, Fixed, 95% CI
1.53 [0.92, 2.54]
1.80 [1.15, 2.84]
2.18 [1.21, 3.94]
1.78 [1.33, 2.39]
0.65 [0.45, 0.95]
0.93 [0.75, 1.14]
0.98 [0.74, 1.28]
1.14 [0.65, 2.02]
1.67 [0.72, 3.86]
0.91 [0.79, 1.05]
1.05 [0.92, 1.19]
Pre-quit NRT Control Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.5 0.7 1 1.5 2
Favours control Favours pre-quit NRT 
Figure 19: A forest plot illustrating the blinding sub-group analysis for the preloading 
meta-analysis (short-term abstinence rates) 
 
   
Study or Subgroup
1.11.1 Blinded
Rose 2006
Schuurmans 2004
Rose 2009
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 0.03, df = 2 (P = 0.98); I² = 0%
Test for overall effect: Z = 2.92 (P = 0.003)
1.11.2 Unblinded
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Bullen 2010
Etter 2009
Rose 1994
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Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 5.40, df = 4 (P = 0.25); I² = 26%
Test for overall effect: Z = 0.23 (P = 0.82)
Total (95% CI)
Total events
Heterogeneity: Chi² = 11.50, df = 7 (P = 0.12); I² = 39%
Test for overall effect: Z = 1.63 (P = 0.10)
Test for subgroup differences: Chi² = 6.30, df = 1 (P = 0.01), I² = 84.1%
Events
10
22
28
60
12
99
32
6
12
161
221
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48
100
191
339
297
549
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24
40
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Events
6
12
15
33
21
97
31
4
6
159
192
Total
48
100
188
336
299
551
160
24
40
1074
1410
Weight
3.1%
6.3%
7.9%
17.3%
10.9%
50.6%
15.9%
2.1%
3.1%
82.7%
100.0%
M-H, Fixed, 95% CI
1.67 [0.66, 4.22]
1.83 [0.96, 3.50]
1.84 [1.01, 3.33]
1.80 [1.21, 2.68]
0.58 [0.29, 1.15]
1.02 [0.79, 1.32]
1.07 [0.69, 1.67]
1.50 [0.48, 4.65]
2.00 [0.83, 4.81]
1.02 [0.84, 1.25]
1.16 [0.97, 1.38]
Pre-quit NRT Control Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.2 0.5 1 2 5
Favours control Favours pre-quit NRT 
Figure 20: A forest plot illustrating the blinding sub-group analysis, for the preloading 
meta-analysis (long-term abstinence rates) 
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Bullen et al. 2010; Hughes et al. 2010), as they all had reasonable and similar attrition rates 
across conditions at follow-up points. Hughes et al. (2010) did have differential drop-out over 
the pre-quit period, reporting the rate of completion of baseline and pre-quit surveys as 57% 
in the preloading arm and 82% in control arm (p< 0.0001). Although data on abstinence are 
based on ITT, we had to use data on responders only for assessing the effect of the 
intervention on the mediators and this potential bias should be borne in mind. The remaining 
three studies (Rose et al. 1998; Rose et al. 2006; Rose et al. 2009) were rated as ‘Unclear’ for 
incomplete outcome data, either because they did not report drop-out past the quit day, or 
because they did not give drop-out for each group separately.  
 
Another potential bias relates to biochemical validation of abstinence (Table 5). Studies that 
did not validate abstinence could potentially over-estimate it. Five studies (Rose et al. 1994, 
Rose et al. 1998; Schuurmans et al. 2004; Rose et al. 2006; Rose et al. 2009) validated 
abstinence at both short- and long-term follow-ups, and two studies validated at long-term  
follow-up only (Etter et al. 2009; Hughes et al. 2010). Bullen et al. (2010) was the only study 
that did not verify abstinence biochemically. Validation had occurred in a small subset of the 
participants and was then generalised to the whole population, however this was only for  
point prevalence not continuous abstinence. We chose not to use these rates over self-reported 
continuous abstinence rates, based on the assumption that we would not expect the proportion 
of participants claiming abstinence, but failing validation, to differ between arms, and the 
conclusion of the SRNT Subcommittee on Biochemical Verification (2002) that studies with 
limited face-to-face contact, and where data collection is by telephone are unlikely to benefit 
from biochemical verification because of higher refusal rates. In reality the extent that self-
report inflates abstinence rates rarely differs across conditions. This is supported by the only 
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two included studies that allowed comparison of validated and non-validated quit rates in this 
analysis (Etter et al. 2009; Hughes et al. 2010). They both found that the proportion of 
biochemically non-validated participants who claimed to be abstinent did not vary 
significantly across conditions (p=0.86 and p=0.61 respectively).  
 
Finally we generated and examined funnel plots to establish whether our results may be 
subject to publication bias. These plots were largely asymmetric with the smaller studies 
providing more positive results and the larger studies indicating less positive effects 
(Appendix 26). 
 
4.4 Discussion 
This updated meta-analysis reports modest evidence of a weak favourable effect of nicotine 
preloading on abstinence. However, this effect did not achieve significance for short- or long-
term abstinence rates and is substantially weaker than the effects reported in previous meta-
analyses (Shiffman and Ferguson 2008; Stead et al. 2008). Furthermore, results were clouded 
by heterogeneity, particularly for short-term outcomes.  
 
The evidence also suggested little apparent effect on users' positive or negative 
reinforcements for smoking and minimal effect on reported cravings during preloading. 
Despite this, some studies (Etter et al. 2009; Rose et al. 1994, Rose et al. 1998; Rose et al. 
2006; Bullen et al. 2010) reported reductions in smoking intensity, daily cigarette 
consumption and dependence, but this varied from study to study. It was hypothesised that a 
reduction in these variables would lead to a reduction in withdrawal intensity post-quit, 
thought to drive return to smoking, however there was no evidence of this, and there was 
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reasonable evidence that preloading did not enhance adherence to post-quit NRT. The two 
studies (Etter et al. 2009; Hughes et al. 2010) that reported reductions in cigarette 
consumption and measured change in self-efficacy showed contrasting results, therefore we 
are unable to conclude whether preloading increased self-efficacy, mediated by the decrease 
in cigarette consumption pre-quit. There was weak evidence that preloading with patch was 
more effective than with gum, reaching significance for short-term abstinence, but only 
approaching significance for long-term abstinence; and a very weak non-significant effect of 
intensity of pre-quit behavioural support on the effect of preloading. Overall, none of our 
mediational hypotheses received strong support, but many studies did not report on these 
mediators and none have conducted tests of mediation. Similarly there was very little 
evidence of any influence of moderators on the effect of preloading, and the only studies that 
did report an effect appeared to be contradictory. One study (Rose et al. 2009) reported that 
preloading was more effective than control in less dependent smokers, with no difference in 
effect in highly dependent smokers, whereas another (Schuurmans et al. 2004) reported that 
preloading was more effective than control in heavier smokers, with no difference in effect in 
lighter smokers. 
 
This review and meta-analysis was originally carried out to update the existing meta-analyses 
of nicotine preloading to support an application for funding. Due to the time constraints this 
necessitated the review cannot be classified entirely as systematic, as study eligibility and data 
extraction was not carried out by two independent reviewers. Nevertheless the review was 
carried out with a clear structure, as recommended by the Cochrane Collaboration (including 
searches, study eligibility assessment, data extraction and quality assessment), and all stages 
of the review were overseen by a second reviewer. As a result, we believe this review to be of 
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a high quality. For the comparable time period, we identified the same literature as the 
previous Cochrane Review (Stead et al. 2008), which was carried out systematically, and 
since publication we have not been notified of any studies that we missed. Therefore, at the 
time of writing, we believe that this review incorporates all extant literature and represents an 
update on previously published reviews (Shiffman and Ferguson 2008; Stead et al. 2008).  
 
The previous reviews both resulted in substantially more positive effect estimates of 
preloading with large confidence intervals, although in the case of Shiffman and Ferguson 
(2008) this may be partly caused by the fact that a random-effects model was used, rather than 
fixed-effects. However, Stead et al. (2008) carried out a fixed-effect analysis, as used in this 
study. Our more negative result appears to be due to including recent, large, more negative 
studies (Etter et al. 2009; Bullen et al. 2010; Hughes et al. 2010). There are several reasons 
why these studies could be more negative than the earlier studies. Two of the three studies 
(Etter et al. 2009; Hughes et al. 2010) provided short-acting NRT for preloading and the 
strongest evidence of sub-group differences was from dividing studies by whether or not they 
used a nicotine patch. These two studies also asked participants to use the (short-acting) NRT 
to reduce their smoking. This could undermine the efficacy of preloading because it is likely 
to retain the natural rise and fall of blood nicotine levels, and mean participants experience the 
positive and negative reinforcement that is thought to be related to the development and 
maintenance of tobacco addiction. However, the evidence that NRT preloading with patches 
did not have marked effects on positive or negative reinforcement casts some doubt on this. A 
further reason relates to the intensity of behavioural support, because two of the three studies 
provided very limited support pre-quit, or self-help only. There was very weak support for the 
hypothesis that support intensity matters and therefore that this explains the more negative 
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findings of later studies. A final issue is that the funnel plots were noticeably asymmetric, 
with large negative studies and small positive studies, raising the possibility of publication 
bias. However, as there were potentially important methodological differences between the 
studies, this does not itself prove publication bias. Overall, there were too few studies to 
simultaneously control for several key methodological differences in meta-regression, to 
investigate these issues further.  
 
Another way that this analysis builds on previous investigations is the focus on potential 
mediators and moderators of the effect of preloading on abstinence. However, these data were 
sometimes incompletely reported. For example, data had to be extracted from graphs and/or 
they were reported insufficiently to allow meta-analysis, by not reporting the number of 
participants in the analysis, or standard deviations. In some studies, data on mediators and 
moderators were collected and we believe analysed, but not reported, fuelling concerns that 
only statistically significant results were presented. The extracted mediators and moderators, 
however, do not appear to be convincing explanations for the effect of preloading or 
differences between trials, and therefore this weakness is unlikely to be giving a false picture. 
This finding may highlight that this is an area where measurement and reporting could be 
improved and that the question of whether preloading is effective, how it might be effective, 
and in whom it might be most effective is still largely unanswered. 
 
However, it is important to acknowledge that theories of dependence, such as those 
investigated in this review (i.e. self-efficacy) are social constructs, and so may differ based on 
the experiences of the participant (West 2006). As smokers find it hard to introspect and 
communicate about these concepts questionnaires are developed in an attempt to capture the 
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underlying structure of the concept. However a concept as defined by one person will not 
necessarily resonate with another, and may change over time relative to experience. These 
limitations need to be considered when carrying out analyses of the sort included here, and 
may to some extent explain the lack of conclusions we are able to draw.  
 
Although the evidence is weak, we believe that the most plausible hypothesis is that 
preloading undermines the learning process that led to addiction and it is this that leads to 
enhanced cessation. Weak support was provided for this with our comparison of nicotine 
patches with short-acting NRT. However it is important to note that the type of NRT used was 
not the only substantial difference between the studies in each of the sub-groups of this 
analysis. As previously mentioned the studies that used short-acting NRT for preloading both 
also asked participants to reduce their cigarette consumption during the pre-quit period, 
whereas the control group were asked to quit abruptly (Etter et al. 2009; Hughes et al. 2010). 
Therefore there is no way of knowing whether the effect detected in these studies is a function 
of instructions of how to quit, type of NRT used, or both. To investigate this it would be 
useful to examine the effect of preloading using acute NRT in participants asked to smoke as 
normal.  
 
If NRT preloading does work in the way outlined above then longer preloading could be more 
helpful. Evidence of this was too scanty to draw conclusions, because nearly all studies used 
the same length of preloading. Taking the evidence as a whole, we believe that future 
preloading RCTs might reasonably choose to use a patch and a longer period of preloading. A 
full mediation analysis of theoretically possible mediators, perhaps using the framework we 
propose, and appropriate moderators, would also be helpful.  
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The efficacy of preloading could depend on the intensity of behavioural support. Until 
recently, people were advised not to smoke and use NRT concurrently, and, as a result, they 
may feel reluctant to use nicotine preloading. Behavioural support during preloading could 
address these concerns increasing the likelihood of adherence to treatment, and thus 
increasing the likelihood of abstinence. However there was little evidence for this. Perhaps 
participants were not worried about smoking and using NRT at the same time, or this issue 
was addressed satisfactorily at the baseline behavioural support session. Regardless of this 
finding, it seems important to have a counselling protocol that encourages therapists to elicit 
patients' concerns and seeks to address these. 
 
To assess whether issues in the design, conduct, or reporting of studies affected the apparent 
efficacy of preloading we carried out a quality assessment. In most cases judgements 
indicated that studies were either unlikely to cause bias or that the evidence was unclear. The 
only studies that were judged to be a potential cause of bias were those that were unblinded, 
where participants and therapists (where used) were aware of treatment allocation. We carried 
out a sub-group analysis to test whether this could influence the effect estimate, which 
showed a significant difference between those studies that blinded participants and those that 
did not. If a placebo effect had occurred then we would expect that the effect of preloading 
would be higher in the unblinded studies, however the opposite was the case, with preloading 
more effective than placebo in blinded studies, but only as effective as control in the 
unblinded studies. This suggests that failure to blind was not a bias in this review. However, 
there were differences between the blinded and the unblinded studies- for example two of the 
three largest unblinded studies used short-acting NRT (Etter et al. 2009; Hughes et al. 2010)- 
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which were associated with lower efficacy, and it could be this or other differences between 
studies that partly explain this unexpected finding. 
 
Based on the previous apparently conclusive meta-analyses, some smoking cessation clinics 
have routinely recommended preloading treatment. This update gives no strong evidence of 
efficacy and suggests routine use is not supported by evidence. Nor does this review give any 
basis for selecting a sub-group of patients who might benefit more from preloading. If 
preloading is used, we would select the patch, over a short-acting form of NRT. Patients could 
be told to smoke freely, to try to smoke as normal, or to reduce their consumption, but there 
are no data to suggest which instruction would be most efficacious. Other data indicate that 
concurrent smoking and NRT use is safe and patients could be strongly reassured of this 
(Fagerstrom & Hughes 2002). However, further trials are required to improve the precision of 
the estimate of effect of preloading, to try and establish the cause or causes of the 
heterogeneity in the current trials, and to enhance understanding of the mechanisms and 
moderators of action. By improving understanding of these mechanisms clinicians may have a 
basis for deciding which patients would benefit from preloading, and therefore be able to offer 
targeted cost effective treatment. 
 
4.5 Response to Rose (2011): Nicotine preloading: The importance of a 
pre-cessation reduction in smoking behaviour 
After publication of the above review in Psychopharmacology (Lindson & Aveyard 2011a; 
Appendix 3), Jed Rose, the lead author of four of the included studies (Rose et al. 1994; Rose 
et al. 1998; Rose et al. 2006; Rose et al. 2009), submitted a corresponding Letter to the 
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Editors (Rose 2011).  Our published response (Lindson & Aveyard 2011b; Appendix 4) was 
as follows. 
 
Rose (2011) raises two discussion points.  Firstly, that the effect of nicotine preloading may 
be correlated with the extent to which smokers reduce smoking during preloading, and 
secondly that the use of measures of non-continuous abstinence may underestimate the effect 
of preloading. 
 
Rose (2011) cites within study data supporting the first point. For example Rose et al. (2010) 
found that participants who reduced cotinine concentration more than 50% were three times 
more likely to be abstinent than those who reduced less. This was also observed in a recent 
trial of four weeks of varenicline preloading (Hajek et al. 2011). We agree that these findings 
could offer insight into the mechanisms by which preloading has its effects. Therefore we 
investigated this further using data from our meta-analysis (Lindson & Aveyard 2011a) to 
make between study comparisons, using sub-group analysis.  Four of the eight studies asked 
participants to smoke freely during the preloading period, and provided data on pre-quit 
reduction in smoking in the preloading arm.  The only common marker of reduction reported 
was cpd. The two studies reporting reduction of less than 50% of baseline cpd gave a RR of 
1.83 (95% CI= 0.97, 3.47), while those reporting a reduction of more than 50% gave a RR of 
1.04 (95% CI= 0.81, 1.34) for long-term abstinence. However the difference between sub-
groups was not significant (Figure 21). These data therefore do not suggest that the ability of 
preloading to suppress smoking is a good explanation for the between study heterogeneity we 
observed in our review.  
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Figure 21: A sub-group analysis comparing the effect of NRT preloading on long-term 
abstinence in studies where participants reduced their cpd by less than 50%, and in 
studies where participants reduced by more than 50% 
 
In response to Rose’s (2011) second point we investigated the suggestion that “studies finding 
the largest effects of nicotine preloading used as an outcome measure continuous and 
complete smoking abstinence assessed from the quit date on.”, again using sub-group 
analysis. When measuring long-term abstinence prolonged or point prevalence rates were  
used for three studies resulting in a pooled RR of 0.95 (95% CI= 0.68, 1.34), and a RR of 
1.25 (95% CI= 1.01, 1.53) for the studies using continuous abstinence.  However the test for 
sub-group differences was not significant (Figure 22).  
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Figure 22: A sub-group analysis comparing the effect of NRT preloading on long-term 
abstinence in studies where continuous abstinence was used and studies where 
prolonged or point prevalence abstinence were used as the outcome measure 
 
Rose et al. (2009) suggest that trials not reporting continuous abstinence underestimate the 
true benefit of preloading, because in a real-life setting participants will not be supported to 
continue NRT during lapses after quit day. This may be so, but it is also likely that adherence 
to preloading would be lower outside a trial than within it for the same reasons. Until recently, 
people were advised not to smoke and use NRT concurrently.  The message to the contrary is 
not well-known, as we have witnessed in our own trial (Lindson et al. 2009a). Instructions to 
preload or to continue NRT during a lapse are party to the same discriminations by smokers. 
In fact preloading may present more of an issue due to the prolonged nature of the 
concomitant usage. 
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In conclusion we agree that both points raised by Rose (2011) are important, but they do not 
appear to explain heterogeneity between studies. Further within trial analyses are needed, in 
particular focusing on differences between active and placebo conditions, as in Rose’s recent 
studies (Rose et al. 2009; Rose et al. 2010).  It would be useful to understand why those 
people who reduce their smoking do so- the mediators of reduction. Given the uncertainty 
over the size of the benefit and mechanism(s) of action, we suggest a further trial of nicotine 
preloading is needed. 
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CHAPTER 5: A QUALITATIVE STUDY OF SMOKERS’ 
EXPERIENCES OF DIFFERENT QUITTING METHODS: 
ABRUPT, REDUCTION AND NICOTINE PRELOADING 
 
5.1 Background 
As outlined in Chapter 1 smoking reduction prior to quitting and nicotine preloading are 
methods that could be used to increase smoking quit rates. Surveys have revealed that 
providing support for smoking reduction is likely to be a popular approach to cessation 
(Hughes et al. 2006; West 2008), which suggests that if it were adopted by the NHS SSS it 
may encourage more smokers to take-up this type of support. In addition the Cochrane 
Review reported in Chapter 3 suggests that if offered it would be unlikely to result in quit 
rates markedly different to those currently achieved through quitting abruptly. Therefore, the 
next stage should be to establish the best way to implement a smoking reduction approach in 
clinical practice. Stop smoking services do not provide supported reduction programmes, so 
the way these programmes might best operate is unclear. However a limited number of studies 
investigating reduction have looked at the feasibility of reduction methods, reducing smoking 
whilst using NRT versus placebo, and the relative efficacy of different reduction methods. In 
some cases the goal was cessation and in others simply reduction.  These studies have used a 
range of methods to reduce smoking, which we have categorised into three broad types: 
unstructured, cigarettes per day (cpd) and smoke free periods (sfp) reduction. The following 
sections (5.1.1– 5.1.3) provide a narrative review of some of these methods, including some 
studies that have aimed to establish the best ways to carry out reduction. We conducted a 
search to find trials incorporating a reduction method or comparing two or more types of 
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reduction, using MEDLINE, Google Scholar, PsychINFO, SRNT abstract search, a citation 
search, and contact with key authors. We have not distinguished between studies that enrolled 
participants who were not ready to quit smoking and encouraged them to reduce, and studies 
that enrolled participants ready to quit.  Motivation to quit is fluid in many smokers (Hughes 
et al. 2005) and evidence shows that most people who are not ready to quit, but want to 
reduce, are more willing to quit in the end (Hughes & Carpenter 2006; Asfar et al. 2011). A 
systematic review would have been time consuming and outside the scope of this thesis, 
nevertheless, although not exhaustive this review should provide further justification for the 
reduction methods used in RRT (Chapter 2), and provide the background knowledge needed 
to appreciate participants’ responses to the interview study reported from Section 5.1.4 
onwards. 
 
5.1.1 Smoking reduction methods 
5.1.1.1 Unstructured reduction 
The first group of studies specify only that participants should reduce their smoking, and 
usually do not give either a specific goal or a specific method of how to do so.  Cummings et 
al. (1988) provided participants with suggestions of how to reduce, for example by setting 
daily goals or changing habits, but ultimately the decision was left with participants.  Other 
studies have told participants to reduce their smoking, using NRT as a substitute for cigarettes 
(Fagerstrom et al. 1997; Bolliger et al. 2000; Batra et al. 2005; Rennard et al. 2006).  These 
studies, utilising unstructured reduction methods have found that reducing smoking whilst 
using NRT is safe and feasible, and more successful than simply reducing with no 
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pharmacotherapy (Wang et al. 2008; Moore et al. 2009).  A majority (92%) of participants in 
one study thought this was a good method to give up smoking (Fagerstrom et al. 1997), and 
despite a number of the studies only enrolling participants who were either unwilling or 
unable to quit, a number of participants had successfully quit smoking at follow-up (Hughes 
& Carpenter 2006).   
 
5.1.1.2 Cigarettes per day reduction 
The second more specific method of reduction advises smokers to reduce by giving depleting 
target numbers of cpd, sometimes with advice on how to control smoking to achieve this 
target.  A study by Gunther et al. (1992) asked participants to reduce by a set number of 
cigarettes per week until they reached abstinence. Depending on the amount they smoked at 
baseline this varied between five and ten cigarettes.  The remaining cigarettes for each week 
could be smoked at any time.  Shapiro et al.’s (1971) cpd approach was more structured and 
designed to divorce smoking from associated environmental cues, by providing participants 
with a new signal to smoke, which had no meaning to the individual.  This signal was 
provided by either a paging device or watch timer, which was programmed to go off at fixed 
or random time intervals.  In the first week of the study the timer/pager was set to go off at 
intervals that ensured smoking was at the individuals’ baseline rate.  For the remaining weeks 
the daily rate of smoking was reduced by four cigarettes at the beginning of the programme 
and by two at the end, so that the median number of weeks participants were in the 
programme was between seven and nine. Participants were asked to smoke only on 
timer/pager cues, not to refuse smoking on these cues, unless in a situation where smoking 
was illegal or impossible, and not to make-up for missed cigarettes.  Participants were almost 
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uniformly enthusiastic about the intervention and the possibility it gave to reduce smoking.  
At follow-up, six weeks after the termination of the programme, participants reported that 
they had reduced their daily cigarette consumption, from baseline, by a median of 43%. 
Cinciripini et al.’s (1994) approach was a variation of this method.  Participants reduced the 
number of cigarettes smoked by two to five per day (dependent on number of cigarettes 
smoked at baseline), by gradually increasing the time between each cigarette smoked (the 
ICI).  Cigarettes were reduced over a three week period; after this participants were expected 
to quit abruptly on a specific day.  The study aimed to produce an initial report of treatment 
efficacy and compared reduction to a control, minimal, self-help treatment where participants 
were given no specific instruction of how to quit, but were given guidance about possible aids 
to cessation.  Seventy-eight percent of participants complied with the reduction schedule in 
the first week, 71% in the second and 68% in the third, and 24 hour abstinence rates superior 
to the control condition occurred at both week five (70.6% versus 24%), and week nine (68% 
versus 18%) of treatment.  Abstinence rates in the reduction group remained high at six month 
and twelve month follow-up (53% and 41% respectively), which compare favourably with 
other cessation programmes (Section 2.1). 
 
Hughes et al. (2010) conducted a study of gradual versus abrupt quitting, which used three 
methods of reducing cpd to reduce smoking to 75% of baseline in week one, 50% of baseline 
in week two and 25% in week three.  Participants were able to choose between the reduction 
methods, and therefore were not randomised. The first method involved increasing ICIs in the 
same way as Cinciripini et al. (1994), whilst in the second and third, participants were asked 
to rank the cigarettes they smoked each day according to how difficult they thought they 
would be to give up. They then progressively gave up either the hardest cigarettes or the 
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easiest cigarettes first.  The report states that the majority of participants chose the ICI method 
(60%); however researchers’ observations suggested that many of the participants did not 
exclusively use their chosen method, or didn’t use any of the suggested methods.  As a result 
the outcomes of the use of the specific reduction methods were pooled into an overall 
reduction group. 
 
5.1.1.3 Smoke-free periods 
The third method of reduction reduces the number of time periods during the day when 
smoking is allowed.  During the remaining time participants may smoke as much as they like. 
Interventions which aim to reduce consumption by reducing cpd could have adverse effects, 
by focusing the smokers' attention on what they are missing.  By nominating periods in which 
smoking is prohibited, and at all other times is allowed, smokers are encouraged to focus on 
successful periods of abstinence, which could in turn raise self-efficacy. Findings from an 
experimental study by Dols et al. (2002) provide further support for this approach- 
participants allocated to a condition in which they expected to smoke but could not do so had 
significantly more cravings than participants allocated to a condition where smoking was 
prohibited.   Marston & McFall (1971) reduced smoking periods by dividing the day into four 
time periods and asking participants to rank these in terms of how difficult they would find it 
to abstain from smoking during this time.  Participants were then asked to first stop smoking 
in the period they had rated most difficult and proceed to eliminate each of the ordered time 
periods until they had stopped smoking entirely.  Kyle & Shiffman (2005) and Shiffman et al. 
(2009) adopted a slightly different approach by asking participants to substitute their smoking 
with a piece of nicotine gum for the first hour after waking, and on each subsequent day to 
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increase this sfp by another hour, using an additional piece of gum.  After a maximum of four 
weeks the sfp covered the entire day, and hence led to abstinence.  Participants who used the 
gum to aid their reduction rather than placebo were significantly more likely to achieve initial 
cessation (2mg gum- OR = 1.42; 4mg gum- OR= 1.90), and six month continuous abstinence 
(2mg gum- OR= 1.80; 4mg gum- OR= 5.96) (Shiffman et al. 2009).   
 
5.1.2 Studies of the relative effect of different reduction methods 
5.1.2.1 Speed of reduction 
Haustein (2002) compared reduction over four weeks, and over 12 months in smokers not 
ready to quit.  Participants were given brief advice to reduce their smoking using unstructured 
reduction. The primary outcome measure was successful reduction, which was measured as 
sustained reduction of 50% of baseline.  The use of short-term rather than long-term reduction 
was more successful at four, six, nine and twelve month follow-up (significant in all cases), 
and an RR of 4.57 (95% CI= 1.00, 20.93) was achieved for confirmed prolonged abstinence at 
4 months post-quit.  Blalock et al. (2003) provide further support for more rapid reduction by 
comparing cpd reduction in a slow reduction group and a fast reduction group in smokers 
wanting to quit. The slow group reduced their cigarettes by 66-99% over a two to three week 
period, and quit in week three or four.  The fast group reduced by 50% during week one and 
quit in week two. Both groups used nicotine patches throughout the reduction period.  Two 
week continuous abstinence rates were 39% in the fast group and 26% in the slow group.  The 
findings therefore favour faster reduction over slower reduction, but the evidence is 
preliminary. 
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5.1.2.2 Structured versus unstructured reduction 
Cinciripini et al. (1995) compared two types of cpd reduction in smokers wanting to quit. The 
first type was scheduled, where ICI was progressively lengthened to accommodate the 
planned reductions in cigarettes.  The second was unscheduled, where participants were 
merely told how many cigarettes they were to smoke each day, and they could smoke them 
when they pleased.  Both groups were given a cigarette allowance of two thirds of baseline in 
week two, one third of baseline in week three, and one third of week two allowances in week 
four.  Both groups were required to quit abruptly in week five.  At one year follow-up 44% of 
the scheduled group were abstainers compared to 18% of the non-scheduled group (p<0.05).   
 
A similar study by Levinson et al. (1971) also found that participants assigned to the 
scheduled group were significantly more likely to be successful quitters at three month 
follow-up than participants assigned to the non-scheduled group.   
 
5.1.2.3 One structured method versus another structured method of reduction 
Riggs et al. (2001) took this one step further by comparing two different methods of 
scheduled cpd reduction in smokers not interested in quitting, but who wished to reduce.  The 
study had a cross-over design so that each participant used each method for two weeks with a 
two week wash-out period in between.  In the hierarchical reduction method, participants 
smoking normally were asked to record all cigarettes they smoked in one week and rate them 
in terms of how difficult it would be to give them up.  They were advised to reduce by giving 
up the easiest first progressing to the harder ones.  In the ICI method participants followed the 
regimen used by Cinciripini et al. (1994), progressively lengthening the interval between 
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cigarettes smoked on a fixed schedule.  In both arms cpd were reduced by 25% in the first 
week of reduction and another 50% of the remaining cigarettes were eliminated in the second 
week.  Participants were encouraged to replace each cigarette with a piece of nicotine gum.  
Both forms of reduction significantly reduced CO levels, with no significant difference 
between groups.  Likert scale ratings of ease of reduction and likeability of treatment also 
showed no significant variation between groups. Therefore Riggs et al. (2001) conclude that 
the two methods are equivalent and future studies could give the choice of either method. 
 
Two methods of increasing sfp were compared by Flaxman (1978).  Both arms utilised a 
method similar to the hierarchical method used by Riggs et al. (2001), developed by Gutmann 
& Marston (1967), where situations leading to cigarette smoking are ranked according to 
perceived difficulty of refraining from smoking in that situation.  Flaxman (1978) asked 
participants to give up smoking in the stimulus situation ranked as easiest first, progressing to 
the most difficult; by progressing to the next most difficult situation every three days.  In one 
group participants were asked to do this until they were not smoking at all, and in another 
group until they were smoking half of their base rates, and then to stop abruptly.  No 
difference in daily post-treatment smoking rates was found between the two groups at follow-
ups (weeks one to eight, and six month).    
 
5.1.3 Tentative conclusions 
Conclusions that can be drawn from this evidence are limited by the quality of some studies, 
for example many had small sample sizes, and/or unclear reporting of abstinence rates or 
reduction success. Therefore the evidence on how reduction is best achieved is weak. 
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Preliminary evidence suggests that reduction is most successful when NRT is used as a 
concomitant aid, when it takes place over a limited time period (weeks rather than months), 
and when structured and/or carried out to a schedule. Additionally, cpd reduction appears to 
be equally successful and popular when carried out using a hierarchical method and when 
achieved by decreasing ICI; but this conclusion applies to reduction only, not reducing then 
stopping.   
 
5.1.4 Study justification  
The RRT, outlined in Chapter 2, was designed to investigate the abstinence rates achieved in 
smokers using behavioural reduction methods in comparison to smokers using an abrupt 
quitting method, similar to that already offered by the NHS SSS. In-line with current practice 
participants using either method are provided with NRT post-quit alongside their behavioural 
support.  However, based on the tentative conclusions drawn from the aforementioned 
reduction studies, a number of further design decisions were made. NRT is provided pre-quit 
day as well as post-quit day in both arms, reduction takes place rapidly over two weeks, and 
participants are advised to follow a structured programme.  Three variations of this core 
smoking reduction method are offered: 1) scheduled cpd (SR); 2) hierarchical cpd (HR); and 
3) smoke-free periods reduction (SFP). With the HR method participants can then go on to 
choose to forgo either their easier (HR-E) or harder (HR-H) cigarettes first.  As the main 
focus of the trial is to compare abstinence rates when quitting abruptly and reducing to quit 
the trial was designed with the power to do as such.  An unfeasibly large number of 
participants would have had to be recruited to compare abstinence rates across the different 
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reduction methods, and so it was decided that participants randomised to the reduction arm 
would choose their method of reduction, rather than being randomised to it. 
 
However another way to investigate the reduction methods further and to gain insight into the 
differences and similarities between abrupt and gradual quitting is to carry out qualitative 
analysis of participants’ feelings about, and experiences of, the methods used.  To our 
knowledge there has been no qualitative investigation of nicotine preloading, and as reported 
above there is almost no data on service users’ opinions of reduction methods.  That which 
exists appears to be based on a few closed questions on intervention acceptability (Shapiro et 
al. 1971; Fagerstrom et al. 1997; Riggs et al. 2001). There are several reasons why asking 
patients about their perceptions of a treatment could be useful.  Firstly it establishes whether 
there is a desire for a treatment service.  If this is not the case then even if the treatment were 
made available it may not be used, regardless of how successful it is. Surveys suggest that 
smoking reduction is a popular route to quitting (Hughes et al. 2006; West 2008), however 
this is in response to a question along the lines of ‘How do you plan to quit?’, and so may not 
reflect whether smokers would specifically wish to access a smoking reduction service.  It 
may also be interesting to establish the desire for an abrupt quitting service, as up until now it 
has been the only treatment option available through the NHS SSS; therefore patients who 
want help to stop have been forced to use this method regardless of whether they thought this 
was suitable or not. As well as establishing overall satisfaction, questioning a patient about a 
service they have experienced also provides the opportunity to ask about things that they may 
have liked or disliked about the method they used, and ways that they feel it may be 
improved, opening up the possibility to tailor the methods more specifically to the needs of 
the user population. Finally asking participants how they think the methods did or did not 
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work for them may provide insight into the mechanisms through which the methods have 
their effects. Qualitative approaches generally offer the opportunity to delve further into a 
topic, and perhaps explore issues that were not anticipated by the researcher.  In topics where 
research is limited, such as smoking reduction and nicotine preloading, this could be valuable; 
thus providing the motivation for this study. 
 
We used qualitative interview methods to explore the opinions of RRT participants about the 
quitting methods used in the study, including the behavioural methods of abrupt quitting and 
reduction to quit, in the form of the SR, HR and SFP methods; as well as the use of NRT prior 
to the quit day (nicotine preloading). This allowed for comparison between smokers using the 
different methods, and who were and were not smoking at four weeks post-quit. 
 
5.2 Method 
5.2.1 Study design and participants 
Participants were recruited from the RRT - a randomised, controlled, non-inferiority trial, 
comparing abrupt quitting with reduction to quit, and utilising nicotine preloading treatment 
in both arms. Participants in RRT are recruited through GP surgeries in the West Midlands, as 
described in Section 2.2.5. They are randomised to one of two trial arms (Section 2.2.6.1).  
Those participants randomised to abrupt quitting are asked to smoke as normal, whilst 
wearing a nicotine patch for two weeks of preloading, and then asked to quit on an agreed quit 
day. Participants in the reduction arm are asked to reduce their smoking over two weeks (to 
50% of baseline cpd/smoking periods at the end of the first week, and to 25% of baseline 
cpd/smoking periods at the end of the second week), and then to quit completely on an agreed 
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quit day.  Participants who reduce their smoking use both nicotine patch preloading pre-quit, 
and an acute form of NRT to replace those cigarettes missed. All participants use NRT in the 
form of patches and an acute form of their choice post-quit day, and use diaries to monitor 
their smoking and NRT use for three weeks following randomisation.  Those participants in 
the smoking reduction arm are asked which of three behavioural methods of reduction (SR, 
HR, SFP) they would like to use (described in Section 2.2.6.3).  They then plan their smoking 
reduction, with the help of their research nurse, using a smoking reduction schedule designed 
for the method of their choice (See Appendix 9, Appendix 10 and Appendix 11 for fictional 
examples of completed schedules). 
 
All participants screened over the phone as eligible to take part in the trial, and booked in to 
have their first appointment between 15th March 2010 and the end of the interview study 
(when theoretical saturation was reached and the last participant had been interviewed- 15th 
December 2010), were sent a PIS for RRT, containing information about the interview study 
(Appendix 5).  At their first visit participants attending during this time period were also told 
about the interview study by their research nurse and asked to complete a consent form for 
RRT, which included an opportunity to opt in or out of also consenting to take part in an 
interview (Appendix 6). We gave interview notes sheets (Appendix 14), providing 
information about the interviews, and topics and questions that may be asked, to those 
participants who consented to take part. Participants were encouraged to make notes on the 
sheet during the cessation programme to aid their recall during the interview, which took 
place at the end of the behavioural support programme.  
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5.2.2 Interviews 
RRT participants, across all study arms, who attended their first trial visit between 15th March 
2010 and November 12th 2010, consented to take part in RRT and the interview study, and 
provided a contact telephone number for the interviews were telephoned approximately five 
weeks post-quit day, from a private room, to see if they were still interested in taking part in 
the study.  Five weeks post-quit was chosen as no other contact regarding the trial was made 
that week.  Therefore it was hoped that participants would not feel the interview was 
burdensome, but their memories of the programme would still be fresh.  Contact was 
attempted at least three times before the attempt to contact any participant was abandoned.  
All interviews were carried out by a researcher (NL), and took place over the phone, in an 
attempt to make participation as convenient as possible and to maximise the number of people 
taking part. A semi-structured interview schedule (Appendix 13) was used to conduct the 
interview, including topics such as first impressions of the quit method used, how easy it was 
to carry out, good and bad points, changes that should be made, feelings over the pre-quit 
period, the use of pre-quit NRT, and why the quitting method worked or didn’t work for 
them; also allowing participants to expand on any issues that they raised independently of 
these. All interviews were recorded using a telephone adapter and digital recorder, and took 
between 10 – 40 minutes to carry out. Recruitment for the interview study ceased when no 
new themes began to emerge during the interviews; therefore when theoretical saturation 
occurred.  
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5.2.3 Data analysis 
All interview sound files were transcribed verbatim by an independent transcription company, 
as the study progressed. This meant that transcripts could be read and findings taken into 
account when interviewing others; adding topics to the interview schedule where relevant. 
Transcripts were imported into NVivo 8 (QSR International Ltd, Melbourne, Australia) and 
read by two researchers (NL & RB). Initial themes were then identified and discussed. Using 
these NL began coding the transcripts in an ongoing and iterative process, and these were 
double-checked by RB. We discussed this analysis regularly as the interviews proceeded. This 
meant that themes and coding were malleable throughout the interviews and analysis. On 
completion of this coding, data was charted thematically (See Appendix 27 for example 
thematic chart) and by case (See Appendix 28 for example case chart), as per the Framework 
approach to qualitative data analysis (Ritchie & Spencer 1994). This allowed us to summarise 
themes, and compare these between different quitting methods, and between those 
participants abstinent and not abstinent at 4 weeks post-quit. Abstinence was measured 
according to the Russell Standard (West et al. 2005), allowing a grace period of two weeks for 
slips (Hughes et al. 2003), and validated by an exhaled CO reading of less than 10ppm. Two 
researchers (NL, AM) summarised and compared a sub-section of charts, to ensure inter-
researcher consistency; the remaining charts were analysed by one researcher (NL) and 
checked by another (RB). Finally charts were used to identify extracts from the transcripts to 
illustrate findings in the Results (Section 5.3). 
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5.2.4 Ethical considerations 
As stated in Section 2.2.15 RRT was reviewed and approved by the National Research Ethics 
Committee (08/H0408/213), the MHRA (2008-006433-28), and local NHS Research & 
Development offices.  A substantial amendment for the interview study, was submitted and 
approved by the National Research Ethics Committee, and the authorities above were 
notified. Written informed consent was obtained from all participating in the interview study.  
Participants were informed that the interview element of RRT was optional, and would not 
affect their participation in the rest of the trial. When consenting participants were contacted 
by telephone they were also asked for their verbal consent and were given the opportunity to 
opt out of the study at that point. We also reminded participants before recording started that 
the interview would need to be recorded to allow for analysis, and asked for their verbal 
consent to do this. Participants enrolled in the interview study were provided with a new 
anonymised study number, independent of their RRT study number.  One file was used to link 
this study number to participant details and this was password protected and kept on an 
encrypted computer. All interview sound and transcription files were stored with no 
identifying information on an encrypted computer, and were also password protected and 
encrypted when sent to or from the transcription company.  All files sent to the transcription 
company were anonymised. 
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5.3 Results 
5.3.1 Participant characteristics 
During the course of the interview study 168 participants recruited into RRT also consented to 
take part in an interview, and five refused. Of the 168 consenting participants 54 were 
contactable at five weeks post-quit, still agreed to be interviewed, could be interviewed at a 
time convenient for interviewer and interviewee, and went on to complete their interview 
(Table 7). We were able to interview participants that had used all of the methods apart from 
HR-D.  This was a reflection of the lack of participants choosing this method of quitting in 
RRT. Participants were recruited from 13 general practices across South Birmingham (six 
practices), Worcestershire (one practice) and Warwickshire (six practices) PCTs. The 
majority of participants were recruited from Warwickshire PCT, and the number of males and 
females in the study were roughly evenly matched. The average age of participants was 56 
years and participants smoked on average 24 cpd at baseline, with an average FTND of six. 
Four weeks after quit day 22 of the 54 participants (41%) were abstinent, according to the 
criteria described in Section 5.2.3. In the following sections we will outline the opinions of 
these participants about the quitting methods used in RRT; taking into account themes that 
were present across methods, differences between perceptions of the abrupt and reduction 
methods, and the different methods of reduction, feelings about nicotine preloading, and 
finally whether there were any differences in participants’ feelings dependent on whether they 
had successfully quit or not at four weeks post-quit. 
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Table 7: Characteristics of RRT interview study participants 
N- number of participants; SR- scheduled reduction method; HR-E- Hierarchical- easy reduction method; SFP- 
smoke-free periods reduction method; PCT- Primary Care Trust; sd- standard deviation; ppm- parts per 
million; IQR- inter-quartile range; cpd- cigarettes per day, FTND- Fagerstrom Test for Nicotine  Dependence 
 
5.3.2 Commonalities across methods 
5.3.2.1 Preference for a particular method 
Most participants said that when they had been asked by their nurse on entering the study 
whether they would prefer the abrupt or reduction method, they did have a preference, which 
 
 
Characteristic 
Study arm 
Abrupt 
quit 
(N=20) 
Reduction to quit Total 
(N=54) 
SR 
(N=10) 
HR-E        
(N=8) 
SFP    
(N=16) 
Recruited from South 
Birmingham PCT (N) 
6 3 3 5 17 
Recruited from 
Worcestershire PCT 
(N) 
4 0 0 5 9 
Recruited from 
Warwickshire PCT (N) 
10 7 5 6 28 
Female (N) 10 5 3 11 29 
Age in years (mean, sd) 54.6, 10 58.5, 8.4 55.1, 12.6 55.9, 9.1 55.8, 9.7 
Baseline CO in ppm 
(median, IQR) 
25, 12 26, 17 24, 7 27.5, 16 26, 12 
Baseline number of cpd 
(median, IQR) 
20, 14 25, 10 22.5, 5 25, 14 24, 10 
Baseline FTND score 
(median, IQR) 
5.5, 1 5.5, 4 6, 3 7, 3 6, 2 
Abstinent at four weeks 
post-quit day (N) 
9 5 1 7 22 
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they backed up with reasons (see Section 5.3.3.1). However, neither method seemed more 
popular than the other overall. In practice, all of the methods used were described by almost 
all participants as easy to understand, to fit in with their lifestyle, and in most cases easy to 
carry out (Box 1, Quotes 1 and 2). 
 
5.3.2.2 Pre-quit preparation period  
Participants generally felt positively towards the period of treatment and preparation for 
quitting.  The opportunity to continue smoking (even if reducing) prior to quitting appears to 
have been judged as an important time of mental preparation, by giving an opportunity to 
think about the quit attempt with the reassurance that cigarettes were still there (Box 1, 
Quotes 3 and 4). Despite this, a few participants had some suggestions to improve the utility 
of this period.  A couple of participants thought that the pre-quit period should be lengthened 
to four weeks to allow for longer reduction when using the reduction method, as they had 
found reduction over two weeks too sudden. Whereas another participant had found it hard to 
give the research nurse information about their usual smoking habits on entering the study, 
and so felt they would have benefited from a baseline period to record these for use when 
planning their reduction schedule. In contrast, two abrupt participants suggested that the pre- 
quit period should be shortened. One participant felt they had already lost the will to smoke 
after one week of the study, and the other would have liked to quit immediately on entering 
the study, as they had felt ready to do so then.   
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Box 1. Commonalities across methods 
Quote 1-Abrupt 
I: When you were given instructions on what you would have to do, did you find them easy to understand or did you 
have any difficulties with them? 
P: No, no absolutely fine 
I: Okay and how did you actually find the method to carry out 
P: It wasn’t hard, it was when it got to the third, fourth week that I was struggling with it. The first few weeks were 
absolutely fine 
I: Do you think it fit in quite well with your lifestyle or did anything get in the way 
P: No, I mean the only thing that’s got in the way is the fact that I live with my husband who’s still smoking. 
 
Quote 2- Reduction (SFP) 
I: When you were given the original instructions- actually what to do- did you find them easy to follow and 
understand? 
P: Yes it was brilliant yep 
I: Right so there was no problems at all understanding?  
P: No 
I: So then did you find the method easy to carry out? So did you find it easy to abstain from smoking when you were 
asked to? 
P: Yes it’s very good, it helped you to space yourself as well which was very good 
I: Did you find it easy to stick to your pre-quit instructions? Did you find that you were able to keep to the schedule 
that you worked out with the nurse? 
P: Yes I did, yes 
I: That’s great. Would you say that the method fit in well with your personal lifestyle, and you as an individual? 
P: Yes very much so. 
 
Quote 3- Abrupt 
P: It does give you time to think about it, if nothing else...I thought the thinking about it for two weeks prior to it, and 
then actually using those inhalers, I think they’re a great idea. 
 
Quote 4- Reduction (SR) 
P: With this way I've found that you had something to look forward to each day, even if your cigarettes were two hours 
apart or three hours apart, it was something to look forward to every day. And then by the time you'd got to the quit 
day it wasn’t so much of a shock to the system- your body. You were already going four hours without a cigarette by 
then anyway. 
 
Quote 5- Abrupt 
P: The diaries did help, cos it just makes you think, and because you’ve got it all week- you have to fill it in by the end 
of the week- you flick through it yourself and you think to yourself ooo that’s terrible that is smoking that much, and 
just that number, yeah it does help. 
 
Quote 6- Abrupt 
P: With the cutting down, each time you know you’ve cut down on another cigarette, and that made it feel- you’d write 
it down- and it made you feel 10 times better because you knew you’d cut down on one more. 
 
Quote 7- Reduction (SR) 
I: Do you think it was useful to be able to record how much you were smoking each day?  
P: Oh yes, because it brings you up short if you've gone one over. And it makes you realise it's written down. Yes I did 
like that. 
 
Quote 8- Abrupt 
 I: Was there anything particularly about that you found helpful, any aspect of it in particular? 
P: The nurse support? 
I: Yeah. 
P: Yeah, I think just having her there, she was very non-judgmental and very approachable, and I think just having 
that person there that you knew you were going to see every week.  Even if we had have smoked I wouldn’t have felt 
uncomfortable with her, but she made me want to quit, she definitely helped me without her realising quite honestly. 
 
Quote 9- Abrupt  
I: Do you think that there’s anything about this method that could stand in the way of people being successful? 
P: No, I think if you’ve made up your mind you definitely want to quit, I think it’s all about will power isn’t it? I don’t 
think it’s anything to do with the method. 
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5.3.2.3 Monitoring 
Another element of all methods consistently regarded positively was monitoring of cigarette 
consumption and feelings about quitting. This was in the form of expired CO level 
measurements, recording cigarettes smoked in diaries and responding to questions about 
levels of craving and confidence. Monitoring was perceived as helpful in three ways: 1) it 
made participants aware of the amount they were usually smoking, which was more than they 
had anticipated (Box 1, Quote 5); 2) participants could see improvement either in the amount 
of cigarettes smoked, their CO levels or their responses to questions, which spurred them on 
(Box 1, Quote 6); and 3) it made them aware when they had not progressed as they would 
have liked (Box 1, Quote 7). 
 
5.3.2.4 Support, NRT & mindset 
As well as the behavioural methods and nicotine preloading treatment used in RRT, several 
other issues appeared pertinent to all participants concerning their RRT quit attempt. Almost 
all participants found the nurse support helpful. They felt that they were given a great deal of 
encouragement and found it useful to be able to talk through their quitting experiences 
weekly.  Seemingly due to this relationship with the nurse a number of participants felt 
spurred on to succeed, so as not to let her down (Box 1, Quote 8). It also appeared that a 
number of participants had not used NRT to aid their quit attempt before and that they found 
the use of NRT in general (rather than for preloading in particular), as well as the use of a 
combination of patches and an acute form of NRT (which has only recently been 
implemented in some NHS SSS) useful.  However, the issue that came across most strongly, 
irrespective of the methods being investigated, was one of personal mindset.  When 
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participants were asked whether they felt the method they used could hamper a quit attempt, 
or when non-abstinent participants were asked whether they thought there was anything about 
the method that had prevented them from quitting, the answer was most commonly “No”.  
Regardless of the method used participants believed that the most important predictor of 
success was a smoker’s personal circumstances and mindset, and therefore if a person is not 
ready to quit then they won’t succeed (Box 1, Quote 9).  
 
Taken together these findings appear to suggest that all of the quitting methods used in RRT 
are feasible to use in clinical practice. Despite the fact that generally participants prefer abrupt 
quitting or reduction to quit, neither is more popular, which perhaps suggests that smokers 
should be given a choice.  The importance of tailoring is further supported by the fact that 
although participants were generally in favour of a pre-quit period, some participants felt this 
could be altered to better fit their individual needs. Despite the interviews being focused on 
the behavioural methods of quitting used and nicotine preloading, participants also 
highlighted the importance of the intensive behavioural nurse support, the use of NRT in 
general and the quitters’ personal circumstances and mindset to the success of the quit 
attempt.   
 
5.3.3 Comparison between the abrupt and reduction to quit methods 
5.3.3.1 Gradual adaptation versus getting it over with 
The only dislike given of the abrupt quitting method was that it was too sudden and extreme 
an approach, likely to invoke panic (Box 2, Quotes 1 and 2).  This was raised by a number of  
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Box 2. Comparison between the abrupt and reduction to quit methods 1 
Quote 1- Abrupt 
P: The abrupt one- the horrible one, the cruel nasty mean one. 
 
Quote 2- Reduction (SFP) 
P: I think the abrupt one kind of frightens people at first, thinking ahhh, I get to this day and that’s it and I think in 
some smokers you panic. 
 
Quote 3- Reduction (HR-E)  
I: How do you think this method could help people to quit? 
P: It’s a lot easier because it’s not just sudden, you’re gradually doing it, so it’s like, oh how can I put it? It just seems 
a lot easier, that your mind and your body get so used to not having so much nicotine and not smoking so much. By the 
time it comes to completely stopping, you’ve already wanted to stop anyway. 
 
Quote 4- Abrupt 
P: I think if you’ve got no will power to actually cut down, then I think that was the best way to do it, just to stop 
abruptly. To make up my mind, and the fact is I was given a date and there was no sort of choice about it, it was a case 
of like well that’s it do it. 
 
Quote 5- Reduction (SR) 
P: I just found it difficult cos there was a lot going on in my life, it was quite stressful and I thought oh I can't do it all. 
I: So was it that you found it clashed with anything particularly in your lifestyle, or that it was just an extra thing to 
worry about? 
P: It was just an extra thing, and things were happening, and oh there was all sorts going on. I thought this is 
ridiculous. 
I: Was there anything actually that you thought was a good point to the method or that you liked about it? 
P: I did like it, but there's just so much going on. 
 
Quote 6- Reduction (SR) 
P: Cos it was abrupt [previous quit attempt] I just stopped. I hid everything, whereas with cutting down gradually it 
was still there in front of me waiting for the next one. Whereas to hide it was great; I hid everything. 
 
Quote 7- Abrupt 
P: Sometimes I didn’t smoke as many as on a normal day without patches. You're obviously going to the routine 
knowing, I was sort of on this course now for me to stop smoking. I think knowing that- whether that was at the back of 
my brain- but I felt I didn’t get the cravings so much. So it naturally cut itself down to be honest.  Not like, 15, 14 and 
then cut down to six or seven. I found that one packet lasted a couple of days, or just under two days. I found it was 
lasting much longer and that's how I could tell, not that I was counting you see. 
 
Quote 8- Abrupt 
P: I reduced 
I: How were you doing that? 
P: Just cutting down each day, having one less cigarette each day, every day I was just cutting down on one cigarette. I 
mean, now I’m not having none at all...even me husband said to me, instead of when you get up in the morning and 
light one up, leave it for about half an hour and then leave it a bit longer, which I did and that works better. That 
helped a lot, doing it like that. 
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participants who also thought they wouldn’t be able to quit abruptly, and that the method 
would be particularly difficult for heavy and/or long-term smokers, such as themselves. In 
comparison participants seemed to think that reducing before quitting would suit this type of 
smoker, as it would not result in the “shock to the system” that abrupt quitting would. One 
participant took this a step further by suggesting that the length of the reduction period should 
be tailored based on the length of time the individual had been a smoker.  
 
The primary reason given for why participants thought reduction worked was that it gave time 
to adapt and prepare the body and mind (Box 2, Quote 3), by becoming used to smoking 
deprivation, and seeing the progress that had already been made through the use of 
monitoring. It therefore seems reasonable to assume that more adaptation may be required in 
those who have been smoking for a longer period of time.  However some of those in favour 
of abrupt quitting thought the reason that it worked was that “it gets it over with”, eliminating 
cues to smoke, such as smoking paraphernalia, so that it is simpler and easier; whereas 
reduction provides the opportunity to back out. As a result one participant thought it would 
take more will power to stop via reduction than to quit abruptly (Box 2, Quote 4). Some 
support was provided for this by the fact that a number of the non-abstinent reduction group 
claimed that they were smoking a reduced amount, but felt they were stuck on the tricky, 
more rewarding cigarettes, which they had left until last during the reduction period. Relapsed 
participants in the abrupt group did not suggest that they felt stuck on particular cigarettes; 
however this could be because they had analysed their smoking less during the course of the 
pre-quit period, and were less conscious of the importance placed on particular cigarettes. A 
small number of participants also found that the reduction approach was too cumbersome and 
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provided something else to worry about alongside outside stressors (Box 2, Quote 5). One 
participant described the programme as a “nuisance” as he often found he was supposed to be 
smoking when he was doing something else, such as gardening. Whereas another found the 
reduction programme difficult because the fact that she was reducing meant that she had 
cigarettes with her, which provided the temptation to smoke as she usually would (Box 2, 
Quote 6).  
 
5.3.3.2 Compliance 
In all methods participants reported some deviation from the instructions they were given, 
however the nature of this non-adherence varied across methods.  Most notably it was not just 
the participants in the reduction to quit arm that reduced their cpd pre-quit.  In fact the 
majority of the participants in the abrupt arm claimed that they did so too. In most of these 
cases the reduction could be interpreted as unintentional, as participants reported that they felt 
that they just could not smoke as much, sometimes as a result of nausea, but were made aware 
of their reduction only through looking back at their diaries (Box 2, Quote 7). However a 
smaller number of these reducers chose to reduce their smoking despite instructions not to.  
For example, one participant admitted to aiming to reduce their smoking by one cigarette each 
day (Box 2, Quote 8), whereas others stopped smoking in particular places or situations, such 
as the car.  
 
Only a small number of people in the reduction arm reported not reducing their smoking over 
the two weeks prior to their quit day, with one participant quitting abruptly after two days.  
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The reason given was that his work got in the way of scheduled smoking times, meaning that 
he was missing cigarettes he could have smoked, and was hardly smoking anyway. The 
participant felt that after not smoking for a period of 24 hours it would seem “daft” to smoke 
another cigarette. In the main, the remainder of participants in the reduction group reported 
trying to keep roughly to the quota of cigarettes they were asked to smoke, but allowed for 
flexibility in scheduling, by not always smoking at the times specified (Box 3, Quotes 1 and 
2).  Some of the reasons given for this were the desire to save cigarettes to smoke at times 
when they would be most rewarding, activities got in the way when smoking should have 
taken place, such as shopping or meetings at work, not feeling the need to smoke at the 
specified time, and a lack of motivation to check their schedule to see when they should be 
smoking.  One of the justifications for the reduction methods is that if smokers smoke only at 
specified times this will break the association with their usual conditioned environmental cues 
(Section 1.2.2).  Therefore a failure to do this may undermine the efficacy of the method. 
However, although participants acknowledged that what they were doing was outside of the 
guidelines, they did not seem to appreciate the impact this may have (Box 3, Quote 2).  This 
could suggest that the potential mechanism of the method was not explained fully to 
participants (as supported by Box 3, Quote 2), or that this explanation was not understood. 
 
5.3.3.3 Pre-quit confidence 
Some participants in both the abrupt and reduction arms reported that their confidence 
increased during the pre-quit period, whereas others reported no change or a decrease.  
However increases in confidence were more common in the reduction arm.  In both arms,  
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Box 3. Comparison between the abrupt and reduction to quit methods 2 
Quote 1- Reduction (HR-E) 
P: I could’ve followed it [the reduction schedule] a bit more closely, but it wasn’t your fault it was my fault. No, 
actually I took the thing on board seriously and we looked through the ones that- the cigarettes- that we could 
dispense with, the peak demand times, and I tried to keep fairly close to that but switched them around a bit. I found 
that some days the early morning craving wasn’t there. I didn’t say well okay I didn’t have one at first in the 
morning so I’m going to have two later on. 
 
Quote 2- Reduction (HR-E) 
P: Sometimes when it was to cut out one at midday, I sort of couldn’t keep to that like a rigid rule, that midday you 
couldn’t have a cigarette....sometimes I’d go from first thing in the morning when I had one until about early evening 
before I had another one...and she  [the nurse] said it doesn’t matter really, she said it’ll work out so it sort of still 
worked out, I’d kept that I was allowed, say to smoke 15 cigarettes a day, I’d sort of worked out that I only did have 
the 15 cigarettes a day. 
I: Do you think doing it that way fit in alright with your lifestyle or was there any times when it clashed with 
anything that you’d usually do? 
P: No because like I say it wasn’t a rigid thing that you had to have one at this time and then you couldn’t have one 
at that time.  
 
Quote 3- Reduction (HR-E) 
I:  After you’d gone over your two weeks reducing and you reached your quit day, how did you feel then about 
quitting? 
P: Good, because I’d cut right down, so like I say I wasn’t buying cigarettes 
I: And over the two weeks where you were reducing, do you think your feelings about quitting changed at all? So do 
you think you got any more confident or any less confident as time went on? 
P: I got more confident. I knew that by the time it came, that was it, I’d be finished. 
 
Quote 4- Reduction (SFP) 
I: Do you think you got any more confident or maybe less confident as you went along? 
P: I think I got a little bit more confident, because you know the puffer thing that counts [CO monitor]. Yeah, I'd like 
to have one of those in the house, because it was 34 on the first one and then it went down to nine, then it went down 
to five. 
 
Quote 5- Reduction (HR-E)  
P: I knew I wouldn’t be able to [quit] on the day when it came. I mean, it’s still my target. I will quit and I’ve come 
down from about, on a bad day 30 to six or seven a day. People say, well you haven’t packed in but to me to come 
down to that low at this stage is quite good. 
 
Quote 6- Reduction (SR) 
I: How do you think this method could help people to quit? 
P: They can plan their day around their smoking to begin with, and it helps them through up to your quit date, 
because you are actually in control of that, it’s your choice and you know when you want to smoke and when you 
can’t smoke, which I think is brilliant. 
 
Quote 7- Abrupt 
I: Do you think there’s any changes that you’d make to the method? 
P: Only maybe that if you do go for a trial like this, you are given the option as to which method you’re going to 
use...between the reduction and the sudden stopping. 
Quote 8- Abrupt 
 I: Do you think there were any problems or bad points or things you didn’t like about it? 
P: I think it would have been nice if we’d had a choice of which way we wanted to do the stopping...you know where 
we did the abrupt or the gradual 
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people whose confidence increased reported that this was due to evidence of their progress so 
far, in the form of a drop in cigarette consumption and/or CO levels, and the reflection of this 
in diary and questionnaire responses (Box 3, Quotes 3 and 4). This may suggest that although 
all participants liked the monitoring element of their programme, it may have had a greater 
impact in the reduction group. 
 
5.3.3.4 Reaction to post-quit reduction 
The majority of both abrupt and reduction arm participants, who weren’t abstinent at the time 
of their interview, claimed to be smoking less than the amount they had at baseline. Based on 
method instructions this is perhaps surprising, as it could be assumed that smoking levels 
would be easier to control for smokers who already had some experience in reducing their 
smoking, and that there would be greater likelihood of returning to previous smoking 
behaviour if these hadn’t been altered at all prior to quit day. However, in reality, participants 
in both arms reduced pre-quit. Abrupt participants provided little opinion of post-quit 
reduction, whereas participants in the reduction arm saw it as a positive. As a result it could 
be feared that participants happy with their reduction would be less likely to attempt to quit in 
the future.  However many of the smokers who claimed to be pleased also said that their 
ultimate goal was still to quit (Box 3, Quote 5). 
 
5.3.3.5 Decision making  
When asked what they liked about the method they used a popular element of reduction was 
that it allowed participants to make decisions, which helped them feel in control (Box 3, 
  CHAPTER 5: RRT INTERVIEW STUDY 
 
 
173 
Quote 6).  When randomised to this arm participants were provided with a choice of one of 
the three reduction methods on offer, and within the HR and SFP methods they also had a say 
about which cigarettes or time periods they cut-out on each day of the programme. In the 
abrupt quitting arm participants were not given these options, and this was reflected in the fact 
that a number of participants suggested that choice between methods should be made 
available (Box 3, Quotes 7 and 8).   
 
In summary of Section 5.3.3 the abrupt method was perceived as both “scary” and an 
opportunity to get quitting over with, whereas reduction was seen as both an opportunity to 
gradually adapt and to back out of the quit attempt, suggesting that personal perceptions of the 
methods varied considerably.  However the process of quitting in practice appeared not to 
differ greatly across arms with many abrupt participants reducing pre-quit- albeit without a 
schedule- whilst many reduction participants exercised flexibility when using their schedules.  
This may explain why non-abstinent participants in both groups were smoking fewer 
cigarettes post-quit; although reducers were more likely to see this as a positive.  Participants 
regarded the monitoring positively; however it may have had more impact in the reduction 
group, as the perceived decline in cigarette consumption was thought to be the cause of 
increased feelings of confidence pre-quit. Finally the availability of choice emerged as a 
poignant issue, as its presence in the reduction method was seen as a good point, whereas the 
lack of it in the abrupt method was seen as a deficiency.  
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5.3.4 Comparison between reduction methods 
5.3.4.1 Reason for reduction method choice 
Participants commonly reported that they had selected their reduction method to fit with the 
demands of their job, particularly for the SFP method; perhaps as this is most easily tailored 
(Box 4, Quote 1).  Participants chose sfp with the nurse and these were reduced on a day to 
day basis, whereas smoking in the SR method was determined by the length of the regular 
ICI, and for the HR method specifying particular cigarettes may have been difficult for people 
whose timetable changed over the week. Participants also reported choosing both the SFP and 
SR methods because they seemed simplest when the nurse explained the three methods. It 
seems likely that participants were using the term simple to encompass the simplicity of 
incorporating the method into their lives. 
 
The HR and SFP methods provided the opportunity to choose whether easier or harder 
cigarettes were foregone first. Most commonly, participants chose to lose easiest cigarettes 
first, illustrated by the fact that no one who used the HR-D method was available for 
interview; mainly due to the lack of participants who chose this method. This approach meant 
that the harder cigarettes were left until last, but most people did not report that reduction 
became harder over time.  The reason for this could be, as one participant suggested, that 
eliminating the easier cigarettes first got the “mind and body working to get rid of the harder 
ones”. The thought of cutting out the harder ones first seemed daunting to some participants 
(Box 4, Quotes 2 and 3), in the same way that abrupt quitting did. A small number of SFP 
participants started by cutting out the harder cigarettes first.  They said that this was to test  
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Box 4. Comparison between reduction methods 
Quote 1- Reduction (SFP) 
P: From the time I got up, and when I went to work, and just all the different things I did in the day, like cooking tea 
and just the certain times when I didn’t smoke, so I did the choosing really, I did all the choosing of sort of when, but 
she made sure that it was reducing down quite a lot. 
 
Quote 2-Reduction (HR-E)  
I: Were you given a choice of whether you eliminated the ones that you found easier first or the ones that you found 
harder first? 
P: I think probably, but had I been given that choice I can't imagine why anybody would choose to give up the harder 
ones, and so it didn't take me long to reject it. 
 
Quote 3- Reduction (HR-E) 
I: Why was it that you chose to eliminate the easier ones first, rather than the harder ones? 
P: It’s the thought of getting up in the mornings and not having a cigarette with a cup of coffee; that was the most 
important one. 
I: Do you think leaving the harder ones until last made it harder for you towards the end or do you think..? 
P: No I actually got down to smoking three a day. 
 
Quote 4- Reduction (HR-E) 
P: I did two things right away, one of which is I decided not to smoke in the car...that was much easier than deciding 
only to have one cigarette in the car or y'know I need to have one on the way to work and not on the way back, so there 
were kind of categories, some of which were very simple  
 
Quote 5- Reduction (SR) 
P: As it got bigger spaces, it did make me clockwatch a bit and I didn’t think- at that stage- I stood much chance of 
packing in. 
 
Quote 6- Reduction (SFP) 
P: If they [other quitters] read it like I read it, you think oh well this is good and then you get into it for a couple days, 
and it’s like wait a minute, I can still smoke 40, 60, 80 cigarettes a day, I just have a specified time that I can smoke. 
 
Quote 7- Reduction (SFP) 
P: I found that in the times when I could smoke, although I wasn’t smoking as many cos obviously it was impossible to 
smoke as many, I found that I was probably smoking more in the times that I could smoke, that’s what it felt like 
anyway. Cos I knew like for three or four hours, I wouldn’t be able to have one, so I just thought I can’t see how this is 
going to work. 
 
Quote 8- Reduction (SFP) 
P: When we initially went on the reduction plan we did tend to try and cram as many in as possible, at the onset, but we 
soon got out of that habit. 
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themselves and whether they would be able to do it.  However, they tended to report the 
method as harder to carry out than those who started with the easier cigarettes first. 
 
5.3.4.2  Scenarios not cigarettes 
The flexibility that participants exercised in their scheduling, contrary to programme 
guidelines (Section 5.3.3.2), was arguably most marked in the HR method. Using this method 
participants were asked to identify each individual cigarette they would usually smoke during 
a day and then reduce by individual cigarettes. However a number of participants claimed to 
have reduced by categories of cigarettes.  They did this by stopping smoking in particular 
places or situations, for example when at work or in the house.  One participant claimed that 
this seemed easier than reducing by individual cigarettes (Box 4, Quote 4). As mentioned in 
the previous section (5.3.4.1), it is understandable that this may be the case if a person’s daily 
timetable, and therefore smoking times, change over the course of the week, meaning that 
they smoke at different times/situations on different days. This is likely to be the case for 
people who work during the week and have the weekend off. 
 
5.3.4.3 Clockwatching 
Some participants reported difficulty clockwatching using both SR and SFP methods. As the 
time lengthened between cigarettes some participants said that they were anxiously waiting 
for the time to come to smoke, and one said that this reduced their confidence (Box 4, Quote 
5). However another participant said that although they did find themselves constantly 
checking their watch initially, this lessened as time went on.  
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5.3.4.4 Is smoke-free periods a reduction method? 
Although most participants using SFP were pleased with the method, some interviewees felt 
that it wasn’t a reduction method. As participants were required to reduce the times in the day 
when they were smoking rather than the cpd, they felt that it would still be possible to smoke 
a considerable amount in the available smoking periods.  One participant, who said she was a 
very heavy smoker, felt that even as the periods decreased she could still have smoked her 
usual amount of cpd (Box 4, Quote 6), whereas another two participants said although they 
thought it would be impossible to smoke their baseline cpd they did find themselves smoking 
more than they usually would in the remaining smoking periods (Box 4, Quotes 7 and 8). 
However, during the course of the pre-quit period participants recognised this issue and all 
three decided to ensure that they did reduce their cpd.  In particular one participant set herself 
cigarette quotas, as in the cpd methods. After this issue was raised I fed this back to 
interviewees, by asking sfp participants if they thought they were reducing their cpd, despite 
not being given a quota to work toward. All of those asked confirmed that they did reduce and 
this was usually estimated to be at a level similar to that specified in the cpd methods (reduce 
to 50% of baseline in the first week, and to 75% in the second week).   
 
A small number of issues arose which were specific to one reduction method or another. 
Participants who reduced using the HR method appeared to find it more intuitive to reduce by 
categories of cigarettes rather than individual cigarettes; whereas in the SR and SFP methods 
clockwatching was raised as an issue, which reduced confidence in a minority. However 
participants chose the SFP and SR methods because they seemed easiest to them. This 
suggests that the choice of reduction methods is likely to be based on personal perceptions 
and circumstances, as the preference for abrupt quitting and reduction to quit appeared to be 
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(Section 5.3.2.1). The majority of participants appeared to prefer and find it simpler to forgo 
easier cigarettes rather than harder cigarettes first, and finally a small number of participants 
quitting using the SFP method found it a challenge without a quota of cigarettes to work 
toward.  
 
5.3.5 Nicotine preloading 
5.3.5.1 Effects of preloading 
The general feeling across both the abrupt and reduction arms was that preloading was 
helpful. This is despite the fact that many participants in the abrupt arm experienced nausea 
during the pre-quit period, which was likely to be due to the use of nicotine patches whilst 
smoking. Nausea has been reported previously in cases such as this (Fagerstrom & Hughes 
2002; Rose et al 2009). However it may also be of note that it is listed as a side-effect of 
nicotine overdose on nicotine patch labels, and so there is a possibility that this was a 
psychological effect manifested through expectation.  
 
Participants who experienced nausea felt that this was a useful part of the method and aided 
their quit attempt. Accordingly a number of the abrupt participants stated that the reason they 
thought preloading was used in the trial was as aversion therapy, to put participants off 
smoking (Box 5, Quote 1). Support for this mechanism came from two sources: 
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Box 5. Nicotine preloading 1 
Quote 1- Abrupt 
P: I think it was to make you so sick of nicotine that you wouldn’t want a cigarette, I don’t know. 
 
Quote 2- Abrupt 
P: I just didn’t like the, it give me leg ache and nausea and stuff, smoking with the patches on...I did enjoy when 
you first go on the course, they tell you to smoke as normal, and the first week I did.  I said to the lady I really, 
really don’t enjoy smoking no more, but I didn’t get to the quit date then I had another week to go, to carry on 
smoking. I really didn’t want to do it; I said I’ll try and she said to me I really do want you to smoke as normal, but 
if you can’t you can’t, and I really couldn’t. I was smoking but it was one or two a day, and I was thinking to 
myself, what’s the point? I would have liked it to be a shorter period of time from when I first seen her to the quit 
date. 
 
Quote 3- Abrupt 
P: I sometimes found it harder because I actually wanted to smoke less for some reason, but not an awful amount 
less. But sometimes, getting towards the evening I would think oh, I haven’t had as many as what I would normally 
have. 
 
Quote 4- Abrupt 
P: Actually the last few days I didn’t quite, I think we worked out that I needed, my normal smoking was about 
twenty-five a day  and I was really struggling to hit the twenty-five, but it was just feeling you know a bit nauseous 
all the time. 
 
Quote 5- Reduction (HR-E) 
I: Did you get on alright with using the patches and smoking at the same time? 
P: At the very start they did make you feel sick actually and you didn’t really wanna smoke. Because you had your 
set times to smoke you did smoke and sometimes you felt a bit queasy. But the less you smoked you know the better 
it got so. 
I: So did you find that you were sometimes even reducing more than you had to? 
P: The first week when I had the patches, and when I had set times when I had to smoke, and some of them 
cigarettes I missed out, to be honest; because it did make you feel a bit queasy. 
 
Quote 6- Reduction (HR-E) 
P: Initially I had the patches and the micro tabs I think. I did give the micro tabs up, I don’t know why, I suddenly 
began to feel quite sort of ill, and I was fine when I cut those out. 
 
Quote 7- Reduction (SR) 
P: I do think the patches didn’t do much for me, but the gum itself has been great. I stick a piece of gum in me 
mouth whenever I felt like a cigarette and that gets rid of the urges, but the patches I was a bit disappointed in 
them. Didn’t seem like they did much for me, but the gum has been great, yeah. 
 
Quote 8- Reduction (SFP) 
P: The patches, they didn’t seem to do a lot for me and then I did ask if I could use the inhalator. I found that a bit 
more helpful. 
 
Quote 9- Reduction (SR) 
P: The actual false cigarette thing [nicotine inhalator] was really good it really felt like you were having a 
cigarette. 
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1) Participants who felt positive about stopping smoking on their quit day because 
smoking had become intolerable, and who claimed that it was a relief to be able to 
stop (Box 5, Quote 2); and 
2) As previously mentioned in Section 5.3.3.2, the many participants in the abrupt 
quitting arm of the study that reported a reduction in their smoking pre-quit, despite 
being advised to smoke as normal.  In most cases, participants did not appear to strive 
to reduce, it seemed to occur because they did not feel the need to smoke (Box 5, 
Quote 3) or because they felt nauseous (Box 5, Quote 4).  
 
Only two participants in the reduction arm reported nausea; one of whom managed this by 
reducing smoking further (Box 5, Quote 5), and the other by using less of their acute NRT 
(Box 5, Quote 6).  This suggests that reduction participants were more able to regulate the 
effects of preloading, and this was perhaps what abrupt participants were also doing through 
their reduction (Section 5.3.3.2). It is interesting that this occurred despite participants’ 
assumptions that the purpose of the treatment was as aversion therapy, as this would be 
expected to undermine efficacy.  However, as previously reported reduction in the abrupt arm 
appeared to be largely unintentional, suggesting that the unconscious desire to reduce nausea 
over rode behaviour motivated by an awareness of potential treatment mechanisms. 
Craving reduction was also thought to be a mechanism of preloading, however participants in 
the abrupt arm were more likely to advance this theory, again suggesting that the effect of 
preloading may have been greater in these participants. In the abrupt group, nausea, a loss of 
enjoyment when smoking, and lack of craving often went hand in hand; however, despite the 
fact that nausea was rarely experienced in the reduction group participants did lose some of 
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the will to smoke.  This was mainly attributed to the use of the acute NRT pre-quit, and 
interviewees often reported that they had not felt any effect of the patch (Box 5, Quotes 7 and 
8).  In general reduction participants reported that they used their acute NRT as instructed- 
whenever they had the urge to smoke, outside of scheduled smoking times, instead of a 
cigarette- and that this had reduced their need to smoke (Box 5, Quote 7). One participant 
explicitly said that they felt that their inhalator was a good substitute for their cigarettes (Box 
5, Quote 9).  
 
5.3.5.2 Lack of effect 
Despite what appeared to be strong effects of preloading in some participants a few 
interviewees reported that they had felt no effect of using NRT and smoking at the same time. 
These participants often reported that they believed that preloading would reduce their need to 
smoke, but were disappointed when this was not the case (Box 6, Quote 1). In fact one 
participant claimed that her smoking actually increased during the pre-quit period.  When 
asked why this was she said that she had been under a lot of stress at the time, however she 
also thought she had built up an association between the patch and smoking. The fact that she 
had been told that she could preload enhanced this, giving her no incentive to control her 
smoking with the patch on (Box 6, Quote 2). 
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Box 6. Nicotine preloading 2 
Quote 1- Abrupt 
P: I thought the patches would be stronger and have more of an effect. I mean, they were supposed to have a bit of a 
knock-on effect where you feel like you didn’t want to smoke but I didn’t feel that at all...I really wanted it to help, I 
really wanted it to cure me. 
 
Quote 2- Abrupt 
I: Were you still smoking the same amount [pre-quit], would you say than before you started the study? 
P: Yes, I did, I smoked more as well, which is quite odd. 
I: Do you think there’s any reason why you..? 
P: Oh yes, it was a stressful situation that arose, so yes....The first couple of days I thought I wouldn’t have tried to 
smoke as many as I usually did, but sort of the second half of the day, I did any way, which shocked me because I 
thought, right, I’ve got a patch on, I shouldn’t want to smoke so many but as time went on I did and I smoked more. 
And even I think I put a patch on and lit a cigarette at the same time. It was almost like they went together; it was a 
bit strange...I hoped that it would work this way, but it didn’t, it just enhanced the fact that you could smoke and 
wear patches, and still be a smoker to me. 
 
Quote 3- Abrupt 
P: The irritation they [nicotine patches] caused to me where they were stuck on my arms and so on, was such that it 
started off that I couldn’t sleep with them on ...So by this time I was into the sort of second week of this, and really I 
hadn’t been able to take advantage of the patch. The diary I filled in said have you used the nicotine patches this 
week and if not can you explain. So I put a no, i.e. complete inability to sleep after being in bed for about five hours.  
 
Quote 4- Reduction (SR) 
P: I've stopped using the patches completely because of the way they affect my skin...quite severely. 
 
Quote 5- Abrupt 
P: When they told me- look here’s the patches, the highest one, but carry on smoking the same amount, I was 
absolutely shocked with that. I was shocked. 
 
Quote 6- Abrupt 
I: What did you think about the instructions to smoke and be on the patch at the same time? 
P: Well I was obviously a bit wary from years ago, they used to say doing such a thing was a real taboo thing to do, 
but, I kind of placed my faith in, people having better knowledge of the situation than I had. 
 
Quote 7- Reduction (HR-E) 
P: When I was told that the advice you shouldn’t do them [smoking and using NRT] together was wrong I was very 
happy to believe it, and I formed my evidence myself that it wasn’t right. 
 
Quote 8- Reduction (SFP) 
I: How did you feel about the nicotine replacement therapy that you used, and using the patches as you were 
smoking? 
P: No problems at all. I have tried that in the past, a few years ago. I have tried quite a few times, when people were 
saying well you shouldn’t be doing that because of the nicotine in your body, and it's like well what is nicotine? And 
in the past I found it helped. 
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5.3.5.3 NRT issues 
Another potential problem with preloading, reported commonly across both study arms, were 
issues with the NRT used, such as skin irritation, sleep disturbance and trouble getting the 
patches to stay on.  Some participants discontinued their NRT as a result of these (Box 6, 
Quotes 3 and 4), but most people who experienced these problems did not. Even though 
participants experienced side-effects, they still believed that NRT was helpful.  However, it is 
important to keep in mind that not all non-compliance is intentional.  The fact that a number 
of participants struggled to keep the patches on, exacerbated by a period of warm weather 
during the study, may mean that the levels of nicotine entering the blood stream were not as 
high as expected, or higher in some people than others. 
 
5.3.5.4 Previous opinion and past experience 
Overall few people intentionally did not adhere to preloading, even though, until recently 
quitters were warned against smoking and using nicotine patches concurrently. Many 
participants were aware of the warnings and reported surprise at being asked to preload (Box 
6, Quote 5); however they trusted the expertise of the research team (Box 6, Quotes 6 and 7). 
Nevertheless, there were a few participants who still did not accept the “logic” of preloading 
and were worried that they were putting too much nicotine in their body, based on previous 
advice. One participant thought that the combination of the two could be fatal.  
 
Only one participant reported that they had used nicotine preloading treatment in the past.  
She had decided to do so based on her perception of nicotine as a non-harmful component of 
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cigarette smoking. This participant was happy to preload for a second time and found it useful 
on both occasions (Box 6, Quote 8).   
 
In summary of the issues raised regarding preloading, the unintentional pre-quit reduction 
reported in the abrupt group was most likely due (at least in part) to the effects of this 
treatment; such as nausea and loss of the will to smoke.  Participants from the reduction group 
were less likely to report that they had lost the will to smoke or experienced nausea, and 
preferred their acute forms of NRT to patches. This may point to two different routes to the 
efficacy of preloading: 1) when used to quit abruptly- as aversion therapy; and 2) when used 
to reduce and then quit- to facilitate reduction through substitution. However some 
participants in both arms reported that they felt no effect of preloading at all.  There were also 
problems reported with the NRT, although this didn’t seem to greatly affect intentional 
adherence rates, and people tended to report finding preloading helpful regardless of this and 
the nausea experienced. Based on past experience many participants were surprised that they 
were asked to preload, but were willing to do so, and only one participant had used the 
technique before. 
 
5.3.6 Comparison between quitters and non-quitters 
5.3.6.1 The importance of preloading 
In the abrupt group, most participants who achieved abstinence also experienced nausea or 
loss of desire to smoke, and felt that preloading had been useful to them. Some of these 
participants had also felt ready to quit on their quit day (Box 7, Quote 1). Non-quitters 
however, felt no such effects, with only one person disconfirming the general rule. Therefore,  
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 Box 7. Comparison between quitters and non-quitters 
 
Quote 1- Abrupt- quitter 
P: I was praying for the quit day to tell you the truth, because I didn’t enjoy smoking with the patches on. 
 
Quote 2- Reduction (SR)- quitter 
P: I liked the way you prepared yourself for it, because you was given a cut-off date, this was two weeks ahead, from 
when you first started. So you could slowly prepare yourself for that date, which I found better for me personally. I’d 
made my mind up that that date was the last date and I think the last day I only smoked about three cigarettes anyway. 
 
Quote 3- Reduction (SFP)- non-quitter  
P: I think that on the courses, it’s like changing a thought process, not just having the nicotine therapy. It could help 
with a bit more time spent on thought therapy, as to why we smoke and what makes us pick the cigarettes up in the first 
place. I’ve just started reading this book- that’s what makes me think now, well why do you need that cigarette. I just 
think anything that can be put there to help a smoker, rather than just giving them the therapy, like the nicotine 
replacement thing. Maybe a lot more talking could be done about cigarettes. I mean we all know what they do to us, but 
it’s like changing a thought process in your mind really. I think that could benefit. 
 
Quote 4- Abrupt- non-quitter  
P: I didn’t want to do it that way [abrupt], it was the other way [reduction] I wanted to do. 
I: Was there any particular reason why you would have preferred to do it that way? 
P: Because I knew I wouldn’t be able to. 
I: And you still think the same do you? That it’s not changed, or has it changed at all during the course of the study? 
P: No, not really. 
 
Quote 5- Reduction (SR)- quitter 
I: When you were first told that you were going to be reducing before quitting what were your first impressions of 
doing it that way? 
P: I wasn’t very happy. 
I: So would you have preferred the abrupt quitting? 
P: Then I would. But I wouldn’t if I was doing it again. 
 
Quote 6- Reduction (HR-E)- non-quitter 
I: You said that before the study if you’d been given the choice you would have quit abruptly, so do you think your 
opinion has changed at all over the course of the study, or do you think it has stayed the same? 
P: No, it has changed, because I do honestly believe that if I’d have quit abruptly when I had that bad weekend and I 
just smoked, I actually do believe I would have gone back to smoking like 20 a day and not just 5. 
 
Quote 7- Reduction (HR-E)- non-quitter 
P: I knew I wasn’t going to be able to quit on that quit day, but I was quite chuffed that I’d managed to slice it down, 
and the nurses seemed to agree with me on that. I mean they didn’t encourage me to say oh, well you didn’t quit, carry 
on, but they sympathised with the fact that I had drastically reduced and was making a solid effort to try. 
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that fewer non-quitters claimed to reduce their smoking pre-quit than quitters, provides further 
support for the theory that preloading was responsible for the pre-quit reduction in the abrupt 
group. 
 
Comparison between quitters and non-quitters in the HR group was hard as only one of the 
eight participants had quit.  However it also appeared that preloading had a larger impact on 
quitters than non-quitters in the scheduled reduction group.  As in Section 5.3.5.1 the 
emphasis was more on the effect of the acute NRT, than the patch. 
 
5.3.6.2 Side-effects of NRT 
Another potential impact of NRT on quitting in the abrupt group was highlighted by the fact 
that quitters didn’t mention any of the problems with NRT highlighted in Section 5.3.5.3, 
such as skin irritation and sleep problems, whereas non-quitters commonly did.  The most 
intuitive explanation is that adherence to NRT treatment (when preloading and/or post-quit) 
was affected by these issues. However this conflicts with the finding that preloading non-
adherence seemed low in contrast to reports of NRT problems.  It may be that quitters also 
experienced NRT issues, but these didn’t seem significant enough to mention, as they were 
more focused on the positives of the quit attempt. 
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5.3.6.3 Preparation and monitoring 
Quitters were more likely to stress the value of the preparation and monitoring (Sections 
5.3.2.2 and 5.3.2.3) than were non-quitters (Box 7, Quote 2). In fact one of the non-quitters in 
the SFP group specifically pointed out that they would have liked the programme to offer 
more intensive behavioural support, with the opportunity to talk about individual cigarettes 
and the reasons for smoking them (Box 7, Quote 3).  The discrepancy between the experience 
of this participant and others who highlighted the preparation and monitoring as a good point 
could suggest that some nurses focused on this more than others, that some participants didn’t 
focus as much on this type of preparation independently, or that some quitters have a greater 
need for psychological therapy than others. 
 
5.3.6.4 Post-quit opinions of quitting methods 
Finally there was variation between the abrupt and reduction groups in terms of the 
association between smoking status and the opinions of participants about the quitting method 
they had used. Those participants in the abrupt group who had managed to quit and stay 
abstinent reported that they were happy with the abrupt method and would use it again; 
however those who were smoking said that they wished that they’d been in the reduction 
group and would try the reduction to quit method in future (Box 7, Quote 4).  In contrast both 
quitters (Box 7, Quote 5) and non-quitters (Box 7, Quote 6) in the reduction arm were 
satisfied with their method and would use it again. This may be because reduction had been 
encouraged in the reduction group and so was seen as a favourable outcome (Box 7, Quote 7).  
Therefore despite not quitting these participants felt that they had achieved something. This is 
supported by the finding that many reduction to quit, non-quitters, smoking a reduced rate at 
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the time of interview were pleased with this outcome, whereas those in the abrupt group did 
not seem to find it significant (Section 5.3.3.4). 
 
To summarise Section 5.3.6, participants in both the abrupt and reduction to quit arms of the 
study, who were abstinent at the time of interview, reported a larger effect of preloading than 
the non-quitters, as well as a greater importance of monitoring variables such as cpd, CO, and 
confidence as part of their quit attempt. As well as this more importance was put on preparing 
for the quit attempt psychologically by quitters in the reduction arm, whereas in the abrupt 
group NRT issues were more commonly reported in non-quitters. Interestingly, although non-
abstainers in the abrupt group were likely to prefer the reduction to quit method at the time of 
interview, non-quitters who had used the reduction to quit method did not report that they 
would also use the alternative method (abrupt) if they tried to quit again.  This may be due to 
the normalisation and encouragement of reduction throughout the reduction programme, 
meaning that post-quit reduction was seen as a success rather than a failure to quit.   
 
5.4 Discussion 
5.4.1 Exploration of findings 
Little qualitative research has been carried out examining the attitudes and beliefs of smokers 
about the method that they use to quit; in particular exploring nicotine preloading, abrupt 
quitting and smoking reduction approaches. This interview study aimed to do this, in order to 
gain insight into the methods that would be most popular and therefore useful in practice, and 
how these may work. 
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Although people generally approved of the method that they were allocated at random, and 
judged it feasible and comprehensible, findings demonstrate that smokers preferred a 
particular method of quitting prior to allocation; although these preferences varied.  This was 
true when specifying a desire to quit abruptly or by reducing, and when choosing between the 
SR, HR and SFP methods. Some participants viewed abrupt quitting as intimidating, whereas 
others thought that it was best to get the discomfort over with quickly.  Reduction was 
thought to provide the opportunity to back out of the attempt, but also to adapt the body and 
mind to quitting. This suggests that there is a potential demand for both methods of quitting 
used in RRT. However despite these preferences many participants stressed throughout their 
interview the importance of personal mindset to the success of the quit attempt, which 
appeared to be classed as more important than the method of quitting used.  This suggests that 
although smokers think the method of quitting is important, ensuring that they are ready to 
quit before embarking on this method should be the priority. This focus on personal mindset 
and willpower has been commonly found across qualitative smoking cessation research (for 
example Rollins & Lennox Terrion 2010; Ashford et al. 2011; Beck 2011).   
 
After the quit attempt people’s preference for the method of quitting they would use in future 
was related to the method they had used to try to quit, and its success on this occasion. Those 
smokers who had quit were more likely to say they preferred whichever method they had 
used. Whereas in the abrupt group non-quitters were more likely to say that they wouldn’t 
quit that way in the future, and would reduce first.  However non-quitters in the reduction to 
quit group would be happy to stick with the reduction method for future quit attempts.  This is 
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perhaps surprising, as in terms of quitting the attempt would be deemed unsuccessful. 
However reduction targets were set throughout the pre-quit period, and therefore achievement 
of these had been reinforced and praised.  This may have led to participants seeing reduced 
smoking as an achievement in itself.  Although many of the abrupt quitters had also reduced 
their smoking pre-quit they didn’t seem to acknowledge this as a positive.  One of the fears 
associated with the use of the reduction to quit method is that it will undermine the quit 
attempt, as reduction may be seen as a favourable alternative (Hatsukami et al. 2004). 
However little support was offered for this, as those participants in the reduction arm who had 
successfully reduced their smoking post-quit still expressed a wish to quit altogether. This 
tentatively supports the findings of Hughes & Carpenter (2006) and Asfar et al. (2011), who 
found an association between smoking reduction and future quitting. A follow-up of RRT 
participants would be beneficial to establish whether this desire was fulfilled, and therefore 
whether there was an association between reduced post-quit smoking and future abstinence, as 
well as to compare associations between the abrupt and reduction to quit arms.  
 
Monitoring and mentally preparing for the quit attempt over the pre-quit period, were seen as 
positives of all the methods.  The significance of these components may be further supported 
by the fact that they were highlighted more by quitters than non-quitters. This could explain 
why structured reduction methods have been found to be more successful than unstructured 
ones (Levinson et al. 1971; Cinciripini et al. 1995). With a structured approach there is 
perhaps a greater likelihood of more uniform stepped-down reduction, leading to more 
visible, regular achievements when monitoring, which could result in increased confidence, as 
reported in Section 5.3.3.3.  
  CHAPTER 5: RRT INTERVIEW STUDY 
 
 
191 
 
The fact that the pre-quit period lasted for two weeks was generally liked. This is encouraging 
as past evidence suggests that a shorter smoking reduction period is favourable to a longer one 
(Haustein 2002; Blalock et al. 2003). However a very small number of participants suggested 
slight alterations to the length, which may suggest that tailoring to individual preference 
would be worth consideration. Allowing for this element of choice would probably be popular 
with service users, as the opportunity to make decisions about treatment programmes was 
generally highlighted as a good point in the reduction arm, where this was most prominent.    
 
Other issues relevant to the reduction arm were, firstly, participants preferred to drop the 
cigarettes that they deemed easiest first, leaving the harder cigarettes to forgo last. People who 
favour reduction are likely to shy away from abrupt cessation, which means that immediately 
cutting out their most rewarding cigarettes is likely to be unpopular. Secondly some 
participants reported that they were clockwatching when carrying out the SR and SFP 
methods, which some thought reduced their confidence; however despite this no difference in 
reported clockwatching was found between quitters and non-quitters, suggesting that it was 
not detrimental to the quit attempt.  Thirdly, a small number of participants questioned 
whether the SFP method was a reduction method, because it did not specify the number of 
cigarettes to smoke each day; however participants that used the method did smoke fewer 
cigarettes over time. Despite the feelings of the minority, and the suggestion by one that a 
quota of cpd should be provided to work toward, the method was generally popular. Therefore 
turning this method into another cpd method may be a mistake, as it would remove some of 
the variation and therefore choice available between methods. Also, as discussed in Section 
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5.1.1.3 a potential positive of SFP methods is the focus on what is being achieved (sfp) rather 
than what is being missed (cigarettes).  However this highlights that this method may not suit 
all quitters, and that it may be necessary to emphasise that target quotas of cigarettes will not 
be used when presenting this as a quitting option.  
 
Finally, the smokers in the reduction arm exercised a good deal of flexibility when working 
through their reduction schedules. This occurred perhaps most notably in the HR group, 
where some participants reduced by categories of cigarettes rather than individual cigarettes. 
As a result it may be beneficial, in future, to slightly tweak the method so that categories of 
cigarettes rather than individual cigarettes are eliminated, as in Flaxman (1978) (Section 
5.1.2.3). However depending on the categories chosen this may lead to reductions that are too 
big or small to be sustained over the reduction period, and each individual and their proposed 
schedule would need to be assessed for suitability.  There was some evidence that flexibility 
across reduction methods was because participants didn’t appreciate methods’ possible 
mechanisms of action, and that nurses perhaps did not stress these enough.  Therefore in 
future it may also be possible to combat some non-adherence through detailed lay 
explanations, reiterated throughout the programme, of why the methods may work, and why it 
is important to stick to instructions. 
 
There was also significant non-adherence to the instruction not to reduce cigarette 
consumption in the abrupt quitting group, where most people did reduce. Although a number 
of smokers did this deliberately, most appeared to do so as a result of nausea and the lack of a 
desire to smoke.  It seems most likely that these feelings were due to the nicotine preloading 
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that took place in both the abrupt and reduction to quit study arms, and that reduction was an 
attempt to regulate these effects. Spontaneous reduction such as this has been observed in 
previous studies of nicotine preloading (Bolliger et al. 2000; Fagerstrom et al. 2000). Using 
the quantitative findings of RRT we should be able to tell the exact amount of participants in 
the abrupt quitting arm who reduced their smoking pre-quit, whether this was correlated with 
saliva cotinine levels, and therefore whether it was a result of preloading. Preloading appeared 
to be a more poignant issue in the abrupt group in comparison to the reduction group, and in 
quitters in comparison to non-quitters; perhaps suggesting that those who felt less or no effect 
of preloading were less likely to quit in both arms. In the abrupt group the negative 
experiences of nausea may have built up an association with smoking, which over shadowed 
its usual positive associations, in turn discouraging smoking after the quit day. If this is the 
case then effects such as nausea could be used as a marker of treatment success, and guide 
treatment during an abrupt quitting programme.  This is something that would need to be 
tested further- perhaps by experimentally testing emotional responses to smoking 
paraphernalia after nicotine preloading- and again RRT data could be used to investigate an 
association between reports of nausea and abstinence. Claims by smokers in the reduction arm 
that they felt less of the effects of preloading suggest that even though the abrupt quitters 
claimed to reduce, this was unlikely to be to the extent achieved in the reduction group. It is 
also supported by the modest finding, in Chapter 4, that there was less of an effect of 
preloading in smokers reducing and using acute NRT, than smokers who quit abruptly using 
patches (Section 4.3.5.1). However, the majority of the reduction group still felt preloading 
was helpful to them; although the effect of the patch appeared to be non-significant when 
compared to that of acute NRT.  
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The difference in emphasis and reported effects of preloading could suggest that the 
mechanisms of treatment differ when a person is reducing their smoking to quit compared to 
when they are quitting abruptly.  Participants in the abrupt group hypothesised that preloading 
was used as a form of aversion therapy; this was not the case in the reduction group where 
emphasis was put on the use of acute NRT as a substitute for cigarettes. This is in keeping 
with the biological mechanisms of addiction outlined in Section 1.2.3, which suggest that the 
doses of nicotine delivered in acute NRT, such as gum or inhalator are likely to mirror some 
of the effects of the nicotine inhaled in cigarettes, by activating AChRs in the brain, leading to 
a release of DA in the NA (Balfour 1994).  This therefore, at least partially, satisfies the urge 
to smoke without smoking a cigarette. If this is the primary mechanism of action when 
reducing, then use of patches in these circumstances may be questionable. However these 
reflections by participants are only based on their own conscious awareness; there may have 
been unconscious benefits of the patch in both the abrupt and reduction arms.  Also, 
participants in the abrupt quitting arm did not use acute NRT pre-quit, and it is possible that if 
they had this would have been viewed similarly to how it was in the reduction arm. If either, 
or both, of these possibilities are true then preloading mechanisms of action across trial arms 
may be more similar than participant responses suggest. 
 
Side-effects of NRT were a commonly reported problem across study arms. These are issues 
that are known to commonly occur (through research studies and anecdotal evidence) when 
using NRT, such as skin irritation, sleep disturbance and trouble getting the patches to stay 
on, whether use is before or after the quit attempt (Campbell 2003; Schneider et al. 2004; 
Ebbert et al. 2007). Although these findings are nothing new they could affect adherence to 
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preloading.  However despite this and participants’ experiences of nausea, levels of adherence 
to the preloading treatment were still reported to be high and it was judged as helpful to the 
quit attempt.  Therefore the reason why quitters cited NRT problems less frequently than non-
quitters is not immediately obvious. It may be that quitters merely down played their own 
problems with the NRT, or that there was a lack of effect in some participants due to 
difficulty in keeping the patch stuck to the skin. Although until recently there were warnings 
against using NRT whilst smoking, and only one participant had previously used the 
approach, the majority of participants reported that they were happy to accept the advice of 
their research nurse, and partake in the preloading treatment.  RRT should allow for the 
quantitative comparison of NRT side-effects with adherence rates, in an attempt to ascertain 
why NRT issues may have been noted more frequently in non-quitters than quitters.  
 
5.4.2 Study strengths 
A major benefit of studies such as this is it gives the opportunity to explore a subject where 
little information is already available, without constraining data analysis within the 
boundaries of what is already ‘known’. During the interviews participants were given 
opportunities to raise any issues that they felt poignant and were encouraged to expand on 
these. As the study was run alongside RRT it also gave the opportunity to ask about the wide 
variety of methods that were used in the study, and allowed for comparison across arms, as 
well as comparison between quitters and non-quitters.  The ability to compare, through the 
use of charting, is one of the strengths of the Framework approach (Ritchie & Spencer 1994).   
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5.4.3 Potential weaknesses 
A potential weakness of the study was that interviews were carried out 5 weeks post-quit, so 
that some responses were based on retrospective recall.  This could mean that accounts were 
clouded by memory loss or subsequent experiences of quitting. For example, quitters 
appeared to find preloading, monitoring and post-quit preparation a more significant part of 
their attempt than non-quitters. As stated above this could suggest that these factors 
influenced efficacy, but could also simply be that non-quitters were less likely to highlight 
any positives of the method.  This is not supported by the finding that non-quitters in the 
reduction arm were still happy with the method that they used, however it needs to be given 
consideration when interpreting these results. Also, participants were asked which method 
they would have chosen pre-quit and which method they would use if they were to quit again.  
Again we could expect the first response to be clouded by the latter; however the results 
suggest that this wasn’t the case, as many participants’ responses differed across questions. 
As a way to eliminate this potential bias it would perhaps have been beneficial to interview 
participants at different stages of their quit attempt.  This would however have lead to more 
intensive input from participants into the existing schedule of weekly appointments and daily 
diary completion, and would most likely have reduced recruitment rates into the interview 
study considerably. 
 
Unfortunately we were unable to interview a participant who had used the HR-D method, as 
only a small number of people chose this approach, and those who did were not contactable. 
However due to the design of RRT there was bound to be variation in the number of 
participants choosing each reduction method. The lack of HR-D participants merely reflects 
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that this method was unpopular, as discussed in Section 5.3.4.1.  The sample is also limited by 
the fact that the majority of participants were recruited from Warwickshire PCT, which is 
ranked as an area of ‘very low’ deprivation (Health Protection Agency 2011a), whereas South 
Birmingham is ranked as ‘high’, with 100% of the population living in urban areas (Health 
Protection Agency 2011b). Again this is a reflection on the relative ease of recruiting practices 
and patients from Warwickshire PCT to take part in RRT, and needs to be considered when 
generalising the results to other quitting smokers. Similarly the characterisitics of those RRT 
participants who agreed to be interviewed and took part in the interview study may differ 
from those who did not take part. However, caution needs to be exercised when generalising 
from the findings of any qualitative research, as samples are rarely indicative of the larger 
population; instead the emphasis should be on gaining insights into behaviour, with a focus on 
individual differences. If desired these can then go on to be tested before generalisation 
occurs. 
 
5.4.4 Implications for research 
As briefly touched upon above, something that should be taken into account regarding 
participants’ responses to our interviews, as in any research that relies on participant response, 
is that they are reflections on what participants believe to be true, but may not be mirrored by 
objective measures. These reflections are useful as they give insights into what may be the 
case when measured more objectively, but also what is of importance to the service user, and 
so could affect things such as service uptake and adherence rates. Further investigation would 
be beneficial to test the insights that emerged through these interviews, some of which were 
proposed throughout Section 5.4.1. Other examples are that secondary outcomes of RRT 
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could be used to ascertain whether confidence levels changed over the pre-quit period and 
whether this differed between arms, thereby testing the assertion that smokers in the reduction 
to quit arm felt more confident as they reduced. Secondly, participants’ explanations suggest 
that the mechanisms of preloading may differ when carried out alongside reduction and abrupt 
quitting. It may be possible to test this to some extent using RRT, as we shall be able to 
compare saliva cotinine levels and reports of nausea across the abrupt and reduction arms.  It 
will be difficult to tease apart the mechanisms using measures of cravings as both routes 
would be likely to lead to a reduction in these, but in different ways. Preloading’s 
mechanisms of action are likely to influence the type of NRT best used to preload, and so the 
relative efficacy of different types of NRT could help to indicate the mechanisms at work. 
The best way to objectively test the optimum use of NRT when preloading, during smoking 
reduction, would be to conduct a randomised controlled trial comparing the use of patch 
alone, patch plus acute NRT, and acute NRT alone.   
 
5.4.5 Implications for practice 
Differences in the perceptions of all the methods across individuals, suggest that an approach 
which may be helpful to one participant may not be helpful to another, and therefore choice 
could be beneficial. This choice would also be likely to appeal to service users, and therefore 
may mean that more people choose to quit through the NHS SSS. The finding that 
participants who unsuccessfully quit abruptly were keen to try another method next time, 
rather than doing the same thing again, also suggests that if reduction were offered service 
users may increase. The popularity of reduction even in those who failed to quit using the 
method suggests that this popularity may be more enduring than that of the abrupt approach.  
  CHAPTER 5: RRT INTERVIEW STUDY 
 
 
199 
Again, this would make service users who fail to quit more likely to go on to use the service 
again. 
 
However the approach that a reduction method should take is still not entirely clear.  The 
interview findings suggest that the SR, HR-E and SFP methods are all helpful and feasible 
approaches, but research still needs to be carried out to see whether these methods result in 
comparable quit rates.  If that were the case then we would recommend that service users be 
given a choice of the three methods. However, it could put some quitters at a considerable 
disadvantage if any of the methods were significantly less successful than the others. 
 
Many participants (particularly quitters) in both the abrupt and reduction to quit groups stated 
that they found some element of monitoring useful, whether this was in the form of regular 
measurement and recording of CO, cpd and/or attitudes toward quitting.  As there is little 
reason to think that a focus on this component of a quitting method would be damaging we 
would recommend that this is taken into consideration when designing any method of 
quitting.  Although findings suggest that participants found preloading helpful, and those that 
quit felt more effects, limitations of the method mean that these need to be taken into account 
alongside more objective measures of treatment efficacy before any recommendations can be 
made for use in clinical practice. 
  CHAPTER 6: CONCLUSIONS 
 
 
200 
CHAPTER 6: CONCLUSIONS 
 
6.1 A Summary of the thesis 
Chapters 2 to 5 of this thesis each document a piece of research, and as such incorporate their 
own discussion points and conclusions.  These conclusions are summarised in Table 8.  The 
aim of this final Chapter is to revisit these conclusions, consider them in light of one another, 
and to relate them back to the original research objectives.  These objectives were originally 
set out in Section 1.6 and were as follows: 
 
1) To assess the relative efficacy of reduction to quit compared with abrupt cessation; 
2) To assess whether nicotine preloading enhances abstinence rates relative to the use of 
NRT post-quit day only, and the means by which preloading enhances efficacy; 
3) To explore the experiences of smokers who use reduction to quit, abrupt quitting and 
nicotine preloading, to ascertain the popularity of these approaches, and to gain 
insight into the best method(s) of implementation, and potential mechanisms of 
action. 
 
Chapter 2 detailed a literature review, which supplied the justification for a new RCT 
comparing the efficacy of abrupt quitting and smoking reduction to quit.  The protocol for the 
proposed trial, which will contribute to the fulfilment of objectives of 1) and 3), followed.   
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Table 8: Conclusions from Chapters 2 to 5 
Chapter        Conclusions 
Chapter 2   A preliminary review of existing trials showed evidence that neither abrupt quitting nor reduction to 
quit provide superior quit rates. However, they had small sample sizes, were not reported according 
to recently accepted standards (Moher et al. 2001; West et al. 2005), and do not report on 
mechanisms of action. We therefore concluded a new trial was required.  
 Based on preliminary reviews, we concluded that smoking reduction is most likely to succeed and 
lead to cessation if supported by pre-quit NRT, and that using NRT prior to quitting abruptly may 
promote abstinence. Therefore, we determined that the control group- following an abrupt quitting 
protocol- should also use nicotine preloading to balance any effect of preloading across conditions. 
 Preliminary trial evidence suggests that reduction to quit is most effective when reduction takes 
place over weeks rather than months, and so the trial protocol proposes rapid two week reduction. 
Chapter 3  A meta-analysis of RCTs comparing abrupt quitting with reduction to quit suggests that the quit 
rates from either approach are similar. 
 There was no evidence that either reduction or abrupt cessation was more effective when examined 
in sub-group analyses of trials that provided self-help versus more intensive behavioural support, or 
pre-quit NRT versus no pre-quit NRT in the reduction arms. 
 There was insufficient evidence that reduction, typically supported by NRT, led to more adverse 
events than abrupt cessation. Trials reported adverse events differently, which made drawing 
conclusions difficult.  A meta-analysis of trials of NRT versus placebo for smoking reduction shows 
strong evidence that NRT assisted cessation is safe (Moore et al. 2009).  
 Findings are not consonant with data from observational studies (Cheong et al. 2007; West & Fidler 
2011), which show that people who reduce to quit, rather than quit abruptly, are much less 
successful. One explanation might be that efficacy depends on the method used to reduce. 
Chapter 4  The updated meta-analysis of eight RCTs, comparing nicotine preloading to controls, found a very 
weak non-significant effect of preloading on abstinence, in contrast with previous meta-analyses.  
However, although this provides no support for routine use, it is not possible to conclude that the 
preloading is ineffective due to high heterogeneity. 
 Sub-group analysis, by type of NRT, showed evidence of a larger effect of patch than acute NRT at 
short-term follow-up. However there was no strong evidence that patch was more effective than 
acute NRT at long-term follow-up. 
 We examined evidence that the effect of preloading was mediated through reducing the reward of 
smoking, increasing confidence in quitting, or increasing adherence to medication. The evidence 
suggested that preloading did not increase confidence and lead to increased post-cessation 
adherence.  There was slight evidence that preloading reduced reward from smoking. The evidence 
was clouded by lack of reporting of mediators. 
 No substantial evidence of moderators of the effect of preloading were found. There was little 
evidence that intensity of behavioural support influenced treatment success. Adherence to 
preloading treatment appeared high, perhaps suggesting that smokers are happy to smoke and use 
NRT at the same time, despite previous warnings not to do so. 
Chapter 5  Quitting methods used in RRT (abrupt, reduction- SR, HR and SFP) appear to be feasible, 
understandable, and perceived as useful. However preference for a method and reasons for this 
varied, suggesting that there is a demand for a variety of quitting options. When a choice was given 
to reduce by easier or harder cigarettes first, choosing harder was largely unpopular, suggesting that 
this approach may not improve uptake to services if offered. 
 When asked to choose a method to quit should they relapse, successful quitters said they would use 
the same method again.  However people randomised to abrupt and reduction, who failed to achieve 
abstinence, said they would try reduction to quit. Perhaps because people see achieving reduced 
smoking as a success. If reduction were offered as part of the NHS SSS this approach  could 
encourage more people to re-use the SSS if not successful, and might be most enduring. 
 Smoking reduction necessarily involves self-monitoring of smoking behaviour, whereas abrupt 
quitting does not.  However in RRT, even those following the abrupt programme self-monitored.  In 
both arms participants reported that self-monitoring and consequent mental preparation for quitting 
was useful. Regardless of the method used, including a period of self-monitoring could enhance the 
efficacy of behavioural support programmes. 
 Participants advanced two explanations for the efficacy of preloading. Firstly that it reduced 
cravings and secondly that it was aversive, making smoking unpleasant. No studies in the 
preloading review (Chapter 4) reported the degree to which participants found smoking aversive and 
so future studies should examine this.  However aversion was reported mainly in the abrupt arm.  If 
this is the mechanism, it suggests that only non-reducing preloading is likely to result in a benefit, 
and there was weak support for this in Chapter 4. 
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Chapter 3 is a systematic review and meta-analysis of existing trials comparing abrupt 
quitting and reduction, and so the results also contributed to objective 1). Chapter 4 reported a 
similar literature review and meta-analysis, however the aim of this was to fulfil objective 2), 
by using existing trials to compare nicotine preloading treatment to placebo, or no pre-quit 
nicotine treatment.  Finally Chapter 5 explored the results of the interview study outlined as 
part of the trial protocol in Chapter 2, in order to fulfil objective 3). As a result my 
overarching conclusions are as follows. 
 
6.2 Both abrupt quitting and reduction to quit should be offered as 
quitting options by smoking cessation services 
In the past trials comparing smoking reduction to quit and abrupt quitting have had small 
sample sizes. By conducting the meta-analysis reported in Chapter 3 we combined these 
studies to come up with a summary effect estimate, with an N of 3760.  This effect estimate 
suggests that neither approach is superior to the other. This provides support for the use of 
either or both approaches by smoking cessation services, both inside and outside the NHS; 
although a comparison of the cost-effectiveness of these approaches would also be beneficial. 
The main aim of the NHS SSS in offering a reduction to quit approach would be to draw in 
people who would only use reduction, and therefore increase the reach of behavioural support.  
However because people who would have used abrupt cessation might choose reduction to 
quit instead, this necessitates trials to test the relative effectiveness.  The participants included 
in our meta-analysis were randomised to either reduction to quit or abrupt quitting and 
therefore provide no information about whether smokers would actually choose either 
approach if both were on offer.  Surveys of smokers have previously found that a number of 
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smokers quitting without support plan to, or have chosen to take a reduction approach 
(Hughes et al. 2006; West 2008). Findings from the RRT interview study, reported in Chapter 
5, add to this, as questioning took place within the context of a supported quit attempt. We 
found that different people favoured different approaches, with a demand for both abrupt 
quitting and reduction to quit methods. Not only this, but the methods used in RRT were 
judged to be both feasible and understandable.  This suggests that if offered smokers would 
take up a reduction approach to quitting, and that this wouldn’t then overshadow the 
popularity and uptake of the abrupt method.  It should be taken into account that, although the 
participants specified preferences, they had all agreed to take part in the trial, which 
necessitated agreement to be randomised to either approach.  However, some participants 
specified that they would have preferred to have a choice of methods, so by offering this, 
services such as the NHS SSS are likely to appeal to more smokers, and attract smokers who 
would not otherwise have used behavioural support and perhaps medication. At present a 
feasibility pilot is being carried out in the NHS SSS, on behalf of the Department of Health, 
of a menu of quitting options available to smokers (Routes to Quit), including the following 
approaches: 
 Abrupt quitting (as currently provided); 
 Rapid reduction (for up to 4 weeks before quitting); 
 Medication only (without a behavioural support programme); 
 Gradual reduction (for up to 36 weeks); 
 Self care (verbal and written advice and an open door policy for future support). 
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Service users are offered the abrupt approach first but if it is refused are offered the next 
method in the list, and so on, as above (Robinson 2010). The findings of the pilot will be a 
valuable means to assess the opinions of both service users and providers of the combination 
of approaches, within a pragmatic setting. 
 
Our interview study also uncovered another potential mechanism by which offering a 
reduction option could increase use of the NHS SSS. Although quitters who quit abruptly said 
they would not wish to use the same method to quit next time, those who used the reduction 
method said they would use it to quit again. If this is mirrored outside this study then at 
present smokers who unsuccessfully quit abruptly through the NHS SSS have no alternative 
to turn to for their next attempt, and so may be unlikely to revisit the SSS (although, as 
previously mentioned in Section 1.4 this is contrary to surveys which have found that 
satisfaction with the NHS SSS is generally high (May et al. 2009; May & McEwen 2011).  
However, if reduction were offered as an alternative then unsuccessful quitters using either 
the reduction or abrupt approaches may still feel inclined to use the services again, and opt for 
the reduction method, giving the services a more enduring popularity with individuals.  As the 
NHS SSS has been found to achieve quitting success rates of almost four times as high as 
when smokers seek no support to quit (West 2010), any action which could potentially 
encourage more people to use services, and keep using these services in the wake of an 
unsuccessful quit attempt, would be beneficial. 
 
However there are two caveats to these conclusions.  Firstly that none of the trials included in 
the meta-analysis in Chapter 3 were non-inferiority trials.  Therefore the strength of the 
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conclusion we can draw is limited to the fact that neither reduction to quit nor abrupt quitting 
had superior quit rates.  Only a dedicated non-inferiority trial will be able to tell us whether 
reduction is non-inferior to abrupt quitting  (within a pre-specified margin of non-inferiority). 
Thus we designed RRT (protocol reported in Chapter 2) which- as well as following 
recognised trial and smoking research guidelines (for example Moher et al. 2001; West et al. 
2005) to ensure high quality- is powered to detect non-inferiority, and therefore will provide a 
valuable addition to the existing literature. It needs to be taken into consideration however 
that to ensure feasibility of the trial the non-inferiority margin is fairly large, so that the trial 
will only be powered to detect non-inferiority of up to 9.5%.  In some cases if a method was 
found to be 9.5% less effective than another this may be deemed as a significant difference, 
however in this case we believe that a difference this large would not deter the NHS SSS from 
utilising reducing smoking to quit as well as abrupt quitting. Nevertheless, non-inferiority 
need not be essential to the provision of a gradual approach to quitting, as the extra people 
that it may bring into services could outweigh a reduced success rate, leading to an increase in 
those quitting smoking overall. However if non-inferiority is not achieved it is only fair to 
make those quitters who do not have a firm preference for either method aware that one 
approach is more successful than the other, so that they are fully informed before making a 
decision about which way to quit.  
 
Secondly, all the studies included in the meta-analysis (Chapter 3), were RCTs and provided 
participants with either self-help therapy or behavioural support.  As previously mentioned 
(Section 1.4.2) observational studies have found that reducing to quit without support, does 
not give the same success rates as abrupt quitting (Cheong et al. 2007; West & Fidler 2011).  
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Therefore although the evidence presented in this thesis provides support for the use of both 
methods through smoking cessation services, at present there is little support for the use of 
reduction to quit by those who do not seek support, and so we should be specific about the 
way that reduction to quit is recommended to the general public. It seems likely that one of 
the key issues is that reduction should lead to a quit day.  It is notable that this was a feature 
of all the trials reviewed in Chapter 3. 
 
6.3 More research is needed into how people should be advised to reduce 
their smoking  
As described above, this thesis provides evidence that reducing smoking to quit is a method 
worthy of consideration, for use by the NHS SSS. However the literature reviews carried out 
in Chapters 3 and 5 show that there are many possible ways that this reduction could be 
carried out, and that these different methods may have varying rates of success. The 
difference in the conclusions of RCTs and observational studies, comparing reduction to quit 
to abrupt quitting, supports this. Section 5.1.2 documents the very limited research that has 
been carried out comparing different approaches. More needs to be done to ensure that if 
reduction to quit services are adopted by smoking cessation services they are designed in a 
way that optimises success.  The findings reported in Chapter 5 suggest that overall the SR, 
HR and SFP methods were all generally liked and feasible, however there may be some 
elements that are more favourable to a user than others, for example, cutting out harder 
cigarettes first was considerably less popular than cutting out easier ones first. Although user 
opinion such as this is important when designing an intervention it needs to go hand in hand 
with accurate effect estimates.  It is possible that it is advisable to tackle difficult cigarettes 
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first, and with strong encouragement and support patients could be encouraged to reduce 
using this unpopular method.  
 
Further research comparing the efficacy of different reduction to quit approaches is necessary; 
in particular we are unaware of any study that has compared the efficacy of a cpd and sfp 
approach to reduction. Although participants in RRT are carrying out variants of both 
methods, they were not randomised to these, and the trial is not sufficiently powered to make 
this comparison. On the other hand there could be barriers to carrying out an RCT of this sort. 
A recruitment criterion for all RCTs is that participants are happy and suitable to be 
randomised to any study arm. However different reduction methods are likely to suit different 
types of people; for example the SR method might be hard for someone who has a job to carry 
out, as they may find it hard to smoke on each ICI due to inference with job tasks or smoke-
free laws. This may limit the number of people who could be recruited into the study, making 
it hard to reach recruitment targets, and limiting the generalisability of the findings.  
 
Another way to gain insight into ways that an intervention could be manipulated to achieve 
optimal success is by investigating possible mediators and moderators of the effect.  The 
mediators and moderators of the effects reported in Chapter 3 were not investigated, as this is 
beyond the scope of a Cochrane Review.  However, although data concerning this, in the 
reports of included studies, appears sparse we do plan to formally extract the relevant data to 
see whether these can be combined and analysed, and if any conclusions can be drawn. A 
mediation analysis is also planned as part of the analysis plan for RRT. This should help to 
establish, whether reduction works by manipulating the neuropsychological pathways of 
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addiction, as proposed in Section 1.2.2, or whether it works by increasing self-efficacy pre-
quit, which some participants suggested was the case in Chapter 5 (Section 5.3.3.3). It could 
also be used to strengthen the observational efficacy data, from the SR, HR and SFP study 
arms.  If abstinence outcomes provide evidence that one of the reduction methods is more 
successful than the others, and this is supported by complementary changes in mediators, this 
provides stronger evidence that enhanced efficacy is due to features of the method, rather than 
differences in participants across methods.   
 
If analyses of the sort proposed here were carried out we may gain an indication of whether 
one reduction method is considerably more successful than any other, and if so should be used 
singularly alongside abrupt quitting, or whether a number of approaches result in similar quit 
rates, and so a menu of options would be more appropriate.  We found from our interviews 
(Chapter 5), that being able to make choices about the method used to quit was valued greatly 
by participants, and so offering this may present another opportunity to encourage more 
people to use SSS. 
 
6.4 Further research is needed before nicotine preloading is recommended 
and used in practice 
We also propose that more research is needed investigating nicotine preloading, before it is 
recommended to the general population and offered as part of SSS, for the following reasons. 
  CHAPTER 6: CONCLUSIONS 
 
 
209 
6.4.1 Efficacy of preloading is still uncertain 
Our Cochrane Review (Chapter 3) suggested that neither abrupt quitting nor reduction to quit 
was more successful whether participants used acute NRT pre-quit or not, and previous 
research suggests that concurrent smoking and NRT use is safe (Fagerstrom & Hughes 2002; 
Stead et al. 2008; Moore et al. 2009). However this cannot tell us the efficacy of NRT 
preloading relative to standard use of NRT. Whilst previous meta-analyses (Shiffman & 
Ferguson 2008; Stead et al. 2008) found a significant benefit of using NRT pre-quit, our 
updated meta-analysis (Chapter 4) found no such effect; although a sub-group analysis 
showed some evidence of a small but significant effect of nicotine patch preloading, at short-
term follow-up only.   
 
However, it would be wrong to dismiss preloading, because the summary estimate might be 
misleading. The meta-analyses in Chapter 4 showed considerable heterogeneity, which was 
not eliminated by splitting trials into the patch/acute NRT sub-groups.  Despite investigations 
of mediators and moderators, and suggestions by Rose (2011), described in Section 4.5, we 
were unable to identify a likely source of this heterogeneity.  Additionally many participants 
from the RRT interview study (Chapter 5) reported that they experienced effects of 
preloading, such as nausea and loss of the will to smoke, and despite the fact that some of 
these were unpleasant they judged preloading as helpful to their quit attempt, and reported 
high adherence (high adherence was also found in studies included in the meta-analysis in 
Chapter 4).  Taken together we believe that the previous favourable meta-analyses, the 
heterogeneity in our more recent meta-analysis, and the encouraging response from treatment 
users provide justification for a further trial of nicotine preloading. This has been planned and 
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recently approved by the National Institute for Health Research (NIHR), and will have almost 
two thirds of the participants (N=1786) included in the most up-to-date meta-analysis 
(N=2813). 
 
6.4.2 The cause of the heterogeneity in preloading trials (Chapter 4) needs to 
be established 
As raised above we were unable to establish the cause of the heterogeneity present in the 
preloading meta-analysis (Chapter 4), however as mentioned in Section 4.1 and Section 6.3 in 
the context of reduction to quit methods, knowing the cause of this heterogeneity and 
therefore potential moderators of the effect, could inform the best ways to offer or manipulate 
treatment to secure the best quit rates. Mediators could also be used to do this; however there 
was also insufficient evidence to support any mediational pathways. The lack of good 
evidence for any of the mediators and moderators investigated in Chapter 4 may be because 
these factors did not influence the effect, but may also, at least partly, have been due to the 
standards of reporting, and that these differed across studies. For example, only a small effect, 
if any, was seen of preloading on pre- and post-quit cravings. This could suggest that 
preloading does not influence the neuropsychological mechanisms of addiction, described in 
Section 1.2.3; however based on the low quality of evidence we think that it is premature to 
draw this conclusion. 
 
One potential mediator of the effect of preloading, which was not investigated in Chapter 4, 
was nausea, and this leads to the hypothesis that nicotine preloading may act as a form of 
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aversion therapy.  This hypothesis was put forward by the participants of the RRT interview 
study (Chapter 5), who quit smoking abruptly. Loss of craving was also observed as a result 
of treatment by participants in both the abrupt and reduction arms.  This would suggest that 
mechanisms such as these afford further study.  For example, it may be possible to measure 
whether aversive conditioning has taken place under experimental conditions, by exposing 
smokers undergoing preloading and control treatment to smoking paraphernalia and/or cues 
pre- and post-quit, and measuring whether these invoke negative emotional and 
commensurate biological responses (such as sympathetic activation). The hypothesis that 
preloading works as aversion therapy was supported by RRT abrupt participants’ claims that 
they reduced their cpd pre-quit, despite instructions to maintain their smoking rate.  However, 
participants in the abrupt cessation arms of three trials included in the analysis in Chapter 3 
also reduced their cigarette consumption, despite not using NRT (Flaxman 1978; Cummings 
et al. 1988; Cinciripini et al. 1995). This suggests that reduction is behaviour common to 
smokers about to quit regardless of the aversiveness of smoking. In the two studies (Flaxman 
1978; Cinciripini et al. 1995) where it could be measured, the reduced consumption was not 
as great as was witnessed in the reduction arms of the study, but its presence, in spite of the 
lack of preloading, may point to another reason for this reduction. By looking at quantitative 
reports of cpd reductions in RRT we should be able to compare the extent of reduction in the 
abrupt arm with that in the reduction arm, and also to that in the Cochrane studies. If the 
reduction is greater than in the Cochrane studies it may suggest that this was at least partially 
mediated by nausea. However a comparison across studies, such as this, would only be able to 
provide very weak evidence. 
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The evidence that participants reduced in both reduction and abrupt quitting arms of studies 
(Chapters 3 and 5), and that neither approach had superior quit rates (Chapter 3) suggest that 
the abrupt quitting and reduction to quit methods may not differ as much in practice and effect 
as they do in their instructions. Along with the limited conclusions that can be drawn about 
the success of nicotine preloading, at present we are unable to present interventions that will 
provide quit rates greater than those already available.  However providing smoking reduction 
methods in the NHS SSS may still increase overall population quit rates. If, as Michie (2009) 
proposed, reduction provides a goal which is in the first instance more in-line with current 
behaviour, then it could, if offered, both encourage more people to quit in the first place, and 
encourage those people who would like to reduce, or merely want to be offered a choice, to 
use behavioural support. This could in turn increase the likelihood that they would use 
medication to aid their attempt. There is evidence that both of these enhance success 
(Lancaster & Stead 2005; Stead et al. 2008).  Anything, such as this, which can improve the 
rate of decline in smoking prevalence, will improve our chances of meeting the DoH’s target 
(presented in Section 1.1) to reduce smoking prevalence to 10% by 2020.
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APPENDIX 1: PUBLISHED RRT PROTOCOL (LINDSON ET AL. 2009a) 
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APPENDIX 2: PUBLISHED COCHRANE REVIEW (LINDSON ET AL. 2010) 
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APPENDIX 3: PUBLISHED NICOTINE PRELOADING REVIEW (LINDSON & 
AVEYARD 2011a) 
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APPENDIX 4: PUBLISHED RESPONSE TO ROSE’S (2011) LETTER TO THE 
EDITORS (LINDSON & AVEYARD 2011b) 
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APPENDIX 5: RRT PARTICIPANT INFORMATION SHEET 
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APPENDIX 6: RRT CONSENT FORM 
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APPENDIX 7: RRT CASE REPORT FORM 
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APPENDIX 8: EXAMPLE DAY OF RRT ABRUPT ARM PRE-QUIT DIARY 
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APPENDIX 9: EXAMPLE COMPLETED WEEK 1 SR REDUCTION SCHEDULE 
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APPENDIX 10: EXAMPLE COMPLETED WEEK 1 HR-E REDUCTION SCHEDULE 
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APPENDIX 11: EXAMPLE COMPLETED WEEK 1 SFP REDUCTION SCHEDULE 
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APPENDIX 12: EXAMPLE DAY OF RRT REDUCTION ARM PRE-QUIT/QUIT 
DAY DIARY 
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APPENDIX 13: RRT SEMI-STRUCTURED INTERVIEW SCHEDULE 
 
 Which quit method did you use?  
 
 (Reduction only) Did you choose method? If so why?  
 
 (Hierarchical reduction only) Why did you choose to eliminate the easier/harder 
cigarettes first as opposed to the harder/easier ones? 
 
 What were your first impressions of the quit method?  
 
 How easy did you find the instructions to understand and follow? Why? 
 
 How easy was the method to carry out? 
 
 (Smoke-free periods only) Did you end up reducing your cigarettes per day as well as 
smoking periods over the two week reduction? 
 
 Were there any times when it was easier or harder? 
 
 (Hierarchical (easy) reduction only) Considering that you eliminated the hardest 
cigarettes last do you think this made reduction harder as you went on? 
 
  (Hierarchical (difficult) reduction only) Considering that you eliminated the hardest 
cigarettes first do you think this made reduction easier toward the end of the reduction 
period? 
 
 Did you manage to stick to the pre-quit instructions? Why? 
 
 Were there any good points to the method?  
 
 Were there any problems or bad points with the method?  
 
 Did it fit in with your lifestyle? Why was that? 
 
 Would you make any changes to the method?  
 
 What did you think to the materials that you used (schedules/diaries)? 
 
 What are your feelings about the nurse support that you received? 
 
 What did you think to how the nicotine replacement therapy was used as part of the 
method? 
 
 Were there any personal strategies or techniques that you used to help you along? 
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 How did you feel when you reached your quit day? 
 
 Did your feelings about quitting change at all in the 2 weeks between your first 
appointment and your quit day? 
 
 Are you pleased with method you used or not?  
 
 Why do you think it worked or didn’t work for you? 
 
 How do you think people quit smoking? With this in mind do you think this method 
could help people to quit? 
 
 When people have made their minds up and try to quit smoking, are there things that 
they do that can reduce their chances of making it successfully? With this in mind do 
you think this method could prevent people from quitting? 
 
 Would you choose this method if you quit again?  
 
 Would you recommend this method to someone else? 
 
 Had you attempted to quit before this study? If so which method of quitting did you 
use? How did that method compare to the method you used this time?  
 
 Before the study if you had been given the choice how would you have quit?  
 
 Following the study how would you choose to quit? Why? 
 
 Has your opinion changed pre to post study? Why? 
 
 (If still smoking) Has the trial changed your smoking behaviour at all or are you 
smoking the same as before the trial? 
 
 Any other comments?  
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APPENDIX 14: PARTICIPANT NOTES SHEET FOR THE RRT INTERVIEW 
STUDY 
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APPENDIX 15: RRT ADVERSE EVENT REPORTING 
 
Definitions 
Adverse event 
An adverse event (AE) is any untoward medical occurrence in a clinical investigation subject 
administered a product or medical device; the event need not necessarily have a causal relationship 
with the treatment or usage. Examples of AEs include but are not limited to: 
 abnormal test findings, 
 clinically significant symptoms and signs, 
 changes in physical examination findings, 
 hypersensitivity, and 
 progression/worsening of underlying disease. 
Additionally, they may include the signs or symptoms resulting from: 
 drug overdose, 
 drug withdrawal, 
 drug abuse, 
 drug misuse, 
 drug interactions, 
 drug dependency, 
 exposure in utero. 
Failure of expected pharmacological action or therapeutic benefit alone (i.e. lack of efficacy) is not 
necessarily an AE. 
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Definition of serious adverse event (SAE) 
A serious adverse event or serious adverse drug reaction is any untoward medical occurrence at any 
dose that: results in death, is life-threatening (immediate risk of death), requires inpatient 
hospitalisation or prolongation of existing hospitalisation, results in persistent or significant 
disability/incapacity, and/or results in congenital anomaly/birth defect.  An important medical event 
may not be immediately life-threatening and/or result in death or hospitalisation. However, if it is 
determined that the event may jeopardise the subject and may require intervention to prevent one of 
the other outcomes listed in the definition above, the important medical event should be reported as 
serious. Examples of such events are intensive treatment in an emergency room or at home for allergic 
bronchospasm; blood dyscrasias or convulsions that do not result in hospitalisation; or development of 
drug dependency or drug abuse.  
 
Definition of adverse reaction (AR) 
Means any untoward and unintended response in a subject to an investigational medicinal product 
which is related to any dose administered to that subject. 
 
Definition of suspected serious adverse reaction (SSAR) 
Means an adverse reaction that is classed as serious and which is consistent with the information about 
the medicinal product in question set out 
a) in the case of a licensed product, in the summary of product characteristics (SmPC) for 
that product, or  
b) in the case of any other investigational medicinal product, in the Investigator’s Brochure 
(IB) relating to the trial in question 
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Definition of suspected unexpected serious adverse reaction (SUSAR) 
Means an adverse reaction that is classed as serious and which is not consistent with the information 
about the medicinal product in question set out 
a) in the case of a licensed product, in the summary of product characteristics  (SmPC) for 
that product 
b) in the case of any other investigational medicinal product, in the Investigator’s Brochure 
relating to the trial in question 
 
Monitoring and reporting adverse events  
All observed or volunteered adverse events regardless of treatment group or suspected causal 
relationship to any of the nicotine replacement therapies will be reported as described in the following 
sections.  For all adverse events, the investigator will pursue and obtain information adequate both to 
determine the outcome of the adverse event and to assess whether it meets the criteria for classification 
as a serious adverse event requiring immediate notification to the sponsor, the UK National Health 
Service (NHS) Research and Development (R&D) office, and the Research Ethics Committee (REC). 
The investigator will assess causality. For adverse events follow-up by the investigator is required 
until the event or its sequela resolve or stabilise.   
 
Severity Assessment 
If required on the adverse event case report forms, the investigator will use the adjectives mild, 
moderate, or severe to describe the maximum intensity of the adverse event.  For purposes of 
consistency, these intensity grades are defined as follows:  
 Mild- Does not interfere with subject’s usual function.  
 Moderate- Interferes to some extent with subject’s usual function.  
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 Severe- Interferes significantly with subject’s usual function.  
Note the distinction between the severity and the seriousness of an adverse event. A severe event is not 
necessarily a serious event. For example, a headache may be severe (interferes significantly with 
subject’s usual function) but would not be classified as serious unless it met one of the criteria for 
serious adverse events, listed above.   
 
Causality Assessment  
The investigator’s assessment of causality must be provided for all adverse events (serious and non-
serious). An investigator’s causality assessment is the determination of whether there exists a 
reasonable possibility that the investigational product caused or contributed to an adverse event. If the 
investigator’s final determination of causality is unknown and the investigator does not know whether 
or not investigational product caused the event, then the event will be handled as “related to 
investigational product” for reporting purposes. If the investigator’s causality assessment is “unknown 
but not related to investigational product”, this should be clearly documented on trial records.  In 
addition, if the investigator determines a serious adverse event is associated with trial procedures, the 
investigator must record this causal relationship, as appropriate, and report such an assessment in 
accordance with the serious adverse event reporting requirements, if applicable.   
 
Exposure In Utero  
The license for nicotine replacement therapy (NRT) does not exclude use in pregnancy and the 
National Institute for Health and Clinical Excellence (NICE) guidelines allow such use.  We will 
exclude pregnant or breast feeding women because the dose and format of NRT advised for pregnant 
women is different from that used in our protocol.  Consequently, we will adjust the dose of NRT 
should a woman become pregnant during treatment.   
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The CI/PI’s responsibilities and processes for evaluating AEs 
Each AE will be evaluated for seriousness, causality, expectedness and severity. The responsibility for 
this will lie with Dr Paul Aveyard, the Principle Investigator (PI), and then reported to the Sponsor. 
The study team will be taught and have access to documents explaining how to assess AEs and SAEs 
and decide whether any event requires further expedited reporting by the Sponsor.  
 
The CI/PI’s responsibilities, definitions and criteria for the evaluation of SAEs  
If the AE is assessed as serious Dr Aveyard will report the event to the sponsor immediately or within 
24 hours of being made aware of the event. An initial verbal report can be made but will be followed 
promptly with a detailed written report on the trial SAE form. 
 
Evaluation of AEs for Causality 
 Not Related.  Onset of the event as relative to administration of the product is not reasonable; or, 
another cause itself can explain the occurrence of the event 
 Unlikely to be related.  Onset of the event as relative to administration of the product is 
possible but another cause itself can explain the occurrence of the event, or there are no 
reasonable grounds for suspecting that the product could have caused the event. 
 Possibly related.  Onset of the event as relative to administration of the product is 
reasonable; however the event could have been due to another, equally likely, cause   
 Probably related.  Onset of the event as relative to administration of the product is reasonable and 
is more likely explained by the drug than by any other cause. 
 Definitely related.  Onset of the event as relative to administration of the product is reasonable and 
there is no other cause to explain the event; or a re-challenge (if feasible) is positive. 
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Recording of AEs 
Dr Aveyard will record all AEs on to the appropriate Trial Recording Form and copies filed in the 
subject’s notes.  
 
Sponsor’s responsibilities for AE recording and reporting 
The sponsor will obtain all AE records and perform an evaluation with respect to seriousness, 
causality and expectedness. Expedited reporting will be required where the AE has a possible causal 
relationship to the trial intervention, and/or is unexpected. 
 
What the Sponsor will do following receipt of SAE report from Chief 
Investigator/Principal Investigator 
On receipt of each and every SAE form the sponsor will provide an evaluation of ‘expectedness’. All 
SAEs related to the medication that are both unexpected and serious, are subjected to expedited 
reporting. Other safety issues also qualify for expedited reporting, where they might alter the current 
risk-benefit assessment of the investigational medicinal product (IMP); or where the issue may be 
sufficient to consider changes in the IMP administration or overall conduct of the trial, i.e. new events 
that relate to the conduct of the trial or the development of the IMP likely to affect the safety of 
subjects ie: lack of efficacy of an IMP in the treatment of a life threatening disease, single case 
reporting of an expected SAE, but with an unexpected outcome, an increase in the rate of occurrence, 
or severity of an expected SAE, judged to be clinically important post study SUSARs that occur after 
the subject has completed a trial. 
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Timeframes in which the Sponsor will submit expedited reports to the Research Ethics Committee 
(REC) and to the Medicines and Healthcare Products Regulatory Agency (MHRA) 
 
Fatal/life threatening SUSARs 
The sponsor will inform the REC of the above as soon as possible, but no later than 7 calendar days 
after he has first knowledge of the minimum criteria for expedited reporting. 
 
Non-fatal and non-life threatening SUSARs 
The sponsor will report all other SUSARs and safety issues to the REC as soon as possible but no later 
than 15 calendar days after he has first knowledge of the minimum criteria for expedited reporting. 
 
Reporting other safety issues 
A letter entitled Safety Report will be sent to the REC where other safety issues also qualify for 
expedited reporting by the sponsor. The first page will contain the EudraCT number, title of the trial 
and the trial protocol code number. 
 
The Co-ordinator of the main REC will acknowledge receipt of safety reports within 30 days.
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APPENDIX 16: COCHRANE REVIEW SEARCH STRATEGIES 
 
 
a) MEDLINE search strategy 
1. cold turkey.mp [mp=title, abstract, heading word, table of contents, key concepts] 
2. (schedul* adj3 smok*).mp 
3. (cut* down or cut-down).mp 
4. (({Gradual* or abrupt*}) adj3 (reduction or reduce* or quit* or stop* or abstin* or abstain*              
    or cessat*)).mp 
5. fading.mp 
6. taper*.mp 
7. controlled smoking.mp 
8. 1 or 2 or 3 or 4 or 5 or 6 or 7 
9. RANDOMIZED-CONTROLLED-TRIAL.pt 
10. CONTROLLED-CLINICAL-TRIAL.pt 
11. CLINICAL-TRIAL.pt 
12. Meta analysis.pt 
13. exp Clinical Trial/ 
14. Random-Allocation/ 
15. randomized-controlled trials/ 
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16. double-blind-method/ 
17. single-blind-method/ 
18. placebos/ 
19. Research-Design/ 
20. ((clin$ adj5 trial$) or placebo$ or random$).ti,ab. 
21. ((singl$ or doubl$ or trebl$ or tripl$) adj5 (blind$ or mask$)).ti,ab. 
22. (volunteer$ or prospectiv$).ti,ab. 
23. exp Follow-Up-Studies/ 
24. exp Retrospective-Studies/ 
25. exp Prospective-Studies/ 
26. exp Evaluation-Studies/ or Program-Evaluation.mp. 
27. exp Cross-Sectional-Studies/ 
28. exp Behavior-therapy/ 
29. exp Health-Promotion/ 
30. exp Community-Health-Services/ 
31. exp Health-Education/ 
32. exp Health-Behavior/ 
33. 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24  
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      or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 
34. smoking cessation.mp. or exp Smoking Cessation/ 
35. “Tobacco-Use-Cessation”/ 
36. “Tobacco-Use-Disorder”/ 
37. Tobacco-Smokeless/ 
38. exp Tobacco-Smoke-Pollution/ 
39. exp Tobacco-/ 
40. exp Nicotine-/ 
41. ((quit$ or stop$ or ceas$ or giv$) adj5 smoking).ti,ab. 
42. exp Smoking/pc, th 
43. 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 
44. 9 or 10 or 11 45. 33 and 43  
46. (animals not humans).sh.  
47. (44 or REVIEW.pt.) and 43  
48. 47 not 46  
49. 45 not 47  
50. 45 not 47 not 46  
51. exp Smoking/ 
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52. 33 and 51  
53. 52 not 45  
54. 53 and 44  
55. (53 and 44) not 46 
56. 53 not 54  
57. 53 not 54 not 46 
58. 57  
59. 55  
60. 50  
61. 48 
62. 59 or 61 
63. 8 and 62 
64. 60 or 58 
65. 8 and 64 
66. 63 or 65 
 
 
b) PsycINFO search strategy 
1. cold turkey.mp  
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2. (schedul* adj3 smok*).mp 
3. (cut* down or cut-down).mp 
4. (({Gradual* or abrupt*}) adj3 (reduction or reduce* or quit* or stop* or abstin* or   
    abstain* or cessat*)).mp 
5. fading.mp 
6. taper*.mp 
7. controlled smoking.mp 
8. smoking cessation.mp. or exp Smoking Cessation/ 
9. (antismoking or anti-smoking).mp. 
10. (quit$ or cessat$).mp 
11. (abstin$ or abstain$).mp 
12. (control adj smok$).mp 
13. exp behavior modification/ 
14. 9 or 10 or 11 or 12 or 13 
15. tobacco-smoking/ 
16. (smok$ or cigar$ or tobacco$).mp. 
17. Prevention/ 
18. 15 or 16 
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19. 14 and 18 
20. 17 and 18 
21. 8 or 19 or 20 
22. 6 or 4 or 1 or 3 or 7 or 2 or 5 
23. 22 and 21 
 
c)  EMBASE search strategy 
1. cold turkey.mp  
2. (schedul* adj3 smok*).mp 
3. (cut* down or cut-down).mp 
4. (({Gradual* or abrupt*}) adj3 (reduction or reduce* or quit* or stop* or abstin* or    
    abstain* or cessat*)) 
5. fading.mp 
6. taper*.mp 
7. controlled smoking.mp 
8. 1 or 2 or 3 or 4 or 5 or 6 or 7 
9. random$.ti,ab 
10. factorial$.ti,ab 
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11. (cross over$ or crossover$ or cross-over$).ti,ab 
12. placebo$.ti,ab 
13. (double$ adj blind$).ti,ab 
14. (single$ adj blind$).ti,ab 
15. assign$.ti,ab 
16. allocat$.ti,ab 
17. volunteer$.ti,ab 
18. CROSSOVER PROCEDURE.sh 
19. DOUBLE-BLIND PROCEDURE.sh 
20. RANDOMIZED CONTROLLED TRIAL.sh 
21. SINGLE-BLIND PROCEDURE.sh 
22. or/9-21 
23. smoking cessation.mp 
24. exp smoking cessation/ 
25. exp smoking-/ 
26. ((quit$ or stop$ or ceas$ or giv$ or prevent$) adj smok$).mp 
27. exp passive smoking/ 
28. exp smoking habit/ 
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29. exp cigarette smoking/ 
30. or/23-29 
31. 22 and 30 
32. 8 and 31
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APPENDIX 17: COCHRANE REVIEW FLOW DIAGRAM OF STUDY INCLUSION 
Template From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. 
oi:10.1371/journal.pmed1000097
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APPENDIX 18: COCHRANE REVIEW CHARACTERISTICS OF INCLUDED 
STUDIES TABLES 
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APPENDIX 19: COCHRANE REVIEW CHARACTERISTICS OF ONGOING 
STUDIES TABLES 
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APPENDIX 20: COCHRANE REVIEW CHARACTERISTICS OF EXCLUDED 
STUDIES TABLE 
 
Study 
 
Reason for exclusion 
Bernard & Efran 1972 All study arms reduced- two with a goal of quitting, one with a 
goal of controlled smoking. 
Bolliger 2000- The CEASE trial Included participants who were all asked to quit in the same 
way (with nicotine replacement therapy or placebo). 
Bolliger 2000- The Rossette study Included participants who were all asked to reduce with a goal 
of controlled smoking in the same way (with nicotine 
replacement therapy or placebo). 
Bullen et al. 2010 There was no reduction arm. Both arms were asked to smoke as 
they wished before quitting. 
Cinciripini et al. 1994 The control group was not an abrupt quit intervention. 
Participants received a complete ’I Quit Kit’ (developed by the 
American Cancer Society), which included a 7-day smoking 
reduction schedule. 
Daughton et al. 1998 All participants quit in the same way, either using nicotine 
patches or placebo patches. 
Glasgow et al. 1989 Reduction occurred in both trial arms. The key difference 
between arms was post-quit. 
Hatsukami et al. 1988 The reduction arm had a goal of reduced controlled smoking 
rather than quitting smoking. 
Herrara et al. 1995 All groups reduced using nicotine gum or placebo gum. 
Jerome, Fiero et al. 1999 Reduced scheduling was with regard to nicotine gum use. Both 
arms quit abruptly before beginning to use the nicotine gum. 
Marston & McFall 1971 Main outcome was smoking rates. Abstinence rates were not 
reported and not possible to calculate from reported results. 
Rezaishiraz et al. 2007 Participants were asked to restrict themselves to one pack of 
reduced nicotine cigarettes per day during the 2 weeks pre-quit. 
However this instruction was given to both study arms. 
Rose et al. 1998 Neither arm was asked to reduce before quitting. 
Rose et al. 2006 Neither arm was asked to reduce before quitting. 
Rose et al. 2009 Neither arm was asked to reduce before quitting. 
Schuurmans et al. 2004 Neither arm was asked to reduce before quitting. 
Shiffman et al. 2009 Neither arm quit abruptly. Both study arms reduced before 
quitting. 
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APPENDIX 21: PRELOADING REVIEW SEARCH STRATEGIES 
 
 
a) MEDLINE search strategy 
1. (RANDOMIZED-CONTROLLED-TRIAL or CONTROLLED-CLINICAL-TRIAL or    
    CLINICAL-TRIAL).pt. 
2. exp Clinical Trial/ or Random-Allocation/ or randomized-controlled trials/ 
3. 1 or 2 
4. smoking cessation.mp. or exp Smoking Cessation/ 
5. "Tobacco-Use-Cessation"/ 
6. "Tobacco-Use-Disorder"/ 
7. exp Tobacco-/ 
8. exp Nicotine-/ 
9. ((quit$ or stop$ or ceas$ or giv$) adj5 smoking).ti,ab. 
10. exp Smoking/pc, th 
11. 4 or 5 or 6 or 7 or 8 or 9 or 10 
12. nicotine.mp. 
13. NRT.mp. 
14. 12 or 13 
15. (pre-cessation or precessation or (pre adj cessation)).mp.  
16. (pre-loading or preloading or (pre adj loading)).mp.  
17. (pre-treatment or pretreatment or (pre adj treatment)).mp.  
18. (pre-quit or prequit or (pre adj quit)).mp.  
19. ((before adj treat*) or (before adj quit*) or (before adj cessation)).mp.  
20. 15 or 16 or 17 or 18 or 19 
21. 3 and 11 and 14 and 20 
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b) PsycINFO search strategy 
1. smoking cessation.mp. or exp Smoking Cessation/ 
2. (control adj smok$).mp. 
3. tobacco-smoking/ 
4. (smok$ or cigar$ or tobacco$).mp. 
5. 1 or 2 or 3 or 4 
6. (quit$ or cessat$ or abstin$ or abstain$).mp. 
7. 5 and 6 
8. nicotine.mp. 
9. NRT.mp. 
10. 8 or 9 
11. (pre-cessation or precessation or (pre adj cessation)).mp. 
12. (pre-loading or preloading or (pre adj loading)).mp. 
13. (pre-treatment or pretreatment or (pre adj treatment)).mp. 
14. (pre-quit or prequit or (pre adj quit)).mp. 
15. ((before adj treat*) or (before adj quit*) or (before adj cessation)).mp. 
16. 11 or 12 or 13 or 14 or 15 
17. 7 and 10 and 16 
18. from 17 keep 1-70 
 
c) EMBASE search strategy 
1. random$.ti,ab. 
2. factorial$.ti,ab. 
3. (cross over$ or crossover$ or cross-over$).ti,ab. 
4. placebo$.ti,ab. 
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5. (double$ adj blind$).ti,ab. 
6. (single$ adj blind$).ti,ab. 
7. assign$.ti,ab. 
8. allocat$.ti,ab. 
9. volunteer$.ti,ab. 
10. CROSSOVER PROCEDURE.sh. 
11. DOUBLE-BLIND PROCEDURE.sh. 
12. RANDOMIZED-CONTROLLED-TRIAL.sh. 
13. SINGLE-BLIND PROCEDURE.sh. 
14. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 
15. smoking cessation.mp. or exp smoking cessation/ 
16. exp smoking-/ 
17. ((quit$ or stop$ or ceas$ or giv$ or prevent$) adj smok$).mp. 
18. exp smoking habit/ 
19. exp cigarette smoking/ 
20. 15 or 16 or 17 or 18 or 19 
21. (nicotine or NRT).mp.  
22. (pre-cessation or precessation or (pre adj cessation)).mp. 
23. (pre-loading or preloading or (pre adj loading)).mp. 
24. (pre-treatment or pretreatment or (pre adj treatment)).mp. 
25. (pre-quit or prequit or (pre adj quit)).mp. 
26. ((before adj treat*) or (before adj quit*) or (before adj cessation)).mp. 
27. 22 or 23 or 24 or 25 or 26 
28. 14 and 20 and 21 and 27
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APPENDIX 22: PRELOADING REVIEW STUDY ELIGIBILITY FORM 
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APPENDIX 23: PRELOADING REVIEW FLOW DIAGRAM OF STUDY 
INCLUSION 
Template From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. 
doi:10.1371/journal.pmed1000097 
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APPENDIX 24: MANTEL-HAENSZEL RANDOM-EFFECTS META-ANALYSES 
FOR NRT PRELOADING  
 
 
a) Mantel-Haenszel random-effects meta-analysis for nicotine preloading (short-
term abstinence outcome) 
 
  
Study or Subgroup
Hughes 2010
Bullen 2010
Etter 2009
Rose 1998
Schuurmans 2004
Rose 1994
Rose 2009
Rose 2006
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.09; Chi² = 22.66, df = 7 (P = 0.002); I² = 69%
Test for overall effect: Z = 1.26 (P = 0.21)
Events
39
132
61
16
29
10
44
24
355
Total
297
549
154
40
100
24
191
48
1403
Events
60
143
65
14
19
6
24
11
342
Total
299
551
160
40
100
24
188
48
1410
Weight
14.4%
18.0%
16.7%
10.4%
11.5%
6.5%
12.6%
9.9%
100.0%
M-H, Random, 95% CI
0.65 [0.45, 0.95]
0.93 [0.75, 1.14]
0.98 [0.74, 1.28]
1.14 [0.65, 2.02]
1.53 [0.92, 2.54]
1.67 [0.72, 3.86]
1.80 [1.15, 2.84]
2.18 [1.21, 3.94]
1.18 [0.91, 1.54]
Pre-quit NRT Control Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.5 0.7 1 1.5 2
Favours control Favours pre-quit NRT
 
 
 
b) Mantel-Haenszel random-effects meta-analysis for nicotine preloading (long-
term abstinence outcome) 
 
 
 
  
Study or Subgroup
Hughes 2010
Bullen 2010
Etter 2009
Rose 1994
Rose 2006
Schuurmans 2004
Rose 2009
Rose 1998
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.05; Chi² = 11.50, df = 7 (P = 0.12); I² = 39%
Test for overall effect: Z = 1.58 (P = 0.11)
Events
12
99
32
6
10
22
28
12
221
Total
297
549
154
24
48
100
191
40
1403
Events
21
97
31
4
6
12
15
6
192
Total
299
551
160
24
48
100
188
40
1410
Weight
10.7%
27.1%
18.2%
4.9%
6.8%
11.7%
13.1%
7.5%
100.0%
M-H, Random, 95% CI
0.58 [0.29, 1.15]
1.02 [0.79, 1.32]
1.07 [0.69, 1.67]
1.50 [0.48, 4.65]
1.67 [0.66, 4.22]
1.83 [0.96, 3.50]
1.84 [1.01, 3.33]
2.00 [0.83, 4.81]
1.24 [0.95, 1.63]
Pre-quit NRT Control Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.2 0.5 1 2 5
Favours control Favours pre-quit NRT
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APPENDIX 25: PRELOADING REVIEW RISK OF BIAS TABLES 
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APPENDIX 26: PRELOADING REVIEW FUNNEL PLOTS FOR MAIN 
ABSTINENCE OUTCOMES 
 
a) Funnel plot for NRT preloading short-term abstinence outcome 
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b) Funnel plot for NRT preloading long-term abstinence outcome 
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APPENDIX 27: RRT INTERVIEW STUDY EXAMPLE THEMATIC CHART 
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APPENDIX 28: RRT INTERVIEW STUDY EXAMPLE CASE CHART 
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